Quinoline derivatives as modulators and related products of Mas-related G protein receptor X2

By developing compounds that can block MRGPRX2, pseudo-allergic reactions, inflammation and pain problems caused by MRGPRX2 in the prior art are solved, and effective treatment of related diseases is achieved.

CN119095839APending Publication Date: 2024-12-06ESCIENT PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380037000.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-12-22
Filing Date
2023-03-29
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to effectively regulate the Mas-associated G protein-coupled receptor X2 (MRGPRX2), resulting in difficult treatment of related pseudo-allergic reactions, inflammation, pain and autoimmune conditions.

Method used

A compound with structure (I) and its pharmaceutically acceptable salts, isomers, hydrates, solvates or isotopes were developed for use as inverse agonists and competitive antagonists of MRGPRX2 by blocking multiple A chemical entity to regulate MRGPRX2.

Benefits of technology

Effective treatment of MRGPRX2-dependent conditions, such as pseudoallergic reactions, itching, pain and inflammatory conditions, reduces the symptoms and pathological progression of the disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095839A_ABST
    Figure CN119095839A_ABST
Patent Text Reader

Abstract

Provided are methods generally for modulating MRGPRX2, or in particular for treating MRGPRX2 or an MRGPRX2 ortholog dependent condition, respectively, by administering to a subject in need thereof an effective amount of an effective amount of one or more of the following, more specifically, the MRGPRX2 or MRGPRX2 ortholog is contacted with an effective amount of a compound having the structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6 and Rx are as defined herein. Also provided are pharmaceutical compositions containing such compounds, as well as the compounds themselves. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a modulator of Mas-related G protein coupled receptor X2, a product containing the modulator, and a method for using and preparing the modulator. Background Art

[0002] Mas-related G protein receptors (MRGPRs) are a group of orphan receptors with limited expression in very specialized tissues. The functions of most of these receptors are poorly understood. There are eight related receptors in this class that are expressed in humans, of which only four have readily identifiable orthologs in other species (i.e., MRGPR D, E, F, and G). Some of the other four receptors (MRGPRX1, X2, X3, and X4) have specific counterparts in higher species including dogs and horses, but they do not have a single corresponding ortholog in rodents. Summary of the invention

[0003] The present invention is based in part on the identification of MRGPRX2 or MRGPRX2 ortholog modulator compounds. Among the rodent orthologs, mouse mrgprb2 and rat mrgprb3 correspond functionally to human MRGPRX2 in mast cells. MRGPRX2 and its ortholog receptors mediate conditions including: pseudoallergic drug reactions, chronic itching (e.g., pruritus), inflammatory conditions, pain conditions, cancer-related conditions, skin conditions, wound healing, cardiovascular disease, and pulmonary inflammation / COPD. In one embodiment, the expression of MRGPRX2 and its orthologs is primarily limited to mast cells. Mast cells are innate immune cells that reside primarily in sites exposed to the external environment, such as the skin, oral / gastrointestinal mucosa, and respiratory tract. Mast cells express many receptors that respond to mechanical and chemical stimuli. After activation, usually by IgE, mast cells release preformed mediators (e.g., histamine, proteases, and heparin) and newly synthesized mediators (e.g., thromboxane, prostaglandin D2, leukotriene C4, tumor necrosis factor α, eosinophil chemotactic factor, and platelet activating factor) from granules that trigger allergic and inflammatory responses. Histamine dilates postcapillary venules, activates the endothelium, and increases vascular permeability. This leads to local edema, fever, redness, and chemotaxis of other inflammatory cells to the site of release. Histamine also promotes neuronal sensitization that causes pain or itching. MRGPRX2 and its orthologs mediate immunoglobulin E (IgE)-independent activation of mast cells. MRGPRX2 and its orthologs are receptors for (or are sensitive to activation by) a variety of ligands, including basic secretagogues (small cationic molecules), certain drugs (e.g., cationic peptidergic drugs), neuropeptides, and antimicrobial peptides, and are therefore important for non-IgE-mediated pseudoallergic reactions, inflammation, pain, and pruritus conditions. Mast cells can also promote chronic inflammation in the local tissue microenvironment and ultimately polarize to T cells. h 17 immune response to promote the progression of autoimmune disorders. Therefore, modulation of MRGPRX2 or MRGPRX2 orthologs allows for the treatment of autoimmune diseases, pseudoallergic drug reactions, pain, pruritus and inflammatory disorders, such as inflammatory bowel disease, urticaria, sinusitis, asthma, rosacea, endometriosis and other MRGPRX2 or MRGPRX2 ortholog-dependent conditions as explained in more detail below.

[0004] In one embodiment, a method of treating a MRGPRX2 or MRGPRX2 ortholog-dependent condition is provided by administering to a subject in need thereof an effective amount of a pharmaceutical composition of a modulator compound of the invention.

[0005] Therefore, in one embodiment, a compound is provided, the compound having structure (I):

[0006]

[0007] or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R x As defined herein.

[0008] In other embodiments, provided are compounds having Formula (Ia), (Ib), (Ic), (Id), (1e) or (If) as defined herein, or pharmaceutically acceptable salts, isomers, hydrates, solvates or isotopes thereof.

[0009] In yet other embodiments, a pharmaceutical composition is provided, comprising a carrier or excipient and a compound having structure (I) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof.

[0010] In a specific embodiment, a pharmaceutical composition is provided, comprising a substructure of structure (I) having formula (Ia), (Ib), (Ic), (Id), (1e) or (If) as defined herein, or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof.

[0011] In another embodiment, a method is provided for treating a MRGPRX2 or MRGPRX2 ortholog-dependent condition by administering to a subject in need thereof an effective amount of a compound having structure (I) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof.

[0012] In some embodiments, the MRGPRX2 or MRGPRX2 ortholog-dependent condition is one or more of: a pseudoallergic reaction, an itch-related condition, a pain-related condition, a cancer-related condition, an inflammation-related condition, or an autoimmune disorder.

[0013] In one embodiment, a method for treating MRGPRX2 or MRGPRX2 ortholog-dependent conditions is provided, the method comprising administering an effective amount of a compound having structure (I) of Formula (Ia), (Ib), (Ic), (Id), (1e) or (If) as defined herein, or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof.

[0014] In another embodiment, a compound having one or more of the structures disclosed herein or a pharmaceutically acceptable salt, isomer, hydrate, solvate, isotope thereof is provided. DETAILED DESCRIPTION

[0015] As described above, the present invention relates to modulators of MRGPRX2 (or MRGPRX2 orthologs), products containing the modulators, and methods of use and preparation thereof. The present invention is based in part on the identification of MRGPRX2 modulator compounds and MRGPRX2 ortholog modulator compounds. MRGPRX2 and MRGPRX2 orthologs are expressed in mast cells. MRGPRX2 and MRGPRX2 orthologs are receptors for (or are sensitive to activation by) a group of different ligands (including alkaline secretagogues, certain drugs, neuropeptides, antimicrobial peptides), and are therefore important for pseudoallergic reactions, itching, pain, or inflammatory conditions after exposure.

[0016] MRGPRs appear to be sensory receptors that recognize exogenous or endogenous signals / chemicals in their external environment. These receptors may respond to a variety of chemical ligands / agonists. For example, MRGPRX2 recognizes compound 48 / 80, substance P, mastoparan, icatibant, ciprofloxacin, and atracurium as agonist signals. In certain embodiments, the molecules of the present invention regulate MRGPRX2 by acting as inverse agonists capable of blocking a variety of chemical entities and / or as competitive antagonists capable of specifically blocking a single ligand. In one embodiment, such regulation is selective for other MRGPRs (such as MRGPR X1, X3, and / or X4).

[0017] definition

[0018] As used herein, the following terms have the following defined meanings, unless the context indicates otherwise.

[0019] "Modulating" MRGPRX2 means that the compound interacts with MRGPRX2 or a MRGPRX2 ortholog in a manner that causes it to act as an inverse agonist of the receptor and / or as a competitive antagonist of the receptor. In one embodiment, such modulation is partially or completely selective for other MRGPRs (such as MRGPR X1, X3 and / or X4).

[0020] "MRGPR" refers to one or more of the Mas-related G protein-coupled receptors, a group of orphan receptors with limited expression in very specialized tissues (e.g., in mast cells and dorsal root ganglia) and barrier tissues. There are eight related receptors in this class that are expressed in humans, of which only four have readily identifiable orthologs in other species (i.e., MRGPR D, E, F, and G). Based on homology, the other four receptors (MRGPR X1, X2, X3, and X4) do not have a single ortholog in non-human species. Among rodent receptors, mouse mrgprb2 and rat mrgprb3 correspond functionally to human MRGPRX2 on mast cells.

[0021] "MRGPRX2" (also referred to as "MRGX2") or "MGRG3" refers to a member of the MRGPR family that is expressed on mast cells and is capable of mediating IgE-independent activation (e.g., mast cell degranulation) in response to ligand binding. An exemplary human MRGPRX2 amino acid sequence is shown in Uniprot Q96LB1.

[0022] "Effective amount" refers to the amount of a given agent sufficient to achieve a desired effect in a subject treated with the agent. Ideally, an effective amount of an agent is an amount sufficient to inhibit or treat a disease without causing significant toxicity in a subject. The effective amount of an agent will depend on the subject being treated, the severity of the ailment, and the mode of administration of the pharmaceutical composition. In light of the present disclosure, one skilled in the art will appreciate methods of determining an effective amount of a disclosed compound sufficient to achieve a desired effect in a subject.

[0023] "Alkyl" means a saturated or unsaturated straight or branched chain alkyl group having 1 to 8 carbon atoms, in some embodiments 1 to 6 carbon atoms, in some embodiments 1 to 4 carbon atoms, and in some embodiments 1 to 3 carbon atoms. Examples of saturated straight chain alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl. Examples of branched chain alkyl groups include, but are not limited to, isopropyl, isobutyl, sec-butyl, tert-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl. Unsaturated alkyl groups include alkenyl and alkynyl groups as defined below.

[0024] "Alkenyl" means a straight or branched alkenyl group having 2 to 8 carbon atoms, in some embodiments 2 to 6 carbon atoms, in some embodiments 2 to 4 carbon atoms, and in some embodiments 2 to 3 carbon atoms. An alkenyl group is an unsaturated hydrocarbon containing at least one carbon-carbon double bond. Examples of lower alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, and hexenyl.

[0025] "Alkynyl" means a straight or branched chain alkynyl group having 2 to 8 carbon atoms, in some embodiments 2 to 6 carbon atoms, in some embodiments 2 to 4 carbon atoms, and in some embodiments 2 to 3 carbon atoms. Alkynyl is an unsaturated hydrocarbon containing at least one carbon-carbon triple bond. Examples of alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, and hexynyl.

[0026] "Halo" or "halogen" refers to fluorine, chlorine, bromine and iodine.

[0027] "Hydroxyl" refers to -OH.

[0028] "Cyano" refers to -CN.

[0029] Amino refers to -NH2, -NHalkyl or N(alkyl)2, wherein alkyl is as defined above. Examples of amino include, but are not limited to, -NH2, -NHCH3, -N(CH3)2, and the like.

[0030] "Haloalkyl" refers to an alkyl group as defined above in which one or more hydrogen atoms are replaced by halogen. Examples of lower haloalkyl groups include, but are not limited to, -CF3, -CHF2, and the like.

[0031] "Alkoxy" refers to an alkyl group as defined above attached through an oxygen atom (ie, -O-alkyl). Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, n-butoxy, isopropoxy, sec-butoxy, tert-butoxy, and the like.

[0032] "Haloalkoxy" refers to a haloalkyl group as defined above attached through an oxygen atom (ie, -O-haloalkyl). Examples of lower haloalkoxy groups include, but are not limited to, -OCF3 and the like.

[0033] "Cycloalkyl" refers to an alkyl group forming a ring structure, which may be substituted or unsubstituted, wherein the ring is fully saturated, partially unsaturated or fully unsaturated, wherein if unsaturated, the conjugation of the π electrons in the ring does not produce aromaticity. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. In some embodiments, the cycloalkyl group has 3 to 8 ring members, while in other embodiments, the number of ring carbon atoms is in the range of 3 to 5, 3 to 6 or 3 to 7. Cycloalkyl further includes polycyclic cycloalkyl groups, such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl and carenyl, and condensed rings, such as, but not limited to, decahydronaphthyl, etc.

[0034] "Aryl" is a cyclic aromatic hydrocarbon that does not contain heteroatoms. Representative aryl groups include, but are not limited to, phenyl, azulenyl, heptadenyl, biphenyl, indenyl, fluorenyl, phenanthrenyl, triphenylene, pyrenyl, naphthacenyl, chrysenyl, biphenylene, anthracenyl, and naphthyl. In some embodiments, aryl contains 6 to 14 carbons in the ring portion of the group. The terms "aryl" and "aryl group" include fused rings, wherein at least one ring but not necessarily all rings are aromatic, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, etc.). In one embodiment, aryl is phenyl or naphthyl, and in another embodiment, aryl is phenyl.

[0035] "Carbocycle" refers to an alkyl group forming a ring structure, which may be substituted or unsubstituted, wherein the ring is fully saturated, partially unsaturated, or fully unsaturated, wherein if unsaturation is present, the conjugation of the π electrons in the ring may produce aromaticity. In one embodiment, the carbocycle comprises a cycloalkyl group as defined above. In another embodiment, the carbocycle comprises an aryl group as defined above.

[0036] "Heterocycle" refers to aromatic and non-aromatic ring moieties containing 3 or more ring members, one or more of which are heteroatoms, such as, but not limited to, N, O, S, or P. In some embodiments, heterocyclyl groups contain 3 to 20 ring members, while other such groups have 3 to 15 ring members. At least one ring contains heteroatoms, but each ring in a polycyclic system need not contain heteroatoms. For example, both dioxolanyl rings and benzodioxolanyl ring systems (methylenedioxyphenyl ring systems) are heterocyclyl groups within the meaning of this document.

[0037] Heterocyclyl also includes fused ring species, including fused ring species with fused aromatic and non-aromatic groups. Heterocyclyl also includes polycyclic systems containing heteroatoms such as but not limited to quinuclidine, and also includes heterocyclyl with substituents, including but not limited to alkyl, halo, amino, hydroxy, cyano, carboxyl, nitro, thio or alkoxy, bonded to one of the ring members. Heterocyclyl as defined herein can be heteroaryl or a partially or fully saturated cyclic group containing at least one ring heteroatom. Heterocyclyl groups include, but are not limited to, pyrrolidinyl, furanyl, tetrahydrofuranyl, dioxolanyl, piperidinyl, piperazinyl, morpholinyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thienyl, benzothienyl, benzofuranyl, dihydrobenzofuranyl, indolyl, dihydroindolyl, azaindolyl, indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl.

[0038] In one embodiment, the heterocyclyl group comprises a heteroaryl group.

[0039] "Heteroaryl" refers to an aromatic ring moiety containing 5 or more ring members, one or more of which are heteroatoms such as, but not limited to, N, O, and S. Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazyl, pyrazinyl, pyrimidinyl, thienyl, triazolyl, tetrazolyl, triazinyl, thiazolyl, thienyl, oxazolyl, isoxazolyl, benzothienyl, benzofuranyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolyl, isoquinolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, quinoxalinyl, and quinazolinyl. The terms "heteroaryl" and "heteroaryl group" include fused ring compounds, such as those in which at least one ring, but not necessarily all rings, are aromatic, including tetrahydroquinolinyl, tetrahydroisoquinolinyl, indolyl and 2,3-dihydroindolinyl.

[0040] "Isomer" is used herein to encompass all chiral, diastereoisomer or racemic forms (also referred to as stereoisomers, as opposed to structural or positional isomers) of a structure, unless a specific stereochemistry or isomeric form is specifically indicated. Such compounds may be optical isomers enriched or resolved at any or all asymmetric atoms to any degree of enrichment, as is apparent from the diagrams. Both racemic and diastereomeric mixtures, as well as individual optical isomers, may be synthesized to be substantially free of their enantiomers or diastereomeric partners, and these are within the scope of certain embodiments of the invention. Isomers resulting from the presence of chiral centers include a pair of non-superimposable isomers referred to as "enantiomers". A single enantiomer of a pure compound is optically active (i.e., it is capable of rotating the plane of plane polarized light and is designated as R or S).

[0041] "Isolated optical isomers" means compounds that have been substantially purified from the corresponding optical isomers of the same formula. For example, the purity of the isolated isomers can be at least about 80%, at least 80%, or at least 85% by weight. In other embodiments, the purity of the isolated isomers is at least 90%, or at least 98%, or at least 99% by weight.

[0042] "Substantially enantiomeric or diastereomeric" purity refers to the level of enantiomeric or diastereomeric enrichment of one enantiomer relative to the other enantiomer or diastereomer of at least about 80%, and more specifically greater than 80%, 85%, 90%, 95%, 98%, 99%, 99.5% or 99.9%.

[0043] The terms "racemate" and "racemic mixture" refer to an equal mixture of two enantiomers. A racemate is labeled "(±)" because it is optically inactive (i.e., does not rotate plane-polarized light in either direction because its constituent enantiomers cancel each other out). All compounds with an asterisk (*) adjacent to a tertiary or quaternary carbon are optically active isomers that can be purified from the corresponding racemate and / or synthesized by appropriate chiral synthesis.

[0044] A "hydrate" is a compound that exists in association with water molecules. The association may contain a stoichiometric amount of water, such as a monohydrate or a dihydrate, or may contain a random amount of water. As used herein, "hydrate" refers to a solid form; in other words, a compound in aqueous solution may be hydrated but is not a hydrate as the term is used herein.

[0045] "Solvates" are similar to hydrates, except that a solvent other than water is present. For example, methanol or ethanol can form "alcoholates," which likewise can be stoichiometric or non-stoichiometric. As used herein, "solvate" refers to a solid form; in other words, a compound in a solvent solution, while solvated, is not a solvate as the term is used herein.

[0046] "Isotope" refers to an atom with the same number of protons but different numbers of neutrons, and isotopes of compounds of structure (I) include any such compounds in which one or more atoms are replaced by isotopes of the atom. For example, carbon 12 is the most common form of carbon, with six protons and six neutrons, while carbon 13 has six protons and seven neutrons, and carbon 14 has six protons and eight neutrons. Hydrogen has two stable isotopes, deuterium (one proton and one neutron) and tritium (one proton and two neutrons). Although fluorine has multiple isotopes, fluorine-19 has the longest lifetime. Therefore, isotopes of compounds of structure (I) include, but are not limited to, compounds of structure (I) below: wherein one or more carbon 12 atoms are replaced by carbon-13 and / or carbon-14 atoms, wherein one or more hydrogen atoms are replaced by deuterium and / or tritium, and / or wherein one or more fluorine atoms are replaced by fluorine-19.

[0047] "Salt" generally refers to an organic compound in ionic form, such as a carboxylic acid or an amine, combined with a counterion. For example, a salt formed between an acid in anionic form and a cation is called an "acid addition salt." Conversely, a salt formed between a base in cationic form and an anion is called a "base addition salt."

[0048] The term "pharmaceutically acceptable" refers to a pharmaceutical agent that has been approved for human use and is generally non-toxic. For example, the term "pharmaceutically acceptable salt" refers to a non-toxic inorganic or organic acid and / or base addition salt (see, e.g., Lit et al., Salt Selection for Basic Drugs, Int. J. Pharm., 33, 201-217, 1986) (the document is incorporated herein by reference).

[0049] The pharmaceutically acceptable base addition salts of the compounds of the present invention include, for example, metal salts, including alkali metal salts, alkaline earth metal salts and transition metal salts, such as calcium salts, magnesium salts, potassium salts, sodium salts and zinc salts. Pharmaceutically acceptable base addition salts also include organic salts formed from basic amines, for example, N, N'dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.

[0050] Pharmaceutically acceptable acid addition salts can be prepared from inorganic acids or from organic acids. Examples of inorganic acids include hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, sulfuric acid and phosphoric acid. Suitable organic acids can be selected from aliphatic acids, alicyclic acids, aromatic acids, aromatic aliphatic acids, heterocyclic acids, carboxylic acids, and sulfonic acids, examples of which include formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, gluconic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, glucuronic acid, maleic acid, fumaric acid, pyruvic acid, aspartic acid, glutamic acid, benzoic acid, anthranilic acid, 4-hydroxybenzoic acid, phenylacetic acid, mandelic acid, hippuric acid, malonic acid, oxalic acid, pamoic acid (pamoic acid), methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, pantothenic acid, trifluoromethanesulfonic acid, 2-hydroxyethanesulfonic acid, p-toluenesulfonic acid, sulfanilic acid, cyclohexylaminosulfonic acid, stearic acid, alginic acid, β-hydroxybutyric acid, salicylic acid, galactonic acid and galacturonic acid.

[0051] The compounds of the present disclosure (i.e., compounds of structure (I) and embodiments thereof) or pharmaceutically acceptable salts thereof may contain one or more centers of geometric asymmetry, and may therefore give rise to enantiomers, diastereomers and other stereoisomeric forms, which are defined in terms of absolute stereochemistry as (R)- or (S)- or (D)- or (L)- of an amino acid. Thus, the embodiments encompass all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)- or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as chromatography and fractional crystallization. Conventional techniques for preparing / isolating individual enantiomers include chiral synthesis from suitable optically pure precursors or resolution of the racemate (or racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also included.

[0052] Although pharmaceutically unacceptable salts are generally not useful as medicaments, such salts may be useful, for example, as intermediates in the synthesis of compounds of structure (I) (eg, purification thereof by recrystallization).

[0053] As used herein, the phrase "MRGPRX2-dependent condition" means a condition in which activation, oversensitization or desensitization of MRGPRX2 or its orthologs by natural or synthetic ligands triggers, mediates, maintains or enhances a pathological condition. For example, some cationic peptidergic drugs are known to cause pseudoallergic reactions in patients in which MRGPRX2 is sensitive to (or activated by) secretagogues, cationic peptidergic drugs (including icatibant, leuprolide or ganirelix), neutral and anionic peptidergic drugs (e.g., exenatide, glucagon, liraglutide, enfuvirtide, colistimethate), nonsteroidal agonists (atracurium, mivacurium), nonsteroidal antagonist drugs, neuropeptides and antimicrobial peptides. In addition, overexpression of MRGPRX2 and / or overactivation of MRGPRX2 can also make mast cells more susceptible to activation by endogenous and / or exogenous ligands. Without being limited by theory, it is understood that by regulating MRGPRX2, pseudoallergic reactions, itching, pain, inflammatory or autoimmune disorders can be alleviated.

[0054] In some embodiments, MRGPRX2-dependent conditions are conditions caused by IgE-independent activation of MRGPRX2 or its orthologs. IgE-independent activation of MRGPRX2 can induce mast cell degranulation. For example, IgE-independent mast cell activation is associated with some chronic urticaria and other mast cell-mediated conditions that are unresponsive to current anti-IgE or antihistamine therapies. Therefore, the compounds of the present disclosure can be used to treat MRGPRX2-dependent conditions caused by IgE-independent activation of MRGPRX2, and will benefit from regulating MRGPRX2.

[0055] In some embodiments, the MRGPRX2-dependent condition is an itch-related condition, a pain-related condition, a cancer-related condition, a pseudoallergic reaction, or an autoimmune or inflammatory disorder in a human or other mammal.

[0056] As used herein, the phrase "pseudoallergic reaction" refers to an IgE-independent allergic reaction, characterized in that histamine release, inflammation, airway constriction or any combination thereof. Pseudoallergic reactions may be anaphylactic reactions. Pseudoallergic reactions may be caused by a series of cationic substances (collectively referred to as alkaline secretagogues, comprising inflammatory peptides and drugs associated with allergic-type reactions). Therefore, in one embodiment, methods of the present invention are provided to treat pseudoallergic reactions, such as pseudoallergic reactions caused by secretagogues, cationic peptide drugs, anionic peptide drugs, neutral peptide drugs, nonsteroidal antagonist drugs, neuropeptides and antimicrobial peptides. In one embodiment, the pseudoallergic reaction is caused by the following: MCD peptide, substance P, VIP, PACAP, dynorphin, somatostatin, compound 48 / 80, cortistatin-14, wasp venom, meletin, antimicrobial peptides, ciprofloxacin, vancomycin, leuprolide, goserelin, histrelin, triptorelin, cetrorelix, ganirelix, degarelix, octreotide, lanreotide, pasireotide, sermorelin, tesamorelin, icatibant, glatiramer acetate The drugs include tadalafil acetate, teriparatide, pramlintide, bleomycin, exenatide, glucagon, liraglutide, enfuvirtide, colistimethate, succinylcholine, tubocurarine, atracurium, mevicurium, and rocuronium.

[0057] As used herein, the phrase "itch-related condition" means itch associated with any condition (including acute itch and chronic itch). The itch sensation can originate, for example, from the peripheral nervous system (e.g., cutaneous or neuropathic itch) or from the central nervous system (e.g., neuropathic, neurogenic or psychogenic itch). Thus, in one embodiment, the methods of the invention are provided for treating pruritus-related conditions such as chronic pruritus; contact dermatitis; allergic blepharitis; allergic reactions; allergic drug reactions; anaphylactic shock; anemia; atopic dermatitis; bullous pemphigoid; candidiasis; varicella; end-stage renal failure; hemodialysis; cholestatic pruritus; chronic urticaria; contact dermatitis, dermatitis herpetiformis; diabetes; drug allergy, dry skin; dyshidrotic dermatitis; atopic eczema; eosinophilic fasciitis; epidermolysis bullosa; erythrasma; food allergies; folliculitis; fungal skin infections; hemorrhoids; herpes; HIV infection; Hodgkin's disease disease; hyperthyroidism; allergy to iodinated contrast dye; iron deficiency anemia; kidney disease; leukemia, porphyria; lymphoma; mast cell activation syndrome, malignancy; mastocytosis; multiple myeloma; neurodermatitis; onchocerciasis; Paget's disease; pediculosis; polycythemia vera; Prurigo nodularis; lichen planus; lichen sclerosus; pruritus anus; pseudoanaphylaxis; pseudorabies; psoriasis; rectal prolapse; sarcoid granuloma; scabies; schistosomiasis; scleroderma, severe stress, stasis dermatitis; swimmer's itch; thyroid disease; tinea cruris; uremic pruritus; rosacea; amyloidosis cutanea; scleroderma; acne; wound healing; burn healing; ocular pruritus; and urticaria.

[0058] As used herein, the phrase "pain-related condition" means any pain caused by a medical condition. Thus, in one embodiment, the methods of the present invention are provided for treating pain-related conditions such as acute pain, advanced prostate cancer, AIDS-related pain, ankylosing spondylitis, arachnoiditis, arthritis, arthrofibrosis, ataxic cerebral palsy, autoimmune atrophic gastritis, avascular necrosis, back pain, Behcet's Disease (syndrome), burning mouth syndrome, bursitis, cancer pain, carpal tunnel, cauda equina syndrome, central pain syndrome, cerebral palsy, cervical spinal stenosis, Charcot-Marie-Tooth (CMT) disease, chronic fatigue syndrome (CFS), chronic functional abdominal pain (CFAP), chronic pain, chronic pancreatitis, chronic pelvic pain syndrome, collapsed lung (pneumothorax), complex regional pain syndrome (RSD), corneal neuropathic pain, Crohn's Disease, degenerative disc disease, toothache, Dercum's Disease), Dermatomyositis, Diabetic Peripheral Neuropathy (DPN), Dystonia, Ehlers-Danlos Syndrome (EDS), Endometriosis, Eosinophilia-Myalgia Syndrome (EMS), Erythromelalgia, Fibromyalgia, Gout, Headache, Herniated Disc, Hydrocephalus, Intercostal Neuralgia, Interstitial Cystitis, Irritable Bowel Syndrome (IBS), Juvenile Dermatositis, Knee Injury, Leg Pain, Lumbar Pain-Hematuria Syndrome, Lupus, Lyme Disease, Medullary Sponge Kidney (MSK), Meralgia Paresthesia, Mesothelioma, Migraine, Musculoskeletal Pain, Myofascial Pain, Myositis, Neck Pain, Neuropathic Pain, Occipital Neuralgia, Osteoarthritis, Paget's Disease, Parsonage Turner Syndrome Syndrome), pelvic pain, periodontitis pain, peripheral neuropathy, phantom limb pain, nerve compression, polycystic kidney disease, polymyalgia rheumatica, polymyositis, porphyria, post-herniorrhagic pain syndrome, post-mastectomy, post-operative pain, pain syndrome, post-stroke pain, post-thoracotomy pain syndrome, post-herpetic neuralgia (shingles), post-polio syndrome, primary lateral sclerosis, psoriatic arthritis, pudendal neuralgia, radiculopathy, Raynaud's Disease, rheumatoid arthritis (RA), sacroiliac joint dysfunction, sarcoidosis, Scheuemann's Kyphosis Disease, sciatica, scoliosis, shingles,Herpes Zoster, Sjogren's Syndrome, Spasmodic Torticollis, Sphincter of Oddi Dysfunction, Spinocerebellar Ataxia (SCA Ataxia), Spinal Cord Injury, Spinal Stenosis, Syringomyelia, Tarlov Cysts, Transverse Myelitis, Trigeminal Neuralgia, Neuropathic Pain, Ulcerative Colitis, Vascular Pain, or Vulvar Pain.

[0059] As used herein, the term "autoimmune disorder" or "inflammatory disorder" means a disease or disorder caused by and / or directed against an individual's own tissues or organs, or a co-segregation or manifestation thereof, or a condition resulting therefrom. Typically, there may be clinical and laboratory markers of various autoimmune diseases, including but not limited to hypergammaglobulinemia, high levels of autoantibodies, antigen-antibody complex deposits in tissues, clinical benefit of corticosteroid or immunosuppressive therapy, and lymphocyte aggregates in affected tissues. Thus, in one embodiment, the methods of the present invention are provided for treating autoimmune disorders such as chronic inflammation, mast cell activation syndrome, multiple sclerosis, Steven Johnson's syndrome), toxic epidermal necrosis, appendicitis, bursitis, cutaneous lupus, colitis, cystitis, dermatitis, phlebitis, reflex sympathetic dystrophy / complex regional pain syndrome (rsd / crps), rhinitis, tendinitis, tonsillitis, acne vulgaris, sinusitis, rosacea, psoriasis, graft-versus-host disease, reactive airway disorder, asthma, airway infection, allergic rhinitis, autoinflammatory disease, celiac disease, chronic prostatitis, diverticulitis, glomerulonephritis, hidradenitis suppurativa, allergies, intestinal disorders, epithelial intestinal disorders, inflammatory bowel disease, intestinal Irritable syndrome, Crohn's disease, ulcerative colitis, lupus erythematosus, interstitial cystitis, otitis, pelvic inflammatory disease, endometrial pain, reperfusion injury, rheumatic fever, rheumatoid arthritis, sarcoidosis, transplant rejection, psoriasis, lung inflammation, chronic obstructive pulmonary disease, permanent sputum eosinophilia, eosinophilic leukemia, eosinophilic esophagitis, eosinophilic gastritis, eosinophilic duodenitis, eosinophilic gastroenteritis, mast cell gastrointestinal disease, eosinophilic syndrome, aspirin-exacerbated respiratory disease respiratory disease), nasal polyposis, chronic sinusitis, antibody-dependent cell-mediated cytotoxicity, neurofibromatosis, schwannomatosis, tubulointerstitial nephritis, glomerulonephritis, diabetic nephropathy, allograft rejection, amyloidosis, renal vascular ischemia, reflux nephropathy, polycystic kidney disease, liver fibrosis / cirrhosis, autoimmune liver disease, biliary atresia, acute and chronic hepatitis B and C viruses, liver tumors and liver cancer, alcoholic liver disease, polycystic liver disease, hepatobiliary carcinoma, neuromyelitis optica, cardiovascular disease, inflammation induced by bacterial or viral infection, inflammation associated with SARS-CoV-2 infection or its variants and coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome, pneumonia, long / long-term / chronic COVID, post-acute sequelae of COVID-19 (PASC), myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS "brain fog"), and vasculitis.

[0060] As used herein, the phrase "cancer-related condition" means any disease caused by the proliferation of malignant cancer cells. Thus, in one embodiment, the methods of the invention are provided for treating cancer / tumor-related conditions such as adenoid cystic carcinoma, adrenal tumors, amyloidosis, anal cancer, appendix cancer, astrocytoma, ataxia-telangiectasia, Beckwith-Wiedemann syndrome, bile duct cancer, birt-hogg-dube syndrome, bone cancer, brain stem glioma, brain tumor, breast cancer (inflammatory, metastatic, male), prostate cancer, basal cell carcinoma, melanoma, colon cancer, colorectal cancer, bladder cancer, kidney cancer, lacrimal gland cancer, laryngeal and hypopharyngeal cancer, lung cancer (non-small cell, small cell), leukemia (acute lymphoblastic, acute lymphocytic, acute myeloid, B-cell prolymphocytic, chronic lymphocytic, chronic myeloid, chronic T-cell lymphocytic, eosinophilic), liver cancer, Li-Fraumeni syndrome (Li-Fraumeni syndrome), lymphoma (Hodgkin and non-Hodgkin), Lynch syndrome, mastocytosis, medulloblastoma, meningioma, mesothelioma, multiple endocrine neoplasms, multiple myeloma, MUTYH-associated polyposis, myelodysplastic syndrome, nasal and sinus cancer, neuroblastoma, neuroendocrine tumors, neurofibromatosis, penile cancer, parathyroid cancer, ovarian fallopian tube and peritoneal cancer, osteosarcoma, pituitary tumor, pleuropulmonary blastoma, oral and oropharyngeal cancer, thyroid cancer, uterine cancer, pancreatic cancer, Carney complex, brain and spinal cord cancer, cervical cancer, cowden syndrome, craniopharyngioma, desmoid tumor, desmoplastic infantile ganglioglioma, ependymoma, esophageal cancer, Ewing sarcoma. sarcoma), eye cancer, eyelid cancer, familial adenomatous polyposis, familial GIST, familial malignant melanoma, familial pancreatic cancer, gallbladder cancer, gastrointestinal stromal tumors, germ cell tumors, gestational trophoblastic disease, head and neck cancer, hereditary breast cancer and ovarian cancer, hereditary diffuse gastric cancer, hereditary leiomyomatosis and renal cell cancer, hereditary pancreatitis, hereditary papillary renal cancer, hereditary mixed polyposis syndrome, HIV / AIDS-related cancers, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, Kaposi sarcoma, small intestine cancer, stomach cancer, testicular cancer, thymoma and thymic cancer, thyroid cancer, vaginal cancer, vulvar cancer, Werner syndrome, and Xeroderma pigmentosum.

[0061] As used herein, the term "administering" refers to providing a compound as described herein or a pharmaceutical composition comprising the compound. The compound or composition can be administered to a subject by another person, or it can be self-administered by the subject. Non-limiting examples of routes of administration are oral, parenteral (e.g., intravenous), or topical.

[0062] As used herein, the term "treatment" refers to the intervention of signs or symptoms that improve a disease or pathological condition. As used herein, the terms "treatment", "treat" and "treating" with respect to a disease, pathological condition or symptom also refer to any observable beneficial effect of treatment. Beneficial effects can be demonstrated, for example, by the delayed onset of clinical symptoms of a disease in susceptible subjects, a reduction in the severity of some or all clinical symptoms of the disease, a slowing of the progression of the disease, a reduction in the number of recurrences of the disease, an improvement in the overall health or well-being of the subject, or by other parameters that are well known in the art that are specific to a particular disease. Preventive treatment is the treatment applied to a subject who does not show signs of disease or only shows early signs, with the aim of reducing the risk of pathology. Therapeutic treatment is the treatment applied to a subject after the signs and symptoms of the disease appear.

[0063] As used herein, the term "subject" refers to an animal (e.g., a mammal such as a human, dog, or horse), and thus veterinary use is an application specifically contemplated herein. The subject to be treated according to the methods described herein can be a subject who has been diagnosed with a MRGPRX2-dependent condition or a MRGPRX2 ortholog-dependent condition (such as pseudoallergic reactions, itch-related conditions, pain-related conditions, cancer-related conditions, inflammatory or autoimmune disorders). Diagnosis can be performed by any method or technique known in the art. Those skilled in the art will understand that the subject to be treated according to the present disclosure may have undergone standard testing, or may have been identified as being at risk due to the presence of one or more risk factors associated with the disease or condition without examination. The term "patient" can be used interchangeably with the term "subject". A subject can refer to an adult or pediatric subject.

[0064] The Federal Food, Drug, and Cosmetic Act defines "pediatric" as subjects 21 years of age or younger at the time of diagnosis or treatment. Pediatric subpopulations are further characterized as: (i) neonates - birth to the first 28 days of life; (ii) infants - 29 days of age to less than 2 years of age; (iii) children - 2 years to less than 12 years of age; and (iv) adolescents - 12 to 21 years of age. Regardless of the definition, the approved regulatory labeling may contain language specifically modifying the scope of the pediatric population, e.g., pediatric patients up to 22 years of age, based on the susceptible patient population and clinical trial evaluations.

[0065] In another embodiment, the methods described herein for treating a subject suffering from a MRGPRX2-dependent condition (e.g., an itch-related condition, a pain-related condition, a pseudoallergic reaction, or an inflammatory or autoimmune disorder) further comprise administering to the subject a pharmaceutically effective amount of a second therapeutic agent. In one embodiment, the itch-related condition is a pseudoallergic condition.

[0066] In one embodiment, the second therapeutic agent is an antihistamine, such as an H1 receptor antagonist or an H2 receptor antagonist. In one embodiment, the second therapeutic agent is an H1 receptor antagonist antihistamine, such as levocetirizine, loratadine, fexofenadine, cetirizine, desloratadine, olopatadine, diphenhydramine, cyproheptadine or hydroxyzine pamoate. In one embodiment, the second therapeutic agent is an H2 receptor antagonist, such as cimetidine, nizatidine, ranitidine or famotidine. In one embodiment, the second therapeutic agent is a leukotriene receptor antagonist or a leukotriene synthesis inhibitor, such as montelukast, zafirlukast, pranlukast, or a 5-lipoxygenase inhibitor (e.g., zileuton, hypericumperforatum). In one embodiment, the second therapeutic agent is an immunomodulator, such as omalizumab or immunoglobulin therapy. In one embodiment, the second therapeutic agent is a corticosteroid, such as hydrocortisone, cortisone, ethamethasoneb, triamcinolone, prednisone, prednisone, or fludrocortisone. In one embodiment, the second therapeutic agent is a tricyclic antidepressant that can relieve itching, such as doxepin, amitriptyline, or nortriptyline. In one embodiment, the second therapeutic agent is an anti-inflammatory drug, such as dapsone, sulfasalazine, hydroxycholoroquine, or colchicine. In one embodiment, the second therapeutic agent is an immunosuppressant, such as cyclosporine, methotrexate, mycophenolic acid, or tacromilus.

[0067] The second therapeutic agent can be administered simultaneously, separately or sequentially with the compound of the present disclosure. If administered simultaneously, the second therapeutic agent and the compound of the present disclosure can be administered in separate dosage forms or in the same dosage form.

[0068] In another embodiment, a method for treating a subject with an itch-related condition is provided, the method comprising administering to the subject a pharmaceutically effective amount of a compound of structure (I) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, or a pharmaceutical composition thereof. In one embodiment, the itch-related condition is urticaria, pruritus, atopic dermatitis, dry skin, psoriasis, contact dermatitis or eczema. In another embodiment, a method for treating a subject with an inflammation or autoimmune-related condition is provided, the method comprising administering to the subject a pharmaceutically effective amount of a compound of structure (I) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, or a pharmaceutical composition thereof. In one embodiment, the inflammation or autoimmune-related condition is sinusitis, asthma, rosacea or endometriosis.

[0069] In another embodiment, a method of treating a subject suffering from a pain-related condition is provided, the method comprising administering to the subject a pharmaceutically effective amount of a compound having structure (I) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, or a pharmaceutical composition thereof. In one embodiment, the pain-related condition is chronic pelvic pain syndrome, endometriosis pain, fibromyalgia, migraine or postoperative pain.

[0070] Compound

[0071] As described in detail above, the present disclosure provides compounds that show significant activity as MRGPRX2 antagonists. Therefore, one embodiment provides a compound having the following structure (I):

[0072]

[0073] or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein:

[0074] R 1 Cycloalkyl, aryl, heterocyclic, -(CH2) n Q, -CHQR, -(CH=CH) n Q or -CQ(R)2, where Q is C 1-6alkyl, aryl, cycloalkyl, heterocyclyl, -OR, -CH2C(O)OR, -C(O)OR, -C(O)NHR, -OC(O)R, -CX3, -CX2H, -C(X)H2, -CN, -N(R)2, -N(R)C(O)R, -N(R)C(O)OR, or -N(R)S(O)2R, and wherein R 1 and / or Q is optionally replaced by one or more R q replace;

[0075] Each R is independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R)2, alkylamino, -(CH2) n R', X, aryl, cycloalkyl, heteroaryl or heterocyclyl, or two R groups together with the atoms to which they are attached form a double bond, a carbocycle or a heterocycle, wherein R is optionally substituted with one or more of X, haloalkyl or haloalkoxy;

[0076] Each R q Independently C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, oxo, -OR, -SR, -O(CH2) n R, -OX3, -OX2H, -O(X)H2, -C(O)OR, -C(O)R, -OC(O)R, X, -CX3, -CX2H, -C(X)H2, -CN, - N(O)2, =NH, -N(R)2, -N(R)C(O)R, -N(R)S(O)2R, S(O)2R, -B(OR)2, -C(H)Q'R, -O(CH2) n Q' or -(CH2) n Q', where Q' is C 1-6 alkyl, aryl, cycloalkyl, heterocyclyl, OR', -C(O)OR', -OC(O)R', X, -CX3, -CX2H, -C(X)H2, -C(CH3)2X, -C(CH3)2OH, -CN, -N(R')2, -N(R')C(O)R' or -N(R')S(O)2R', and wherein R q and / or Q' is optionally replaced by one or more R Y replace;

[0077] R 2 , R 3 , R 4 , R 5 and R 6 Independently H, C 1-6 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, -OR, -C(O)OR, -OC(O)R, X, -CX3, -CX2H, -C(X)H2, C(X)2R, -C(X)(R)2, -CN, -N(R)2, -N(R)C(O)R, -N(R)S(O)2R or S(O)2R;

[0078] Each R x Independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, -OR, -C(O)OR, -OC(O)R, X, -CX3, -CX2H, -C(X)H2, -CN, -N(R)2, -N(R)C(O)R, -N(R)S(O)2R or S(O)2R, or R X With R 1 together to form a heterocyclic ring;

[0079] Each R Y Independently C 1-6 Alkyl, cycloalkyl, oxo, X, -CX3, -OR or -C(O)OR;

[0080] W is N or CR w ;

[0081] Z is N or CR z ;

[0082] R w It is H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocyclyl;

[0083] R z It is H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocyclyl;

[0084] Each R' is independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 alkynyl, -OR, aryl, cycloalkyl, heteroaryl or heterocyclyl;

[0085] each X is independently F, Cl, Br or I; and

[0086] Each n is independently 0, 1, 2, 3, 4 or 5.

[0087] In some embodiments, R is C optionally substituted with one or more of X, haloalkyl, or haloalkoxy. 1-6 alkyl.

[0088] In yet another embodiment, provided is a compound of formula (1a):

[0089]

[0090] or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein:

[0091] R 1a Is a cycloalkyl, -(CH2) n Q, -CHQR or -CQ(R)2;

[0092] Q is cycloalkyl, -OR, -C(O)OR, -OC(O)R, -CX3, -CX2H, -C(X)H2, -CN, -N(R)2, -N(R)C(O)R, or -N(R)S(O)2R; and

[0093] Where R 1a and / or Q is optionally replaced by one or more R q replace.

[0094] In one embodiment, R 1a It is a cycloalkyl group.

[0095] In some embodiments, R 1a and / or Q is replaced by one or more R q In other embodiments, the substituent is selected from C 1-6 Alkyl, C 2-6 Alkenyl, aryl, cycloalkyl, heterocyclic, -OR, -O(CH2) n R, -OX3, -OX2H, -O(X)H2, -C(O)OR, -C(O)R, -OC(O)R, n Q', where Q' is C 1-6 alkyl, aryl, cycloalkyl, heterocyclyl, OR', -C(O)OR', -OC(O)R', X, -CX3, -CX2H, -C(X)H2, -CN, -N(R')2, -N(R')C(O)R', or -N(R')S(O)2R'. In yet other embodiments, the substituent is C 1-6 Alkyl, aryl, heterocyclic, -OR, -CN, -C(O)OR or -(CH2) n Q'.

[0096] In yet other embodiments, optionally one or more R q Replaced by R 1a Has one of the following structures:

[0097]

[0098] In yet other embodiments, R 4 and R 6 Independently C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 In some embodiments, R 6 is X, -CX3, -CX2H or -C(X)H2. In yet other embodiments, R 6 It is -CF3, -CF2H or CFH2.

[0099] In one embodiment, R x It's H.

[0100] In another embodiment, a compound of formula (1a) is provided, wherein W is N, and Z is CH. In yet another embodiment, a compound of formula (1a) is provided, wherein W is CH, and Z is N.

[0101] In one embodiment, a compound of formula (1b) is provided:

[0102]

[0103] or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein:

[0104] R 1b is aryl, -(CH2) n Q, -CHQR and -CQ(R)2,

[0105] wherein Q is aryl, -OR, -C(O)OR, -OC(O)R, -CX3, -CX2H, -C(X)H2, -CN, -N(R)2, -N(R)C(O)R or -N(R)S(O)2R, and

[0106] Where R 1b and / or Q is optionally replaced by one or more R q replace.

[0107] In one embodiment, R 1bIn another embodiment, R 1b It is phenyl.

[0108] In some embodiments, R 1b and / or Q is replaced by one or more R q In other embodiments, the substituent is selected from C 1-6 Alkyl, C 2-6 Alkenyl, aryl, cycloalkyl, heterocyclyl, -OR, -SR, -O(CH2) n R, -OX3, -OX2H, -O(X)H2, -C(O)OR, -C(O)R, -OC(O)R, X, -CX3, -CX2H, -C(X)H2 , -CN, -N(R)2, -N(R)C(O)R, -N(R)S(O)2R, S(O)2R, -B(OR)2, -C(H)Q'R or -(CH2) n Q', where Q' is C 1-6 alkyl, aryl, cycloalkyl, heterocyclyl, OR', -C(O)OR', -OC(O)R', X, -CX3, -CX2H, -C(X)H2, -CN, -N(R')2, -N(R')C(O)R' or -N(R')S(O)2R', and wherein R q and / or Q' is optionally replaced by one or more R Y replace.

[0109] In yet other embodiments, optionally one or more R q Replaced by R 1b Has one of the following structures:

[0110]

[0111]

[0112]

[0113] In yet other embodiments, R 4 and R 6 Independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, OR, -C(O)OR, -OC(O)R, X, -CX3, -CX2H, -C(X)H2, -CN, -N(R)2, -N(R)C(O)R, -N(R)S(O)2R or S(O)2R. In specific embodiments, R 6 is X, -CX3, -CX2H or -C(X)H2.

[0114] In some embodiments, R6 It is -CF3, -CF2H or CFH2.

[0115] In one embodiment, R x It's H.

[0116] In another embodiment, a compound of formula (1b) is provided, wherein W is N, and Z is CH. In yet another embodiment, a compound of formula (1b) is provided, wherein W is CH, and Z is N.

[0117] In one embodiment, a compound of formula (1c) is provided:

[0118]

[0119] or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein:

[0120] R 1c is a heterocyclic group, -(CH2) n Q, -CHQR or -CQ(R)2,

[0121] wherein Q is heterocyclyl, -OR, -C(O)OR, -OC(O)R, -CX3, -CX2H, -C(X)H2, -CN, -N(R)2, -N(R)C(O)R or -N(R)S(O)2R, and

[0122] Where R 1c and / or Q is optionally replaced by one or more R q replace.

[0123] In one embodiment, R 1c It is a heterocyclic group.

[0124] In another embodiment, the heterocyclyl group is an aromatic and non-aromatic ring moiety containing 3 or more ring members, one or more of which are heteroatoms, and wherein the heteroatoms are selected from N, O, S, or P.

[0125] In some embodiments, R 1c and / or Q is replaced by one or more R q replace.

[0126] In other embodiments, the substituent is selected from C 1-6 Alkyl, C 2-6 Alkenyl, aryl, cycloalkyl, heterocyclyl, -OR, -SR, -O(CH2) nR, -OX3, -OX2H, -O(X)H2, -C(O)OR, -C(O)R, -OC(O)R, X, -CX3, -CX2H, -C(X)H2, - CN, -N(O)2, =NH, -N(R)2, -N(R)C(O)R, -N(R)S(O)2R, S(O)2R, -C(H)Q'R or -(CH2) n Q', where Q' is C 1-6 alkyl, aryl, cycloalkyl, heterocyclyl, OR', -C(O)OR', -OC(O)R', X, -CX3, -CX2H, -C(CH3)2X, -C(CH3)2OH, -C(X)H2, -CN, -N(R')2, -N(R')C(O)R' or -N(R')S(O)2R', and wherein R q and / or Q' is optionally replaced by one or more R Y replace.

[0127] In some embodiments, one or more R q Replaced by R 1c Has one of the following structures:

[0128]

[0129]

[0130]

[0131]

[0132]

[0133]

[0134]

[0135]

[0136]

[0137] In yet other embodiments, R 4 and R 6 In each occurrence, it is independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, OR, -C(O)OR, -OC(O)R, X, -CX3, -CX2H, -C(X)H2, -CN, -N(R)2, -N(R)C(O)R, -N(R)S(O)2R or S(O)2R.

[0138] In a specific embodiment, R 6 is X, -CX3, -CX2H or -C(X)H2. In yet other embodiments, R 6 It is -CF3, -CF2H or CFH2.

[0139] In one embodiment, R x It's H.

[0140] In another embodiment, a compound of formula (1c) is provided, wherein W is N, and Z is CH. In yet another embodiment, a compound of formula (1c) is provided, wherein W is CH, and Z is N.

[0141] In one embodiment, a compound of formula (1d) is provided:

[0142]

[0143] or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein:

[0144] R 1d It is CQ(R)2,

[0145] Where Q is C 1-6 alkyl, aryl, cycloalkyl, heterocyclyl, -OR, -CH2C(O)OR, -C(O)OR, -C(O)NHR, -OC(O)R, -CX3, -CX2H, -C(X)H2, -CN, -N(R)2, -N(R)C(O)R, -N(R)C(O)OR, or -N(R)S(O)2R, and

[0146] Where R 1d and / or Q is optionally replaced by one or more R q replace.

[0147] In a specific embodiment, Q is selected from C 1-6 Alkyl, aryl, cycloalkyl, heterocyclyl and N(R)C(O)R.

[0148] In other embodiments, R is independently C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, alkylamino, -(CH2) n R', X, H, aryl, cycloalkyl or heterocyclyl.

[0149] In some embodiments, one or more R q Replaced by R 1d Has one of the following structures:

[0150]

[0151] In one embodiment, R 6 is X, -CX3, -CX2H or -C(X)H2. In yet other embodiments, R 6 It is -CF3, -CF2H or CFH2.

[0152] In one embodiment, R x It's H.

[0153] In another embodiment, a compound of formula (1d) is provided, wherein W is N, and Z is CH. In yet another embodiment, a compound of formula (1d) is provided, wherein W is CH, and Z is N.

[0154] In one embodiment, a compound of formula (1e) is provided:

[0155]

[0156] or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein:

[0157] R 1e Yes-CHQR,

[0158] Where Q is C 1-6 alkyl, aryl, cycloalkyl, heterocyclyl, -OR, -CH2C(O)OR, -C(O)OR, -C(O)NHR, -OC(O)R, -CX3, -CX2H, -C(X)H2, -CN, -N(R)2, -N(R)C(O)R, -N(R)C(O)OR, or -N(R)S(O)2R, and

[0159] Each R 1e and / or Q is optionally replaced by one or more R q replace.

[0160] In a specific embodiment, Q is selected from C 1-6 Alkyl, aryl, cycloalkyl, heterocyclyl, -N(R)C(O)R and -N(R)C(O)OR.

[0161] In other embodiments, R is independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, alkylamino, -(CH2) n R', X, aryl, cycloalkyl or heterocyclic.

[0162] In some embodiments, one or more R q Replaced by R 1e Has one of the following structures:

[0163]

[0164] In a specific embodiment, R 6 is X, -CX3, -CX2H or -C(X)H2. In yet other embodiments, R 6 It is -CF3, -CF2H or CFH2.

[0165] In one embodiment, R x It's H.

[0166] In another embodiment, a compound of formula (1e) is provided, wherein W is N, and Z is CH. In yet another embodiment, a compound of formula (1e) is provided, wherein W is CH, and Z is N.

[0167] In one embodiment, a compound of formula (1f) is provided:

[0168]

[0169] or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein:

[0170] R W or R z Independently C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 alkynyl, H, aryl, cycloalkyl, heteroaryl or heterocyclyl.

[0171] In a specific embodiment, R 6 is X, -CX3, -CX2H or -C(X)H2. In yet other embodiments, R 6 It is -CF3, -CF2H or CFH2.

[0172] In one embodiment, R w and R z Both are H.

[0173] In another embodiment, R x It's H.

[0174] In one embodiment, the compound is selected from any one of the compounds listed in the following table or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof.

[0175] surface

[0176] Representative compounds having structure (I)

[0177]

[0178]

[0179]

[0180]

[0181]

[0182]

[0183]

[0184]

[0185]

[0186]

[0187]

[0188]

[0189]

[0190]

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198]

[0199]

[0200]

[0201]

[0202]

[0203]

[0204]

[0205]

[0206]

[0207]

[0208]

[0209]

[0210]

[0211]

[0212]

[0213]

[0214]

[0215]

[0216]

[0217]

[0218]

[0219]

[0220]

[0221]

[0222]

[0223]

[0224]

[0225]

[0226]

[0227]

[0228]

[0229]

[0230]

[0231] In another embodiment, where applicable, representative compounds of structure (I) and formula (Ia) to (1f) include but are not limited to any of the following compounds listed by their IUPAC name and pharmaceutically acceptable salts, isomers, hydrates, solvates or isotopes thereof:

[0232] N-[(1R,3S)-3-{[8-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methoxybenzamide;

[0233] 4-methoxy-N-[(1R,3S)-3-{[3-(trifluoromethyl)isoquinolin-1-yl]amino}cyclohexyl]benzamide;

[0234] 4-methoxy-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0235] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methoxybenzamide;

[0236] 4-methoxy-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0237] N-[(1R,3S)-3-{[7-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methoxybenzamide;

[0238] N-[(1R,3S)-3-{[5-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methoxybenzamide;

[0239] 4-Fluoro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0240] N-[(1R,3S)-3-[(6-chloro-2-methylquinolin-4-yl)amino]cyclohexyl]-4-methoxybenzamide;

[0241] N-[(1R,3S)-3-[(2-cyanoquinolin-4-yl)amino]cyclohexyl]-4-methoxybenzamide;

[0242] N-[(1R,3S)-3-{[2-(difluoromethyl)quinazolin-4-yl]amino}cyclohexyl]-4-methoxybenzamide;

[0243] N-[(1R,3S)-3-{[3-cyano-6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methoxybenzamide;

[0244] 4-methoxy-N-[(1R,3S)-3-{[6-methoxy-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0245] 4-methoxy-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinazolin-4-yl]amino}cyclohexyl]benzamide;

[0246] N-[(1S,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methoxybenzamide;

[0247] N-[(1S,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methoxybenzamide;

[0248] N-[(1R,3R)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methoxybenzamide;

[0249] N-[(1R,3R)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methoxybenzamide;

[0250] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methoxybenzamide;

[0251] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0252] 4-Fluoro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinazolin-4-yl]amino}cyclohexyl]benzamide;

[0253] 4-methoxy-N-[(1R,3S)-3-{[5-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0254] 4-methoxy-N-[(1R,3S)-3-{[7-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0255] 4-{[(1S,3R)-3-(4-methoxybenzamido)cyclohexyl]amino}-2-(trifluoromethyl)quinoline-8-carboxylic acid methyl ester;

[0256] 4-methoxy-N-[(1R,3S)-3-[(naphthalen-1-yl)amino]cyclohexyl]benzamide;

[0257] 4-methoxy-N-[(1R,3S)-3-{[3-(trifluoromethyl)naphthalen-1-yl]amino}cyclohexyl]benzamide;

[0258] 4-methoxy-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-5-yl]amino}cyclohexyl]benzamide;

[0259] 4-methoxy-N-[(1R,3S)-3-{[3-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0260] N-[(1R,3S)-3-{[2-(difluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methoxybenzamide;

[0261] 2-methoxy-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0262] 2-Methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0263] 4-(Dimethylamino)-2-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0264] 3-cyano-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0265] Methyl 3-{[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}benzoate;

[0266] 2-Cyano-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0267] 4-cyano-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0268] 4-Chloro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0269] 3-Fluoro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0270] 2-Fluoro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0271] 2,2-Dimethyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]propanamide;

[0272] 4-Chloro-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0273] 4-cyano-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0274] 3-Fluoro-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0275] 3-Methoxy-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0276] 2-methyl-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0277] 2-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0278] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-methoxybenzamide;

[0279] 6-amino-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-3-carboxamide;

[0280] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(morpholine-4-carbonyl)benzamide;

[0281] 3-Methoxy-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0282] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-methylbenzamide;

[0283] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0284] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0285] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-4-carboxamide;

[0286] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-3-carboxamide;

[0287] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-2-carboxamide;

[0288] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]cyclopropanecarboxamide;

[0289] 2-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]propanamide;

[0290] 3-Methanesulfonamido-N-[(1R,3S)-3-[(2-methoxyquinolin-4-yl)amino]cyclohexyl]benzamide;

[0291] 3-phenyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]propanamide;

[0292] 3-(Dimethylamino)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0293] 4-(Dimethylamino)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0294] 2-Chloro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0295] 2-(Dimethylamino)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0296] 2-ethyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0297] 3-Chloro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0298] 3-Methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0299] 3-ethyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0300] 3-Acetamido-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0301] 4-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0302] 4-ethyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0303] Methyl 4-{[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}benzoate;

[0304] 4-Acetamido-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0305] 4-(4-methylpiperazin-1-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0306] 6-(Dimethylamino)-2-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-3-carboxamide;

[0307] 2-(Methylamino)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0308] 3-(Methylamino)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0309] 4-(Methylamino)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0310] 4-(Morpholin-4-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0311] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4H,5H,6H,7H-pyrazolo[1,5-a]pyridine-2-carboxamide;

[0312] 2-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]acetamide;

[0313] 1-(Pyrazin-2-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]cyclopropane-1-carboxamide;

[0314] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,5-a]pyridine-1-carboxamide;

[0315] 4-Benzyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]morpholine-3-carboxamide;

[0316] 2-[2-(Difluoromethoxy)-6-fluorophenyl]-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]acetamide;

[0317] 2-(5-methoxy-2-methyl-1H-indol-3-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]acetamide;

[0318] 5-cyano-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2H-indazole-3-carboxamide;

[0319] 3-[(4-methoxyphenyl)methoxy]-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,2-oxazole-5-carboxamide;

[0320] 4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0321] 7-(Benzyloxy)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-indole-3-carboxamide;

[0322] tert-Butyl 3-{[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}-1-oxa-2,7-diazaspiro[4.5]dec-2-ene-7-carboxylate;

[0323] 2-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyrazolo[1,5-a]pyrimidine-6-carboxamide;

[0324] 4-propyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,2,3-thiadiazole-5-carboxamide;

[0325] tert-Butyl (3S,4R)-3-(thiophen-3-yl)-4-{[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}pyrrolidine-1-carboxylate;

[0326] 4-[(Quinolin-2-yl)methoxy]-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0327] 2,6-Difluoro-3-(propane-1-sulfonamido)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0328] 5-Benzoyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2,3-dihydro-1H-pyrrolizine-1-carboxamide;

[0329] 2,4-dichloro-3-cyano-5-fluoro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0330] 1-[(4-methoxyphenyl)methyl]-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0331] 3-(2-Chloro-6-fluorophenyl)-5-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,2-oxazole-4-carboxamide;

[0332] 2-Benzyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2,3-dihydro-1H-isoindole-4-carboxamide;

[0333] Ethyl 1-{[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}cyclobutane-1-carboxylate;

[0334] 1-ethyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-5-carboxamide;

[0335] 3,6-Difluoro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-2-carboxamide;

[0336] 2-Oxo-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2H-chromene-6-carboxamide;

[0337] 4-methyl-2-(pyridin-2-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,3-thiazole-5-carboxamide;

[0338] 5-(Trifluoromethyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrrolo[2,3-b]pyridine-3-carboxamide;

[0339] 6-(2-methoxyphenyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-3-carboxamide;

[0340] 2-methoxy-4-(trifluoromethyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,3-thiazole-5-carboxamide;

[0341] 6-(oxan-4-yloxy)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-2-carboxamide;

[0342] 2-Oxo-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H,2H,3H-pyrido[2,3-b][1,4]thiazine-7-carboxamide;

[0343] 2-methyl-3-oxo-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3,4-dihydro-2H-1,4-benzoxazine-6-carboxamide;

[0344] 5-Oxo-1-phenyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyrrolidine-2-carboxamide;

[0345] 5-(Pyridin-3-yloxy)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]furan-2-carboxamide;

[0346] 3-methyl-4-oxo-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3,4-dihydroquinazoline-7-carboxamide;

[0347] 1,4-dimethyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-indole-2-carboxamide;

[0348] 2,6,6-Trimethyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]bicyclo[3.1.1]heptane-3-carboxamide;

[0349] 1-(2,2-difluoroethyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-3-carboxamide;

[0350] tert-butyl N-methyl-N-[(S)-phenyl({[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl})methyl]carbamate;

[0351] 2-(Cyclobutylcarboxamido)-2-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]propanamide;

[0352] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-a]pyrazine-2-carboxamide;

[0353] 1-(3-methoxyphenyl)-5-oxo-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyrrolidine-3-carboxamide;

[0354] 1-Methanesulfonyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]piperidine-4-carboxamide;

[0355] N-(2,6-difluorophenyl)-N'-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]ethanediamide;

[0356] N-[3-({[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}methyl)phenyl]benzamide;

[0357] 1-(2,4-dichlorophenyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]cyclobutane-1-carboxamide;

[0358] 3-(5-Bromo-2-fluorophenyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]propanamide;

[0359] 1-(3-Fluorophenyl)-5-(trifluoromethyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0360] 1-[(4-Fluorophenyl)methyl]-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-indole-3-carboxamide;

[0361] 5-Chloro-1-phenyl-3-(trifluoromethyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0362] (2R,3R)-2-(2-methoxyphenyl)-5-oxo-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]oxolane-3-carboxamide;

[0363] 5-(Thiophen-2-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-3-carboxamide;

[0364] 1-(4-chlorophenyl)-5-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0365] 4-(4-ethylphenyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]butanamide;

[0366] 3-(4-chloro-3-fluorophenyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]propanamide;

[0367] (2S)-3-phenyl-2-[(pyrazin-2-yl)formamido]-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]propanamide;

[0368] 2-Chloro-6-fluoro-3-methoxy-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0369] (2R)-2-(3-acetamidopropionamido)-3-(1H-imidazol-5-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]propanamide;

[0370] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4,5,6,7-tetrahydro-1H-1,3-benzodiazole-6-carboxamide;

[0371] 3-Chloro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-benzothiophene-2-carboxamide;

[0372] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2H-pyrazolo[3,4-b]pyridine-3-carboxamide;

[0373] 3-tert-Butyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-5-carboxamide;

[0374] 1-methyl-3-(2-methylpropyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-5-carboxamide;

[0375] 3-(2-chlorophenyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-5-carboxamide;

[0376] 1-[5-(Trifluoromethyl)pyridin-2-yl]-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]piperidine-4-carboxamide;

[0377] 2-(1H-indol-1-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]acetamide;

[0378] 2-(Morpholin-4-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-4-carboxamide;

[0379] 2-(Thiophen-3-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]acetamide;

[0380] 1-(4-Methylbenzenesulfonyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrrole-3-carboxamide;

[0381] 6-Chloro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-b]pyridazine-2-carboxamide;

[0382] 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]acetamide;

[0383] 6-Oxo-2-phenyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3,6-dihydropyrimidine-4-carboxamide;

[0384] 2-(3-Oxo-3,4-dihydro-2H-1,4-benzoxazin-4-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]acetamide;

[0385] 7-methoxy-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-benzofuran-2-carboxamide;

[0386] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,6-naphthyridine-2-carboxamide;

[0387] 1-(2-Chlorobenzoyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]piperidine-4-carboxamide;

[0388] 5-(Furan-2-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,2-oxazole-3-carboxamide;

[0389] 2-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2H-indazole-3-carboxamide;

[0390] 1-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide;

[0391] 2-[(2,5-dichlorophenyl)formamido]-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]acetamide;

[0392] (1R,4S)-4,7,7-trimethyl-3-oxo-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-oxabicyclo[2.2.1]heptane-1-carboxamide;

[0393] 2-methyl-4-(2-methylbenzamido)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0394] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3,4-dihydro-2H-pyran-6-carboxamide;

[0395] 4-Oxo-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4H-chromene-3-carboxamide;

[0396] 4-Fluoro-3-(trifluoromethoxy)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0397] 2-Phenoxy-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0398] 5-Chloro-2-methoxy-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-4-carboxamide;

[0399] 3-Methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-benzofuran-2-carboxamide;

[0400] 3-(Cyclopropylmethoxy)-4-(difluoromethoxy)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0401] 2-Chloro-4-(4-methylpiperazin-1-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0402] (1r,4r)-4-[(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl]-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]cyclohexane-1-carboxamide;

[0403] 2-(2,3-Dimethylphenyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]acetamide;

[0404] 7-methoxy-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3,4-dihydro-2H-1-benzopyran-3-carboxamide;

[0405] 3,4-dichloro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,2-thiazole-5-carboxamide;

[0406] 3,3-Dimethoxy-1-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]cyclobutane-1-carboxamide;

[0407] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(2-methylpropionamido)benzamide;

[0408] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrrolo[2,3-b]pyridine-4-carboxamide;

[0409] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-methoxybenzamide;

[0410] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2,2-difluoroethyl)-1H-pyrazole-5-carboxamide;

[0411] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-ethyl-4-methyl-1H-pyrazole-5-carboxamide;

[0412] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-fluoroethyl)-1H-pyrazole-5-carboxamide;

[0413] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-propyl-1H-pyrazole-5-carboxamide;

[0414] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(methylamino)benzamide;

[0415] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-indole-4-carboxamide;

[0416] 4-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0417] 4-(1H-imidazol-1-yl)-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0418] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(pyrrolidin-1-yl)benzamide;

[0419] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(1H-1,2,3,4-tetrazol-1-yl)benzamide;

[0420] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-cyclobutyl-1H-pyrazole-5-carboxamide;

[0421] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyrazolo[1,5-a]pyridine-2-carboxamide;

[0422] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-a]pyrimidine-3-carboxamide;

[0423] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-indole-3-carboxamide;

[0424] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrrolo[2,3-b]pyridine-4-carboxamide;

[0425] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2,3-dioxo-2,3-dihydro-1H-indole-7-carboxamide;

[0426] 2-Acetamido-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-4-carboxamide;

[0427] 3-(1-Cyanoethyl)-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0428] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-a]pyridine-6-carboxamide;

[0429] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,3-benzothiazole-7-carboxamide;

[0430] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-ethyl-3-phenyl-1H-pyrazole-5-carboxamide;

[0431] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-cyclopropyl-1H-pyrazole-5-carboxamide;

[0432] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-ethyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide;

[0433] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-phenyl-1H-pyrazole-5-carboxamide;

[0434] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,3-diethyl-1H-pyrazole-5-carboxamide;

[0435] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-ethyl-3-methyl-1H-pyrazole-5-carboxamide;

[0436] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(propan-2-yl)-1H-pyrazole-5-carboxamide;

[0437] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-1H-pyrazole-5-carboxamide;

[0438] 3-Acetamido-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0439] 3-Hydroxy-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0440] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(2-methylpropionamido)benzamide;

[0441] 3-Methanesulfonamido-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0442] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(methylamino)benzamide;

[0443] 3-(Dimethylamino)-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0444] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-(methylamino)benzamide;

[0445] 2-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methanesulfonylbenzamide;

[0446] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-ethyl-1H-pyrazole-5-carboxamide;

[0447] 2-Chloro-4-methylsulfonyl-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0448] 1-ethyl-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-5-carboxamide;

[0449] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-(methylamino)benzamide;

[0450] 2-Cyano-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0451] 2-methoxy-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0452] 2-Chloro-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0453] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-cyanobenzamide;

[0454] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]cyclohexanecarboxamide;

[0455] 1-vinyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-oxabicyclo[2.2.2]octane-4-carboxamide;

[0456] 3-(2-oxopyrrolidin-1-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0457] tert-Butyl (3S)-3-methyl-3-{[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}propanoate;

[0458] Phenyl 3-{[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}propanoate;

[0459] 4-methyl-2-propyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-1,3-benzodiazole-6-carboxamide;

[0460] (1R,2R)-2-(2-Fluorophenyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]cyclopropane-1-carboxamide;

[0461] 1-tert-Butyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-1,2,3-triazole-4-carboxamide;

[0462] 4-Butyramido-3-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0463] 3-(2-Fluorophenyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-5-carboxamide;

[0464] 5-Fluoro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxamide;

[0465] 2-(Pyridin-4-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-1,3-benzodiazole-6-carboxamide;

[0466] 3-(Propan-2-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-5-carboxamide;

[0467] 1-cyano-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]cyclopropane-1-carboxamide;

[0468] 5-Fluoro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-benzofuran-2-carboxamide;

[0469] 2-(1,2-Benzoxazol-3-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]acetamide;

[0470] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-a]pyrimidine-3-carboxamide;

[0471] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2H-1,3-benzodioxole-4-carboxamide;

[0472] 2-Acetamido-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-4-carboxamide;

[0473] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrrolo[2,3-b]pyridine-4-carboxamide;

[0474] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide;

[0475] 2-Oxo-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2,3-dihydropyridine-4-carboxamide;

[0476] 2-Chloro-4-methylsulfonyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0477] 3-Chloro-1-(3-chloropyridin-2-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-5-carboxamide;

[0478] 1-(Pyridin-3-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0479] 4-Fluoro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-indole-3-carboxamide;

[0480] 3-(1H-1,2,4-triazol-1-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0481] 4-Fluoro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2H-indazole-5-carboxamide;

[0482] 4-(3-methyl-5-oxo-2,5-dihydro-1H-pyrazol-1-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0483] 2-(4-Chlorophenyl)-2-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]propanamide;

[0484] 1,3-Dimethyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-thieno[2,3-c]pyrazole-5-carboxamide;

[0485] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,3-benzothiazole-7-carboxamide;

[0486] 3-(1-Cyanoethyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0487] 2-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4H-thieno[3,2-b]pyrrole-5-carboxamide;

[0488] 3-methyl-4-oxo-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3H,4H-imidazo[4,3-d][1,2,3,5]tetrazine-8-carboxamide;

[0489] 6-Fluoro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3,4-dihydro-2H-1-benzopyran-2-carboxamide;

[0490] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyrazolo[1,5-a]pyridine-2-carboxamide;

[0491] 2,3-Dioxo-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2,3-dihydro-1H-indole-7-carboxamide;

[0492] 1-phenyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrrole-2-carboxamide;

[0493] 6-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-benzothiophene-2-carboxamide;

[0494] 3-Chloro-2-iodo-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0495] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-indole-3-carboxamide;

[0496] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-cyanobenzamide;

[0497] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(pyrrolidin-1-yl)benzamide;

[0498] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(methylamino)benzamide;

[0499] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-hydroxybenzamide;

[0500] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(dimethylamino)benzamide;

[0501] 4-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0502] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-acetamidopyridine-4-carboxamide;

[0503] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(1-cyanoethyl)benzamide;

[0504] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(methylamino)benzamide;

[0505] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4,5,6,7-tetrahydro-1H-1,3-benzodiazole-6-carboxamide;

[0506] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-a]pyridine-6-carboxamide;

[0507] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-indole-4-carboxamide;

[0508] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2,3-dioxo-2,3-dihydro-1H-indole-7-carboxamide;

[0509] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,3-benzothiazole-7-carboxamide;

[0510] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-a]pyrimidine-3-carboxamide;

[0511] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-fluoro-2H-indazole-5-carboxamide;

[0512] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(propane-2-sulfonamido)benzamide;

[0513] 2-(1-methyl-1H-indol-3-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]acetamide;

[0514] 2,6-dimethoxy-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyrimidine-4-carboxamide;

[0515] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,2,3-thiadiazole-4-carboxamide;

[0516] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2,6-difluoro-3-(propane-2-sulfonamido)benzamide;

[0517] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2,6-difluoro-3-methanesulfonamidobenzamide;

[0518] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-ethanesulfonamido-2,6-difluorobenzamide;

[0519] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-fluoro-5-(propane-1-sulfonamido)benzamide;

[0520] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyrazolo[1,5-a]pyridine-2-carboxamide;

[0521] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(1H-imidazol-1-yl)benzamide;

[0522] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(1H-1,2,3,4-tetrazol-1-yl)benzamide;

[0523] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-fluorobenzamide;

[0524] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methanesulfonamidobenzamide;

[0525] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-ethanesulfonamidobenzamide;

[0526] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-a]pyrimidine-6-carboxamide;

[0527] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(1,1-dioxo-1λ6-thiomorpholin-4-yl)benzamide;

[0528] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-[1,2,4]triazolo[1,5-a]pyridine-6-carboxamide;

[0529] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-[1,2,4]triazolo[4,3-a]pyridine-6-carboxamide;

[0530] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,5-a]pyridine-7-carboxamide;

[0531] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,5-a]pyridine-6-carboxamide;

[0532] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-a]pyridine-7-carboxamide;

[0533] 3-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0534] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-oxo-2H-chromene-6-carboxamide;

[0535] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-fluoro-3-(propane-1-sulfonamido)benzamide;

[0536] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2H,4H,6H,7H-pyrano[4,3-c]pyrazole-3-carboxamide;

[0537] 2-Chloro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,3-benzothiazole-6-carboxamide;

[0538] 2-(Cyclohexyloxy)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]acetamide;

[0539] 5-Chloro-3-(difluoromethyl)-1-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0540] 2-Acetamido-3-(1H-indol-3-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]propanamide;

[0541] 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]propanamide;

[0542] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-fluoro-3-methanesulfonamidobenzamide;

[0543] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-acetamido-5-methoxybenzamide;

[0544] 5-Bromo-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-cyanobenzamide;

[0545] 4-Bromo-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-cyanobenzamide;

[0546] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,3-benzothiazole-4-carboxamide;

[0547] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2H-pyrazolo[4,3-b]pyridine-7-carboxamide;

[0548] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-methylimidazo[1,2-a]pyridine-6-carboxamide;

[0549] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-methylimidazo[1,2-a]pyridine-6-carboxamide;

[0550] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-methyl-1H-1,3-benzodiazole-6-carboxamide;

[0551] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-cyano-4-fluorobenzamide;

[0552] 2-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-acetamidobenzamide;

[0553] 3-Bromo-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-acetamidobenzamide;

[0554] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2H-indazole-3-carboxamide;

[0555] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3,5-dihydroxybenzamide;

[0556] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(N-methylmethanesulfonamido)benzamide;

[0557] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-(methylamino)benzamide;

[0558] 2-Cyano-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0559] 2-Chloro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0560] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-methylbenzamide;

[0561] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-methoxybenzamide;

[0562] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0563] 2-Chloro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-methanesulfonamidobenzamide;

[0564] 2,6-Difluoro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(propane-1-sulfonamido)benzamide;

[0565] 1-ethyl-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-5-carboxamide;

[0566] 3-(1-Cyanoethyl)-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0567] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(methylamino)benzamide;

[0568] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-hydroxybenzamide;

[0569] 3-(Dimethylamino)-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0570] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-methoxybenzamide;

[0571] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(pyrrolidin-1-yl)benzamide;

[0572] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(1H-1,2,3,4-tetrazol-1-yl)benzamide;

[0573] 4-Chloro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0574] 4-cyano-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0575] 2-Acetamido-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-4-carboxamide;

[0576] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(propane-2-sulfonyl)benzamide;

[0577] 3-Chloro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methanesulfonylbenzamide;

[0578] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methanesulfonyl-3-methylbenzamide;

[0579] 2-Fluoro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methanesulfonylbenzamide;

[0580] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(1H-imidazol-1-yl)benzamide;

[0581] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(propane-2-sulfonamido)benzamide;

[0582] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-indole-3-carboxamide;

[0583] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-a]pyridine-6-carboxamide;

[0584] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrrolo[2,3-b]pyridine-4-carboxamide;

[0585] 3-Fluoro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methanesulfonylbenzamide;

[0586] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-methanesulfonamidobenzamide;

[0587] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(methylamino)benzamide;

[0588] 3-Ethylsulfonamido-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0589] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(2-methylpropionamido)benzamide;

[0590] 3-Acetamido-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0591] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(N-methylmethanesulfonamido)benzamide;

[0592] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,3-benzothiazole-7-carboxamide;

[0593] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-a]pyrimidine-3-carboxamide;

[0594] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3H,3aH-pyrazolo[1,5-a]pyridine-2-carboxamide;

[0595] 3-Fluoro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0596] 2,6-difluoro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-methanesulfonamidobenzamide;

[0597] 3-Ethylsulfonamido-2,6-difluoro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0598] 2-Fluoro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-(propane-1-sulfonamido)benzamide;

[0599] 2-Fluoro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(propane-1-sulfonamido)benzamide;

[0600] 4-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0601] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methanesulfonamidobenzamide;

[0602] 2,6-Difluoro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(propane-2-sulfonamido)benzamide;

[0603] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-1H-pyrazole-5-carboxamide;

[0604] 2-Fluoro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0605] 4-Fluoro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0606] 1-ethyl-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-methyl-1H-pyrazole-5-carboxamide;

[0607] 1-Cyclopropyl-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-5-carboxamide;

[0608] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-methylpropyl)-1H-pyrazole-5-carboxamide;

[0609] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-propyl-1H-pyrazole-5-carboxamide;

[0610] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(propan-2-yl)-1H-pyrazole-5-carboxamide;

[0611] 3-Cyclopropyl-1-ethyl-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-5-carboxamide;

[0612] 1-ethyl-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(propan-2-yl)-1H-pyrazole-5-carboxamide;

[0613] 1,3-Diethyl-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-5-carboxamide;

[0614] 1-ethyl-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methyl-1H-pyrazole-5-carboxamide;

[0615] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-acetamidobenzamide;

[0616] 3-cyano-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0617] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-cyanobenzamide;

[0618] 3-cyano-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0619] 3-Chloro-4-(propan-2-yloxy)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0620] 3-Methyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,2-oxazole-4-carboxamide;

[0621] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]furan-3-carboxamide;

[0622] 6-Chloro-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2H-chromene-3-carboxamide;

[0623] 1,3,5-Trimethyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0624] 2-[5-Fluoro-2-(trifluoromethyl)phenyl]-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]acetamide;

[0625] 2-{5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl}-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]acetamide;

[0626] 4-iodo-1-methyl-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-3-carboxamide;

[0627] 2-methyl-5-{[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}pyrazin-1-ium-1-ol ester;

[0628] tert-Butyl 7-{[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}-1,2,3,4-tetrahydroisoquinoline-2-carboxylate;

[0629] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-[(trifluoromethyl)sulfonyl]benzamide;

[0630] 2-(5-chloro-2H-indazol-3-yl)-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]acetamide;

[0631] Methyl N-[(R)-{[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}(phenyl)methyl]carbamate;

[0632] 5-Bromo-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-indole-7-carboxamide;

[0633] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(trifluoromethanesulfonamido)benzamide;

[0634] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(difluoromethanesulfonamido)benzamide;

[0635] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-hydroxypyridine-4-carboxamide;

[0636] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(N-methylmethanesulfonamido)benzamide;

[0637] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-fluoro-3-methanesulfonamidobenzamide;

[0638] 7-bromo-2-methyl-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-a]pyridine-3-carboxamide;

[0639] 2-amino-3-(1H-imidazol-5-yl)-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]propanamide;

[0640] 2-amino-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4,5-dihydro-1,3-thiazole-4-carboxamide;

[0641] tert-Butyl 7-{[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}-1,2,3,4-tetrahydroisoquinoline-2-carboxylate;

[0642] (2E)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(2,3,4-trimethoxyphenyl)prop-2-enamide;

[0643] 6-Bromo-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-a]pyridine-3-carboxamide;

[0644] 2-Chloro-4-iodo-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-3-carboxamide;

[0645] 2-(2H-1,2,3-triazol-2-yl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0646] 5-Bromo-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-a]pyridine-2-carboxamide;

[0647] tert-Butyl N-[(1S)-2-(pent-4-en-1-yloxy)-1-{[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}ethyl]carbamate;

[0648] 2-Benzyl-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]prop-2-enamide;

[0649] 5-Bromo-2-(methylsulfonyl)-N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyrimidine-4-carboxamide;

[0650] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-ethyl-1H-pyrazole-4-carboxamide;

[0651] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazole-5-carboxamide;

[0652] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0653] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-5-carboxamide;

[0654] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-ethyl-3-(propan-2-yl)-1H-pyrazole-5-carboxamide;

[0655] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-cyclopropyl-1-ethyl-1H-pyrazole-5-carboxamide;

[0656] 5-{[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}-1-ethyl-1H-pyrazole-3-carboxylic acid methyl ester;

[0657] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-ethyl-4,5,6,7-tetrahydro-2H-indazole-3-carboxamide;

[0658] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-methylpropyl)-1H-pyrazole-5-carboxamide;

[0659] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-cyclohexyl-1H-pyrazole-5-carboxamide;

[0660] 1-tert-Butyl-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-5-carboxamide;

[0661] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-cyclopentyl-1H-pyrazole-5-carboxamide;

[0662] 3-Chloro-N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0663] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-oxo-2,3-dihydropyridine-4-carboxamide;

[0664] N-[(1R,3S)-3-{[6-methyl-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(N-methylmethanesulfonamido)benzamide;

[0665] 4-Fluoro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2H-indazole-5-carboxamide;

[0666] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-oxo-2H-chromene-6-carboxamide;

[0667] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4,5,6,7-tetrahydro-1H-1,3-benzodiazole-6-carboxamide;

[0668] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2,3-dioxo-2,3-dihydro-1H-indole-7-carboxamide;

[0669] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-methylimidazo[1,2-a]pyridine-6-carboxamide;

[0670] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-methylimidazo[1,2-a]pyridine-6-carboxamide;

[0671] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-a]pyridine-7-carboxamide;

[0672] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,5-a]pyridine-6-carboxamide;

[0673] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,5-a]pyridine-7-carboxamide;

[0674] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-oxo-2,3-dihydropyridine-4-carboxamide;

[0675] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-[1,2,4]triazolo[4,3-a]pyridine-6-carboxamide;

[0676] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-[1,2,4]triazolo[1,5-a]pyridine-6-carboxamide;

[0677] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]imidazo[1,2-a]pyrimidine-6-carboxamide;

[0678] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide;

[0679] 5-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrrole-3-carboxamide;

[0680] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-chloroethyl)-1H-pyrazole-4-carboxamide;

[0681] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-[1,2,4]triazolo[4,3-a]pyridine-7-carboxamide;

[0682] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2H-pyrazolo[4,3-c]pyridine-7-carboxamide;

[0683] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(difluoromethyl)-1H-pyrazole-4-carboxamide;

[0684] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-1H-pyrazole-4-carboxamide;

[0685] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,3-dimethyl-1H-pyrazole-4-carboxamide;

[0686] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-methyl-1-(propan-2-yl)-1H-pyrazole-4-carboxamide;

[0687] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-6-methylpyridine-3-carboxamide;

[0688] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide;

[0689] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-cyclopropyl-1H-pyrazole-4-carboxamide;

[0690] 3-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(difluoromethyl)-1H-pyrazole-4-carboxamide;

[0691] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(oxetan-3-yl)-1H-pyrazole-4-carboxamide;

[0692] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-cyano-1H-pyrrole-3-carboxamide;

[0693] 2-amino-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-3-carboxamide;

[0694] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-[(dimethylamino)methyl]benzamide;

[0695] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-6-fluoropyridine-3-carboxamide;

[0696] 2-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-1H-imidazole-5-carboxamide;

[0697] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methoxy-3-(methylamino)benzamide;

[0698] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-6-methoxypyridine-3-carboxamide;

[0699] 4-(aziridin-1-yl)-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0700] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-1H-pyrrole-3-carboxamide;

[0701] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,4-dimethyl-1H-pyrrole-3-carboxamide;

[0702] 5-amino-2-chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyridine-3-carboxamide;

[0703] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-methylfuran-3-carboxamide;

[0704] 5-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-cyanoethyl)-1H-pyrazole-4-carboxamide;

[0705] 4-(Dimethylamino)-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]benzamide;

[0706] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-(dimethylamino)-1,3-thiazole-5-carboxamide;

[0707] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-[(2-fluoroethyl)amino]pyrimidine-5-carboxamide;

[0708] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,3-oxazole-2-carboxamide;

[0709] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,2-thiazole-3-carboxamide;

[0710] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2,5-dimethyl-1H-pyrrole-3-carboxamide;

[0711] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-ethyl-1H-pyrrole-3-carboxamide;

[0712] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-methylthiophene-2-carboxamide;

[0713] 2-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrrole-3-carboxamide;

[0714] (4-{[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}phenyl)boronic acid;

[0715] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-ethyl-1H-pyrazole-4-carboxamide;

[0716] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-methyl-1H-pyrazole-4-carboxamide;

[0717] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,5-dimethyl-1H-pyrazole-4-carboxamide;

[0718] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

[0719] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(propan-2-yl)-1H-pyrazole-4-carboxamide;

[0720] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

[0721] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide;

[0722] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

[0723] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-methoxy-1-methyl-1H-pyrazole-4-carboxamide;

[0724] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-ethyl-1-methyl-1H-pyrazole-4-carboxamide;

[0725] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-methoxy-1H-pyrazole-4-carboxamide;

[0726] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-ethyl-3-methyl-1H-pyrazole-4-carboxamide;

[0727] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-cyclopropyl-1H-pyrazole-4-carboxamide;

[0728] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-cyclobutyl-1H-pyrazole-4-carboxamide;

[0729] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-cyclopropyl-1-methyl-1H-pyrazole-4-carboxamide;

[0730] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-ethyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

[0731] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-cyclopropyl-1-methyl-1H-pyrazole-4-carboxamide;

[0732] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-methoxy-1-methyl-1H-pyrazole-4-carboxamide;

[0733] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

[0734] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxamide;

[0735] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-methoxyethyl)-1H-pyrazole-4-carboxamide;

[0736] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-ethyl-5-methyl-1H-pyrazole-4-carboxamide;

[0737] 3-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-1H-pyrazole-4-carboxamide;

[0738] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-phenyl-1H-pyrazole-4-carboxamide;

[0739] 1-Benzyl-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0740] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(oxan-4-yl)-1H-pyrazole-4-carboxamide;

[0741] 3-amino-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-1H-pyrazole-4-carboxamide;

[0742] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-methyl-1H-pyrazole-4-carboxamide;

[0743] 1-ethyl-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0744] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0745] 5-ethyl-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0746] 1-ethyl-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-methyl-1H-pyrazole-4-carboxamide;

[0747] N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,3-dimethyl-1H-pyrazole-4-carboxamide;

[0748] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxamide;

[0749] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2,2-difluoroethyl)-1H-pyrazole-4-carboxamide;

[0750] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-ethyl-5-fluoro-1H-pyrazole-4-carboxamide;

[0751] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-hydroxyethyl)-1H-pyrazole-4-carboxamide;

[0752] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(methoxymethyl)-1-methyl-1H-pyrazole-4-carboxamide;

[0753] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(pyridin-4-yl)-1H-pyrazole-4-carboxamide;

[0754] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(1,1-dioxo-1λ6-thiolan-3-yl)-1H-pyrazole-4-carboxamide;

[0755] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-3-phenyl-1H-pyrazole-4-carboxamide;

[0756] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-cyclopropyl-1-ethyl-1H-pyrazole-4-carboxamide;

[0757] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2,2-difluoroethyl)-3-methyl-1H-pyrazole-4-carboxamide;

[0758] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-cyclopropyl-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxamide;

[0759] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxamide;

[0760] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2,2-difluoroethyl)-5-methyl-1H-pyrazole-4-carboxamide;

[0761] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-cyclopropyl-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxamide;

[0762] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-cyano-1-methyl-1H-pyrazole-4-carboxamide;

[0763] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(3,3,3-trifluoropropyl)-1H-pyrazole-4-carboxamide;

[0764] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-3-(pyridin-3-yl)-1H-pyrazole-4-carboxamide;

[0765] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-3-(propan-2-yl)-1H-pyrazole-4-carboxamide;

[0766] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-cyclopentyl-1H-pyrazole-4-carboxamide;

[0767] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-propyl-1H-pyrazole-4-carboxamide;

[0768] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-[(oxan-4-yl)methyl]-1H-pyrazole-4-carboxamide;

[0769] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-[2-(dimethylamino)ethyl]-1H-pyrazole-4-carboxamide;

[0770] tert-Butyl 4-(4-{[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}-1H-pyrazol-1-yl)piperidine-1-carboxylate;

[0771] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-cyclohexyl-1H-pyrazole-4-carboxamide;

[0772] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-1H-pyrazole-4-carboxamide;

[0773] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(pyridin-3-yl)-1H-pyrazole-4-carboxamide;

[0774] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2,2-difluorocyclopropyl)-1H-pyrazole-4-carboxamide;

[0775] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-fluoroethyl)-1H-pyrazole-4-carboxamide;

[0776] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(cyclopropylmethyl)-1H-pyrazole-4-carboxamide;

[0777] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-[2-(morpholin-4-yl)ethyl]-1H-pyrazole-4-carboxamide;

[0778] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(furan-2-yl)-1-methyl-1H-pyrazole-4-carboxamide;

[0779] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-3-(thiophen-2-yl)-1H-pyrazole-4-carboxamide;

[0780] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(1,3-thiazol-2-yl)-1H-pyrazole-4-carboxamide;

[0781] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-5-sulfamoyl-1H-pyrazole-4-carboxamide;

[0782] 1-tert-Butyl-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0783] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-methylpropyl)-1H-pyrazole-4-carboxamide;

[0784] 1-tert-butyl-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-methyl-1H-pyrazole-4-carboxamide;

[0785] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(pyridin-2-yl)-1H-pyrazole-4-carboxamide;

[0786] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-cyanoethyl)-5-methyl-1H-pyrazole-4-carboxamide;

[0787] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(4-methylpyridin-2-yl)-1H-pyrazole-4-carboxamide;

[0788] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(1,1-dioxo-1λ6-thiolan-3-yl)-3-(propan-2-yl)-1H-pyrazole-4-carboxamide;

[0789] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-methyl-1-(pyridin-4-yl)-1H-pyrazole-4-carboxamide;

[0790] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,3-bis(difluoromethyl)-1H-pyrazole-4-carboxamide;

[0791] 5-amino-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-hydroxyethyl)-1H-pyrazole-4-carboxamide;

[0792] 5-amino-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-1H-pyrazole-4-carboxamide;

[0793] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(difluoromethyl)-3-nitro-1H-pyrazole-4-carboxamide;

[0794] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-hydroxy-2-methylpropyl)-5-methyl-1H-pyrazole-4-carboxamide;

[0795] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-(difluoromethyl)-1H-pyrazole-4-carboxamide;

[0796] 1-(Difluoromethyl)-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0797] 1,3-Bis(difluoromethyl)-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0798] 5-Chloro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0799] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3,5-dimethyl-1H-pyrazole-4-carboxamide;

[0800] 5-amino-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0801] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-fluoroethyl)-3-methyl-1H-pyrazole-4-carboxamide;

[0802] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-fluoroethyl)-5-methyl-1H-pyrazole-4-carboxamide;

[0803] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2H,3H-pyrazolo[3,2-b][1,3]oxazole-7-carboxamide;

[0804] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1,3,5-trimethyl-1H-pyrazole-4-carboxamide;

[0805] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(difluoromethyl)-3-methyl-1H-pyrazole-4-carboxamide;

[0806] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-cyano-1-methyl-1H-pyrazole-4-carboxamide;

[0807] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-methanesulfonamidobenzamide;

[0808] 2-amino-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyrimidine-5-carboxamide;

[0809] N-[(1R,3S)-3-{[2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]propanamide;

[0810] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-methoxy-1-methyl-1H-imidazole-5-carboxamide;

[0811] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-6-[(2-fluoroethyl)amino]pyridine-3-carboxamide;

[0812] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-methyl-1-(piperidin-4-yl)-1H-pyrazole-4-carboxamide;

[0813] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-fluoroethyl)-2-methyl-1H-pyrrole-3-carboxamide;

[0814] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-fluoroethyl)-5-methyl-1H-pyrrole-3-carboxamide;

[0815] 3-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-cyanoethyl)-1H-pyrazole-4-carboxamide;

[0816] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2,2-difluoroethyl)-5-methyl-1H-pyrrole-3-carboxamide;

[0817] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2,2-difluoroethyl)-2-methyl-1H-pyrrole-3-carboxamide;

[0818] 5-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-ethyl-1H-pyrrole-3-carboxamide;

[0819] 3-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(oxetan-3-yl)-1H-pyrazole-4-carboxamide;

[0820] tert-Butyl 3-(4-{[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}-1H-pyrazol-1-yl)azetidine-1-carboxylate;

[0821] 1-(azetidin-3-yl)-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1H-pyrazole-4-carboxamide;

[0822] tert-Butyl (3S)-3-(4-{[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}-1H-pyrazol-1-yl)pyrrolidine-1-carboxylate;

[0823] tert-Butyl (3S)-3-(4-{[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}-1H-pyrazol-1-yl)piperidine-1-carboxylate;

[0824] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-[(3S)-pyrrolidin-3-yl]-1H-pyrazole-4-carboxamide;

[0825] tert-Butyl (3R)-3-(4-{[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}-1H-pyrazol-1-yl)piperidine-1-carboxylate;

[0826] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-[(3S)-piperidin-3-yl]-1H-pyrazole-4-carboxamide;

[0827] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-[(3R)-piperidin-3-yl]-1H-pyrazole-4-carboxamide;

[0828] 5-amino-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-4-carboxamide;

[0829] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-4-carboxamide;

[0830] 5-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-fluoroethyl)-1H-pyrazole-4-carboxamide;

[0831] 3-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-fluoroethyl)-1H-pyrazole-4-carboxamide;

[0832] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methanesulfonyl-1H-pyrazole-4-carboxamide;

[0833] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-fluoro-2-methylpropyl)-3-methyl-1H-pyrazole-4-carboxamide;

[0834] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(difluoromethyl)-1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-4-carboxamide;

[0835] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-(difluoromethyl)-1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-4-carboxamide;

[0836] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-hydroxy-2-methylpropyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

[0837] 3-Chloro-N-[(1R,3S)-3-{[6-fluoro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-4-carboxamide;

[0838] 3-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-ethyl-1H-pyrazole-4-carboxamide;

[0839] 3-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-fluoro-2-methylpropyl)-1H-pyrazole-4-carboxamide;

[0840] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(difluoromethyl)-1-ethyl-1H-pyrazole-4-carboxamide;

[0841] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(fluoromethyl)-1H-pyrazole-4-carboxamide;

[0842] 3-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(fluoromethyl)-1H-pyrazole-4-carboxamide;

[0843] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-cyano-1-(2-fluoroethyl)-1H-pyrazole-4-carboxamide;

[0844] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(difluoromethyl)-1-(2-fluoro-2-methylpropyl)-1H-pyrazole-4-carboxamide;

[0845] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-fluoro-2-methylpropyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

[0846] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(1-methylpiperidin-4-yl)-1H-pyrazole-4-carboxamide;

[0847] 5-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-fluoro-2-methylpropyl)-1H-pyrazole-4-carboxamide;

[0848] 5-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxamide;

[0849] 3-amino-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-fluoro-2-methylpropyl)-1H-pyrazole-4-carboxamide;

[0850] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-cyano-1-(fluoromethyl)-1H-pyrazole-4-carboxamide;

[0851] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-cyano-1-(fluoromethyl)-1H-pyrazole-4-carboxamide;

[0852] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-cyano-1-(difluoromethyl)-1H-pyrazole-4-carboxamide;

[0853] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(difluoromethyl)-1-(fluoromethyl)-1H-pyrazole-4-carboxamide;

[0854] 5-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methyl-1H-pyrrole-3-carboxamide;

[0855] 5-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2,2-difluoroethyl)-1H-pyrrole-3-carboxamide;

[0856] 3-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-methanesulfonyl-1H-pyrazole-4-carboxamide;

[0857] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-hydroxy-2-methylpropyl)-3-methyl-1H-pyrazole-4-carboxamide;

[0858] 3-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(piperidin-4-yl)-1H-pyrazole-4-carboxamide;

[0859] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-cyano-1-(2,2-difluoroethyl)-1H-pyrazole-4-carboxamide;

[0860] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-(difluoromethyl)-1-(fluoromethyl)-1H-pyrazole-4-carboxamide;

[0861] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-cyano-1-(2-fluoroethyl)-1H-pyrazole-4-carboxamide;

[0862] 3-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxamide;

[0863] 3-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-4-carboxamide;

[0864] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-cyano-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxamide;

[0865] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-cyano-1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-4-carboxamide;

[0866] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-cyano-1-(2-fluoro-2-methylpropyl)-1H-pyrazole-4-carboxamide;

[0867] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-fluoro-2-methylpropyl)-1H-pyrazole-4-carboxamide;

[0868] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(piperidin-4-yl)-1H-pyrazole-4-carboxamide;

[0869] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2-fluoroethyl)-1H-pyrrole-3-carboxamide;

[0870] 5-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2,2-difluoroethyl)-1H-pyrazole-4-carboxamide;

[0871] 3-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(2,2-difluoroethyl)-1H-pyrazole-4-carboxamide;

[0872] tert-Butyl (3R)-3-(4-{[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]carbamoyl}-1H-pyrazol-1-yl)pyrrolidine-1-carboxylate;

[0873] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-[(3R)-pyrrolidin-3-yl]-1H-pyrazole-4-carboxamide;

[0874] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-(difluoromethyl)-1-ethyl-1H-pyrazole-4-carboxamide;

[0875] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-cyano-1H-pyrazole-4-carboxamide;

[0876] 6-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5H,6H,7H-pyrrolo[3,4-b]pyridin-7-one;

[0877] 4-amino-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]piperidine-1-carboxamide;

[0878] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(propan-2-yl)piperazine-1-carboxamide;

[0879] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyrrolidine-1-carboxamide;

[0880] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]piperazine-1-carboxamide;

[0881] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-methylpiperazine-1-carboxamide;

[0882] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-fluoro-3-methylpyrrolidine-1-carboxamide;

[0883] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3,3-difluoropiperidine-1-carboxamide;

[0884] 1-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-methyl-3-[(3R)-oxolan-3-yl]urea;

[0885] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5-azaspiro[2.3]hexane-5-carboxamide;

[0886] 1-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-methyl-3-[(3S)-oxolan-3-yl]urea;

[0887] (3S)-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-fluoropyrrolidine-1-carboxamide;

[0888] (3R,4R)-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3,4-difluoropyrrolidine-1-carboxamide;

[0889] (3S)-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-fluoropiperidine-1-carboxamide;

[0890] 5-Chloro-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-1-(propan-2-yl)-1H-pyrrole-3-carboxamide;

[0891] (2R,3R)-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-(hydroxymethyl)-2-methylpyrrolidine-1-carboxamide;

[0892] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-methyl-2H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridine-5-carboxamide;

[0893] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-2-methyl-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridine-5-carboxamide;

[0894] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-4-(2-methylpropanoyl)piperazine-1-carboxamide; and

[0895] N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-3-fluoro-3-methylazetidine-1-carboxamide.

[0896] In certain embodiments, the present invention provides a pharmaceutical composition comprising a compound of any one of structure (I) or formula (Ia) to (1f) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, and at least one pharmaceutically acceptable carrier, diluent or excipient. For example, the active compound is usually mixed with a carrier or diluted by a carrier or encapsulated in a carrier, and the carrier can be in the form of an ampoule, capsule, sachet, paper or other container. When the active compound is mixed with a carrier, or when the carrier acts as a diluent, the carrier can be a solid, semi-solid or liquid material that acts as a medium, excipient or medium for the active compound. The active compound can be adsorbed on a granular solid carrier, such as contained in a sachet. Some examples of suitable carriers are water, saline solution, alcohol, polyethylene glycol, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatin, lactose, clay, sucrose, dextrin, magnesium carbonate, sugar, cyclodextrin, straight-chain starch, magnesium stearate, talc, gelatin, agar, pectin, gum arabic, lower alkyl ethers of stearic acid or cellulose, silicic acid, fatty acid, fatty acid amine, fatty acid monoglyceride and diglyceride, pentaerythritol fatty acid ester, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone. Similarly, the carrier or diluent can include any sustained-release material known in the art such as glyceryl monostearate or glyceryl distearate, alone or mixed with wax.

[0897] As used herein, the term "pharmaceutical composition" refers to a composition containing one or more of the compounds described herein or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof, formulated together with a pharmaceutically acceptable carrier, which may also include other additives, and manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for treating a mammalian disease. The pharmaceutical composition can be formulated, for example, for oral administration in a unit dosage form (e.g., tablets, capsules, caplets, sachets, or syrups); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution without particulate plugs and in a solvent system suitable for intravenous use); for administration to pediatric subjects (e.g., solutions, syrups, suspensions, elixirs, powders for reconstitution as suspensions or solutions, dispersible / effervescent tablets, chewable tablets, lollipops, popsicles, lozenges, oral thin patches, orally disintegrating tablets, and oral spray powders or microparticles); or formulated in any other formulation described herein, including spray-dried dispersions (e.g., single-phase amorphous molecular dispersions of a compound as described herein in a polymer matrix). Conventional procedures and ingredients for selecting and preparing suitable formulations are described, for example, in Remington: The Science and Practice of Pharmacy, 21st edition, Gennaro ed., Lippencott Williams & Wilkins (2005) and The United States Pharmacopeia: The National Formulary (USP 36NF31), published in 2013.

[0898] In certain embodiments, the present invention provides a pharmaceutical composition comprising a compound of any one of structure (I) or formula (Ia) to (1f), or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein the compound or its pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope is in amorphous form. In other embodiments, the compound or its pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope is micronized. In still other embodiments, the compound or its pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope is crystalline.

[0899] In certain embodiments, the present invention provides a pharmaceutical composition comprising a compound of structure (I) or any one of formulas (Ia) to (1f) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein the compound or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof has a particle size distribution. For example, in some embodiments, the D of the compound of structure (I) or any one of formulas (Ia) to (1f) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof is 50 The particle size distribution is in the range of about 500 nm to about 500 μm. In other embodiments, the compound of any one of structure (I) or formula (Ia) to (1f) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof is D 50 The particle size distribution is in the range of about 500 nm to about 1 μm, or about 1 μm to about 50 μm, or about 50 μm to about 100 μm, or about 100 μm to about 150 μm. In still other embodiments, the D of the compound of any one of structures (I) or formulas (Ia) to (1f) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof is 50 The particle size distribution is in the range of about 1 μm to about 10 μm, or about 2 μm to about 8 μm, or about 3 μm to about 7 μm.

[0900] In certain embodiments, the compound of structure (I) or any one of formulas (Ia) to (1f), or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, is 90 The particle size distribution is in the range of about 1 μm to about 1000 μm. In other embodiments, the compound of any one of structure (I) or formula (Ia) to (1f) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof is D 90 The particle size distribution is in the range of about 2 μm to about 100 μm, or about 100 μm to about 200 μm, or about 200 μm to about 300 μm, or about 300 μm to about 400 μm, or about 400 μm to about 500 μm, or about 500 μm to about 600 μm, or about 600 μm to about 700 μm, or about 700 μm to about 800 μm, or about 800 μm to about 900 μm, or about 900 μm to about 1000 μm. In still other embodiments, the D of the compound of any one of structures (I) or formulas (Ia) to (1f), or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof ... 90 The particle size distribution ranges from about 5 μm to about 25 μm, or from about 7 μm to about 23 μm, or from about 9 μm to about 21 μm, or from about 11 μm to about 19 μm.

[0901] In some embodiments, the pharmaceutical composition comprising a compound of structure (I) or any one of formulas (Ia) to (1f), or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, and at least one pharmaceutically acceptable carrier, diluent or excipient further comprises a second therapeutic agent.

[0902] In one embodiment, the second therapeutic agent is an antihistamine, such as an H1 receptor antagonist or an H2 receptor antagonist. In one embodiment, the second therapeutic agent is an H1 receptor antagonist antihistamine, such as levocetirizine, loratadine, fexofenadine, cetirizine, desloratadine, olopatadine, diphenhydramine, cyproheptadine or hydroxyzine pamoate. In one embodiment, the second therapeutic agent is an H2 receptor antagonist, such as cimetidine, nizatidine, ranitidine or famotidine. In one embodiment, the second therapeutic agent is a leukotriene receptor antagonist or a leukotriene synthesis inhibitor, such as montelukast, zafirlukast, pranlukast or a 5-lipoxygenase inhibitor (e.g., zileuton, Hypericum perforatum). In one embodiment, the second therapeutic agent is an immunomodulator, such as omalizumab or immunoglobulin therapy. In one embodiment, the second therapeutic agent is a corticosteroid, such as hydrocortisone, cortisone, inxamethasone, triamcinolone, prednisone, prednisolone or fludrocortisone. In one embodiment, the second therapeutic agent is a tricyclic antidepressant that can relieve itching, such as doxepin, amitriptyline or nortriptyline. In one embodiment, the second therapeutic agent is an anti-inflammatory drug, such as dapsone, sulfasalazine, hydroxychloroquine or colchicine. In one embodiment, the second therapeutic agent is an immunosuppressant, such as cyclosporin, methotrexate, mycophenolic acid or tacrolimus.

[0903] In one embodiment, the second therapeutic agent is an H1 receptor antagonist antihistamine, such as levocetirizine, loratadine, fexofenadine, cetirizine, desloratadine, olopatadine, diphenhydramine, cyproheptadine or hydroxyzine pamoate. In one embodiment, the second therapeutic agent is an H2 receptor antagonist, such as cimetidine, nizatidine, ranitidine or famotidine. In one embodiment, the second therapeutic agent is a leukotriene receptor antagonist or a leukotriene synthesis inhibitor, such as montelukast, zafirlukast, pranlukast or a 5-lipoxygenase inhibitor (e.g., zileuton, Hypericum perforatum). In one embodiment, the second therapeutic agent is an immunomodulator, such as omalizumab or immunoglobulin therapy. In one embodiment, the second therapeutic agent is a corticosteroid, such as hydrocortisone, cortisone, inxamethasone, triamcinolone, prednisone, prednisolone or fludrocortisone. In one embodiment, the second therapeutic agent is a tricyclic antidepressant that can relieve pruritus, such as doxepin, amitriptyline, or nortriptyline. In one embodiment, the second therapeutic agent is an anti-inflammatory drug, such as dapsone, sulfasalazine, hydroxychloroquine, or colchicine. In one embodiment, the second therapeutic agent is an immunosuppressant, such as cyclosporine, methotrexate, mycophenolic acid, or tacrolimus.

[0904] As used herein, the term "pharmaceutically acceptable carrier" refers to any component other than a disclosed compound or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof (e.g., a carrier capable of suspending or dissolving the active compound) and has the properties of being non-toxic and non-inflammatory to the patient. Excipients may include, for example: anti-adherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colorants), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavorings, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, adsorbents, suspending or dispersing agents, sweeteners or water of hydration. Exemplary excipients include, but are not limited to, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, cross-linked carboxymethylcellulose, cross-linked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.

[0905] In certain embodiments, the present invention provides a pharmaceutical composition comprising a compound of any one of structure (I) or formula (Ia) to (1f) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, and at least one polymer carrier. In some embodiments, the pharmaceutical composition is in the form of an amorphous solid dispersion comprising at least one polymer carrier.

[0906] In some embodiments, the polymer carrier includes at least one selected from the group consisting of an enteric polymer, a hydrophilic polymer, a surfactant, an amphiphilic polymer, and a combination thereof.

[0907] In some embodiments, the pharmaceutical composition contains a compound of structure (I) or any one of formulas (Ia) to (1f), or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, and a polymer carrier, the polymer carrier comprising at least one selected from the group consisting of methacrylate polymers, hydroxypropyl methylcellulose phthalate (HPMCP) polymers, hydroxypropyl methylcellulose acetate-succinate (HPMCAS) polymers, cellulose acetylated phthalate (CAP) polymers, starch, sodium carboxymethylcellulose polymers, sodium alginate polymers, polyethylene glycol (PEG), polyethylene Pyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC) polymer, polyvinyl alcohol (PVA), β-cyclodextrin polymer, mannitol polymer, chitosan polymer, carrageenan polymer, hydroxypropyl cellulose (HPC) polymer, polyethylene glycol-polypropylene glycol, lecithin, bile salts, lauroyl polyoxyethylene-32 glyceride, polyethylene oxide (PEO) / polypropylene glycol (PPG) copolymer, PEG-modified starch, vinyl acetate / vinyl pyrrolidone random copolymer, polyacrylic acid, polyacrylate, and polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol (PCL-PVAc-PEG) graft copolymer.

[0908] In some embodiments, the pharmaceutical composition contains a compound of any one of structure (I) or formula (Ia) to (1f), or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, and a polymer carrier, the polymer carrier comprising at least one selected from the group consisting of hydroxypropyl methylcellulose (HPMC) polymer, hydroxypropyl methylcellulose acetate-succinate (HPMCAS) polymer, polyvinyl pyrrolidone (PVP) and hydroxypropyl cellulose (HPC) polymer. In more specific embodiments, the polymer carrier comprises hydroxypropyl methylcellulose acetate-succinate (HPMCAS) polymer. For example, in some embodiments, the polymer carrier comprises HPMCAS-MG.

[0909] In some embodiments, the pharmaceutical composition comprises a compound of any one of structure (I) or formula (Ia) to (1f), or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, and at least one polymer carrier, such that the mass ratio of the compound to the polymer carrier is in the range of about 1:100 to about 50:1. For example, in some embodiments, the mass ratio of the compound to the polymer carrier is in the range of about 1:100 to about 1:50, or about 1:50 to about 1:10, or about 1:10 to about 1:1, or about 1:10 to about 1:1, or about 1:1 to about 10:1, or about 10:1 to about 20:1, or about 20:1 to about 50:1. In other embodiments, the mass ratio of the compound to the polymer carrier is in the range of about 1:1 to about 1:5.

[0910] In some embodiments, the pharmaceutical composition comprises a compound of any one of structure (I) or formula (Ia) to (1f), or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof and at least one polymer carrier, such that the weight percentage of the compound relative to the combined mass of the compound and the polymer carrier is in the range of about 2% to about 70%. In other embodiments, the weight percentage of the compound relative to the combined mass of the compound and the polymer carrier is in the range of about 2% to about 10%, or about 10% to about 20%, or about 15% to about 25%, or about 20% to about 30%, or about 30% to about 40%, or about 40% to about 50%, or about 50% to about 60%, or about 60% to about 70%.

[0911] In certain embodiments, the present invention provides a pharmaceutical composition, the pharmaceutical composition further includes at least one pharmaceutically acceptable excipient. For example, in some embodiments, the pharmaceutical composition includes a compound of any one of structure (I) or formula (Ia) to (1f) or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, at least one polymer carrier as described above and at least one pharmaceutically acceptable excipient. Pharmaceutically acceptable excipients may include, for example, fillers, binders, disintegrants, surfactants, lubricants, glidants, capsule shells and mixtures thereof. Fillers may include, for example, mannitol, microcrystalline cellulose (MCC), silicified microcrystalline cellulose (SMCC) and mixtures thereof. Binders may include, for example, hydroxypropyl methylcellulose (HPMC), polyvidone and mixtures thereof. Disintegrants may include, for example, sodium starch glycolate (SSG), cross-linked sodium carboxymethyl cellulose (CCS) and mixtures thereof. Surfactants may include, for example, sodium lauryl sulfate (SLS), poloxamer and mixtures thereof. Lubricants can include, for example, magnesium stearate (MS), sodium stearyl fumarate (SSF), and mixtures thereof. Glidants can include, for example, silicon dioxide, talc, and mixtures thereof. Capsule shells can include, for example, HPMC capsules or gelatin capsules. Surfactants can include, for example, sodium lauryl sulfate (SLS).

[0912] In some embodiments, the pharmaceutical composition includes at least one solvent. The solvent may include, for example, water and an organic solvent (such as dimethyl sulfoxide, etc.).

[0913] The formulation may be mixed with auxiliary agents that do not react adversely with the active compound. Such additives may include wetting agents, emulsifiers and suspending agents, salts that affect osmotic pressure, buffers and / or coloring substances, preservatives, sweeteners or flavoring agents. If desired, the composition may also be sterilized.

[0914] The route of administration can be any route that effectively transports the active compound of the invention to the appropriate or desired site of action, such as oral, nasal, pulmonary, buccal, subcutaneous, intradermal, transdermal or parenteral, including intravenous, subcutaneous and / or intramuscular. In one embodiment, the route of administration is oral. In another embodiment, the route of administration is topical.

[0915] The dosage form can be administered once a day, or more than once a day, such as twice or three times a day. Alternatively, if the prescribing physician or the prescription information of the drug considers it desirable, the dosage form can be administered at a lower frequency than daily, such as once every other day or once a week. The dosage regimen includes, for example, titrating the dose to the required or useful degree for the indication to be treated, so that the patient's body adapts to the treatment, to minimize or avoid unwanted side effects associated with the treatment, and / or to maximize the therapeutic effect of the compounds of the invention. Other dosage forms include delayed or controlled release forms. Suitable dosage regimens and / or forms include, for example, those listed in the latest version of the Physicians' Desk Reference, which is incorporated herein by reference.

[0916] Appropriate dosages for pediatric patients can be determined using known methods involving body weight, age, body surface area, and model such as Pediatric simulation modeling (CERTARA, Princeton, N.J.), which can be used to establish a pharmacokinetic dosing regimen that takes into account patient age, the individual occurrence of the clearance pathways for eliminating the compound of any one of Formulas (Ia) to (1f), and body surface area (BSA). In one embodiment, the dosage form is formulated to provide a pediatric dose at about 30% to about 100% of the adult dose, or about 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the adult dose.

[0917] In one embodiment, the present invention provides an oral pharmaceutical composition, comprising a compound of structure (I) or any one of formulas (Ia) to (1f), or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, and at least one pharmaceutically acceptable oral carrier, diluent or excipient. In another embodiment, the present invention provides a topical pharmaceutical composition, comprising a compound of structure (I) or any one of formulas (Ia) to (1f), or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, and at least one pharmaceutically acceptable topical carrier, diluent or excipient. For example, an oral pharmaceutical composition is provided to treat cholestatic pruritus, wherein the dosage regimen is, for example, once a day. In one embodiment, a topical pharmaceutical composition is provided to treat atopic dermatitis.

[0918] In another embodiment, a method for preparing a composition of a compound described herein is provided, the method comprising formulating a compound of the present invention with a pharmaceutically acceptable carrier or diluent. In some embodiments, the pharmaceutically acceptable carrier or diluent is suitable for oral administration. In some such embodiments, the method may further comprise the step of formulating the composition into a tablet or capsule. In other embodiments, the pharmaceutically acceptable carrier or diluent is suitable for parenteral administration. In some such embodiments, the method further comprises the step of lyophilizing the composition to form a lyophilized formulation. In some embodiments, the composition is formulated into a pediatric dosage form suitable for treating a pediatric subject.

[0919] In certain embodiments, the present invention provides a compound having structure (I) or any one of formulas (Ia) to (1f), or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof. Such compounds can be synthesized using standard synthetic techniques known to those skilled in the art. For example, the compounds of the present invention can be synthesized using the appropriately modified synthetic procedures described in the following examples and reaction schemes.

[0920] For this reason, the reactions, processes and synthetic methods described herein are not limited to the specific conditions described in the following experimental section, but are intended to be used as guidance to a suitable technician in the field. For example, the reaction can be carried out in any suitable solvent or other reagent to carry out the necessary conversion. Generally, a suitable solvent is a protic or aprotic solvent that does not react with reactants, intermediates or products at the temperature (i.e., the temperature that can be frozen to the boiling temperature range) of the reaction. A given reaction can be carried out in a solvent or a mixture of more than one solvent. Depending on the specific reaction, a suitable solvent for specific post-treatment after the reaction can be used.

[0921] All reagents that are not described in the experimental section for synthesis are commercially available, or are known compounds, or can be formed from known compounds by known methods by those skilled in the art. Compounds and intermediates produced according to the method of the present invention may need to be purified. The purification of organic compounds is well known to those skilled in the art, and there may be several methods to purify the same compound. In some cases, purification may not be required. In some cases, the compound can be purified by crystallization. In some cases, impurities can be stirred out using a suitable solvent. In some cases, the compound can be purified by chromatography, specifically flash column chromatography, using a special or pre-loaded silica gel column and an eluent such as a solvent gradient, such as heptane, ether, ethyl acetate, acetonitrile, ethanol, etc. In some cases, the compound can be purified by preparative HPLC using a method as described herein.

[0922] The purification methods as described herein can provide compounds of the invention having sufficient basic or acidic functionality in the form of salts, such as trifluoroacetate or formate salts in the case of sufficiently basic compounds of the invention, or ammonium salts in the case of sufficiently acidic compounds of the invention. Salts of this type can be converted to their free base or free acid forms, respectively, by various methods known to those skilled in the art, or used as salts in subsequent bioassays. It should be understood that a particular form of a compound of the invention as isolated and as described herein is not necessarily the only form in which the compound can be used in a bioassay to quantify a particular biological activity.

[0923] Chemical names were generated using ChemDraw nomenclature software (version 17.0.0.206) from PerkinElmer Informatics, Inc. In some cases, generally accepted commercially available reagent names were used in place of names generated by the nomenclature software.

[0924] Examples

[0925] General approach

[0926] 1 H NMR (400 MHz) spectra were obtained in deuterated chloroform (CDCl3), deuterated methanol (CD3OD), or dimethyl sulfoxide-D6 (DMSO) solutions. HPLC retention time, purity, and mass spectra (LCMS) were obtained using one of the following methods:

[0927] Method 1: Agilent 1260 Infinity II system equipped with an Agilent Poroshell 120EC-18, 2.7 μm, 4.6 x 100 mm column, at 30 ° C, using H2O containing 0.1% formic acid as mobile phase A, and MeCN containing 0.1% formic acid as mobile phase B. Use ESI detector in positive mode. The gradient is 5-95% mobile phase B in 12 minutes, then maintained at 95% for 1.8 minutes, and then returned to 10% mobile phase B in 0.2 minutes. The flow rate is 1 ml / min.

[0928] Method 2 : A SHIMADZU LCMS-2020 system equipped with a Kinetex EVO C18 2.1X 30mm column (5um particles) was used, using H2O containing 0.0375% trifluoroacetic acid as mobile phase A, and MeCN containing 0.01875% trifluoroacetic acid as mobile phase B. An ESI detector in positive mode was used. The gradient was 5% B at 0.00 min and 5-90% B at 0.00-0.80 min, 90-95% B at 0.80-0.12 min, and then 95-5% B in 0.01 min, held at 5% B for 0.34 min, with a flow rate of 1.5 ml / min.

[0929] Method 3 : Agilent 1200 system equipped with Kinetex C18 50*2.1 mm column (5um particles), using H2O containing 0.037% trifluoroacetic acid as mobile phase A, and using MeCN containing 0.018% trifluoroacetic acid as mobile phase B. Use ESI detector in positive mode. Gradient is 5% B at 0.00 min and 5-90% B at 0.00-0.80 min, 90-95% B at 0.80-0.12 min, and then 95-5% B in 0.01 min, keep at 5% B for 0.34 min, flow rate is 1.5 ml / min.

[0930] Method 4: A SHIMADZU LCMS-2020 system equipped with a Kinetex EVO C18 2.1X 30mm column (5um particles) was used, using H2O containing 0.0375% trifluoroacetic acid as mobile phase A, and MeCN containing 0.01875% trifluoroacetic acid as mobile phase B. An ESI detector in positive mode was used. The gradient was 5% B at 0.00 min and 5-90% B at 0.00-0.80 min, 90-95% B at 0.80-0.12 min, and then 95-5% B in 0.01 min, held at 5% B for 0.34 min, with a flow rate of 1.5 ml / min.

[0931] Method 5 : Agilent 1200 system equipped with Xbridge Shield RP18 2.1*50mm column (5um particles), using H2O containing 10mM NH4HCO3 as mobile phase A, and using MeCN as mobile phase B. Use ESI detector in positive mode. Gradient is 5-95% B in 0.30 minutes and 30-95% B in 0.30-0.80 minutes, keeps 0.4 minutes at 95% B, and then is 95-5% B in 0.01 minutes, flow rate is 1.5 ml / min.

[0932] Method 6 : A SHIMADZU LCMS-2020 system equipped with a Kinetex EVO C18 2.1X 30mm column (5um particles) was used, using H2O containing 0.0375% trifluoroacetic acid as mobile phase A, and MeCN containing 0.01875% trifluoroacetic acid as mobile phase B. An ESI detector in positive mode was used. The gradient was 5% B at 0.00 min and 5-90% B at 0.00-0.80 min, 90-95% B at 0.80-0.12 min, and then 95-5% B in 0.01 min, held at 5% B for 0.34 min, with a flow rate of 1.5 ml / min.

[0933] Method 7: A SHIMADZU LCMS-2020 system equipped with a Chromolith@Flash RP-18E 25-2MM column, using H2O containing 0.0375% trifluoroacetic acid as mobile phase A, and MeCN containing 0.01875% trifluoroacetic acid as mobile phase B. An ESI detector in positive mode was used. The gradient was 5% B at 0.00 min and 5-90% B at 0.00-0.80 min, 90-95% B at 0.80-0.12 min, and then 95-5% B in 0.01 min, kept at 5% B for 0.34 min, and the flow rate was 1.5 ml / min.

[0934] Method 8 : A SHIMADZU LCMS-2020 system equipped with a Kinetex EVO C18 2.1X 30mm column (5um particles) was used, using H2O containing 0.0375% trifluoroacetic acid as mobile phase A, and MeCN containing 0.01875% trifluoroacetic acid as mobile phase B. An ESI detector in positive mode was used. The gradient was 5% B at 0.00 min and 5-90% B at 0.00-0.80 min, 90-95% B at 0.80-0.12 min, and then 95-5% B in 0.01 min, held at 5% B for 0.34 min, with a flow rate of 1.5 ml / min.

[0935] Method 9 : Agilent 1290 Infinity II system equipped with an Agilent Poroshell 120EC-18, 2.7 μm, 4.61 x 100 mm column, at 35 ° C, using H2O containing 0.1% formic acid as mobile phase A, and using MeCN containing 0.1% formic acid as mobile phase B. Use ESI detector in positive mode. The gradient is 5-95% mobile phase B in 8.0 minutes, then maintained at 95% for 1.8 minutes, and then returned to 20% mobile phase B in 0.2 minutes. The flow rate is 0.7 ml / min.

[0936] Method 10 : Agilent 1260 Infinity II system equipped with an Agilent Poroshell 120EC-18, 2.7 μm, 4.6 x 100 mm column, at 30 ° C, using H2O containing 0.1% formic acid as mobile phase A, and MeCN containing 0.1% formic acid as mobile phase B. Use ESI detector in positive mode. The gradient is 5-95% mobile phase B in 5 minutes, then maintained at 95% for 1.8 minutes, and then returned to 20% mobile phase B in 0.2 minutes. The flow rate is 1 ml / min.

[0937] Method 11 : Agilent 1290 Infinity II system equipped with an Agilent Poroshell 120EC-18, 1.9 μm, 2.1 x 50 mm column, at 35 ° C, using H2O containing 0.1% formic acid as mobile phase A, and MeCN containing 0.1% formic acid as mobile phase B. Use ESI detector in positive mode. The gradient is 20-95% mobile phase B in 0.8 minutes, then maintained at 95% for 0.7 minutes, and then returned to 20% mobile phase B in 0.7 minutes. The flow rate is 0.7 ml / min.

[0938] Method 12 : A SHIMADZU LCMS-2020 system equipped with Kinetex EVO C18 2.1X 30mm (2.6um particles) was used, using H2O containing 0.0375% trifluoroacetic acid as mobile phase A, and MeCN containing 0.01875% trifluoroacetic acid as mobile phase B. An ESI detector in positive mode was used. The gradient was 5% B at 0.00 min and 5-95% B at 0.00-0.8 min, 95-95% B at 0.80-1.09 min, and then 95-5% B in 0.01 min, kept at 5% B for 0.1 min, and the flow rate was 1.5 ml / min.

[0939] Method 13 : Agilent 1200\G1956A equipped with Kinetex EVO C18 30*2.1mm, 5um column, using H2O containing 0.0375% TFA as mobile phase A, and using MeCN containing 0.01875% TFA as mobile phase B. The gradient was 5-95% mobile phase B in 0.8 minutes, kept at 95% for 0.4 minutes, then returned to 5% mobile phase B for 0.01 minutes, and kept at 5% for 0.29 minutes. The flow rate was 1.5 ml / min. The ESI detector in positive mode was used.

[0940] Method 14 : Equipped with SHIMADZU LCMS-2020 with EVO C18 2.1x 30mm 5um column, using H2O with 0.0375% TFA as mobile phase A, and MeCN with 0.01875% TFA as mobile phase B. The gradient was 5-95% mobile phase B in 0.8 minutes, held at 95% for 0.15 minutes, then returned to 5% mobile phase B for 0.01 minutes, and held at 5% for 0.04 minutes. The flow rate was 2 ml / min. An ESI detector in positive mode was used.

[0941] Method 15 : Agilent 1100\G1956A equipped with Kinetex@5um EVO C18 30*2.1mm column, using H2O containing 0.0375% TFA as mobile phase A, and using MeCN containing 0.01875% TFA as mobile phase B. The gradient was 5-95% mobile phase B in 0.8 minutes, kept at 95% for 0.4 minutes, then returned to 5% mobile phase B for 0.01 minutes, and kept at 5% for 0.29 minutes. The flow rate was 1.5 ml / min. The ESI detector in positive mode was used.

[0942] Method 16 : SHIMADZU LCMS-2020 equipped with Kinetex EVO C18 2.1X 30mm, 5um column, using H2O containing 0.0375% TFA as mobile phase A, and using MeCN containing 0.01875% TFA as mobile phase B. The gradient was 5-95% mobile phase B in 0.8 minutes, kept at 95% for 0.4 minutes, then returned to 5% mobile phase B for 0.01 minutes, and kept at 5% for 0.04 minutes. The flow rate was 1.5 ml / min. An ESI detector in positive mode was used.

[0943] The pyridine, dichloromethane (DCM), tetrahydrofuran (THF) and toluene used in the procedure are from the Aldrich Sure-Seal bottle preserved under nitrogen (N2). Other solvents are used as is. All reactions are magnetically stirred, and the temperature is the external reaction temperature. Chromatography is usually carried out using a Combiflash Rf rapid purification system (Teledyne Isco company) equipped with Redisep (Teledyne Isco company (Teledyne Isco)) Rf gold normal phase silica gel (SiO2) column or by using a similar system.

[0944] Preparative HPLC purifications were typically performed using one of the following systems: 1) a Waters system equipped with a Waters 2489 uv / vis detector, an Aquity QDA detector, a Waters xBridge Preparative C18 5 μm OBD, 30×150 mm column, and eluted with various gradients of H2O / MeCN (0.1% formic acid) at a flow rate of 30 ml / min; 2) a Teledyne Isco system equipped with a Waters xBridge Preparative C18 5 μm OBD, 30×150 mm column. HP150 UV system and eluted with various gradients of H2O / MeCN (0.1% formic acid) at a flow rate of 42.5 ml / min; or 3) column: Phenomenex Synergi C18 150X 30mm-4μm; mobile phase: [H2O (0.225% formic acid)-MeCN]; B%: 55%-85%, 12 minutes), and usually concentrated using Genevac EZ-2.

[0945] The following additional abbreviations are used: ethyl acetate (EA), triethylamine (TEA), water (H2O), sodium chloride (NaCl), hydrochloric acid (HCl), methanol (MeOH), dimethyl sulfoxide (DMSO), silica gel (SiO2), diisobutylaluminum hydride (DIBAL), trifluoroacetic acid (TFA), 4-dimethylaminopyridine (DMAP), diphenylphosphoryl azide (DPPA), benzoyl peroxide (BPO), 1,1'-bis(diphenylphosphino)ferrocene (dppf), bis(pinacolato)diboron (B2pin2), tetrahydrofuran (THF), 1,4-diazabicyclo[2.2.2]octane bis(sulfur dioxide) adduct (DABSO), azabenzotriazole tetramethylurea hexafluorophosphate (HATU), hydroxybenzotriazole (HOBt), N-methyl Morpholine (NMM), N-bromosuccinimide (NBS), diisopropylethylamine (DIPEA or DIEA), diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD), 2-[2-(dicyclohexylphosphino)phenyl]-N-methylindole (CM-Phos), trifluoromethanesulfonic acid (TfOH), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), isopropanol (IPA), dimethylformamide (DMF), dimethylacetamide (DMA), dichloromethane (DCM), 1,2-dichloroethane (DCE), acetonitrile (MeCN or ACN), 1,1'-thiocarbonyldiimidazole (TCDI), petroleum ether (PE), polyphosphoric acid (PPA), not determined (ND), retention time (RT, tr or t R ), molecular weight (mw), room temperature (rt), hours (h), and not applicable (N / A).

[0946] Solution 1

[0947]

[0948] Reagents: Step 1-1. R1COCl, base (DIPEA), solvent (DCM); Step 1-2. HCl, solvent (1,4-dioxane); Step 1-3. R2X, base (DIPEA), solvent (DMSO, NMP), heating

[0949] Example 1

[0950] Synthesis of Example 1

[0951]

[0952] Step 1-1. Synthesis of tert-butyl ((1S,3R)-3-(4-methoxybenzamido)cyclohexyl)carbamate

[0953]

[0954] To an ice-cold stirred solution of (1S, 3R)-3-amino-1-(Boc-amino)cyclohexane (1.142 g, 1.0 eq., 5.329 mmol) in DCM (30 mL) was added DIPEA (1.377 g, 1.9 mL, 2.0 eq., 10.66 mmol), followed by slow addition of 4-methoxybenzoyl chloride (955 mg, 758 μL, 1.05 eq., 5.60 mmol). The resulting mixture was stirred at room temperature. After stirring for 18 hours, the reaction mixture was filtered, and the filter cake was washed with DCM and dried under high vacuum to obtain tert-butyl ((1S, 3R)-3-(4-methoxybenzamido)cyclohexyl)carbamate (1.659 g, 4.761 mmol, 89% yield).

[0955] LCMS-ESI (m / z) calculated: 348.44; found: 349.2 [M+H] + , retention time = 4.239 min (Method 10).

[0956] 1 H NMR (400MHz, DMSO-d6) δ8.09(d,J=7.9Hz,1H),7.82(d,J=8.4Hz,2H),6.97(d,J=8.4Hz,2H),6.83(d,J=8.1Hz,1H),3.80(s,3H),3. 79–3.71(m,1H),3.31–3.22(m,1H),1.93(d,J=12.0Hz,1H),1.77–1.68(m,3H),1.38(s,9H),1.31–1.17(m,3H),1.11–1.01(m,1H).

[0957] Step 1-2. Synthesis of N-((1R,3S)-3-aminocyclohexyl)-4-methoxybenzamide

[0958]

[0959] To a stirred suspension of ((1S,3R)-3-(4-methoxybenzamido)cyclohexyl)-carbamic acid tert-butyl ester (1.654 g, 1 eq, 4.747 mmol) in EtOH (40 mL) was added 1.25 M hydrogen chloride in 1,4-dioxane (1.731 g, 37.97 mL, 1.25 moles, 10 eq, 47.47 mmol). The resulting mixture was stirred at 50 °C for 17 hours. The reaction mixture was directly concentrated to give a white solid, which was further dried under high vacuum to give N-((1R,3S)-3-aminocyclohexyl)-4-methoxybenzamide hydrochloride (1.331 g, 4.674 mmol, 98%), which was used in the next step without further purification.

[0960] LCMS-ESI (m / z) calculated: 248.44; found: 249.2 [M+H] + , retention time = 1.665 min (Method 10).

[0961] 1 H NMR (400MHz, DMSO-d6) δ8.26(d,J=7.9Hz,1H),8.09(s,3H),7.84(d,J=8.4Hz,2H),6.98(d,J=8.4Hz,2H),3.91–3.81(m,1H) ,3.80(s,3H),3.13–3.05(m,1H),2.12(d,J=11.6Hz,1H),1.91(d,J=12.0Hz,1H),1.78(d,J=12.0Hz,2H),1.44–1.21(m,4H).

[0962] Step 1-3. Synthesis of N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-4-methoxybenzamide (Example 1)

[0963]

[0964] To a pressure vial containing a solution of 4,6-dichloro-2-(trifluoromethyl)quinoline (56 mg, 1.0 eq., 0.21 mmol) and N-((1R,3S)-3-aminocyclohexyl)-4-methoxybenzamide hydrochloride (60 mg, 1.0 eq., 0.21 mmol) in DMSO (2 mL) was charged DIPEA (0.11 g, 0.15 mL, 4.0 eq., 0.84 mmol). The vial was closed and the resulting solution was stirred at 130° C. After stirring at 130° C. for 20 hours, the reaction mixture was cooled to room temperature. The reaction mixture was filtered and the filtrate was purified by preparative HPLC (ISCO ACCQPrep 150) to give N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-4-methoxybenzamide (20 mg, 42 μmol, 20% yield).

[0965] LCMS-ESI (m / z) calculated: 477.91; found: 478.2 [M+H] + , retention time = 7.477 min (Method 9).

[0966] 1 H NMR(400MHz, DMSO-d6)δ8.61(s,1H),8.18(d,J=7.9Hz,1H),7.89(d,J=9.0Hz,1H), 7.83(d,J=8.5Hz,2H),7.74(dd,J=9.0,2.1Hz,1H),7.50(d,J=8.0Hz,1H),7.01–6.8 9(m,3H),4.07–3.98(m,1H),3.92–3.84(m,1H),3.80(s,3H),2.16(d,J=11.9Hz,1H ),1.97(d,J=12.3Hz,1H),1.91–1.78(m,2H),1.60–1.47(m,2H),1.44–1.29(m,2H).

[0967] Example 2

[0968] Synthesis of Example 2

[0969]

[0970] Step 1-1. Synthesis of tert-butyl ((1S,3R)-3-benzamidocyclohexyl)carbamate

[0971] To an ice-cold solution of (1S, 3R)-3-amino-1-(Boc-amino)cyclohexane (1.238 g, 1 eq., 5.777 mmol) in DCM (30 mL) was added DIPEA (1.493 g, 2.0 mL, 2 eq., 11.55 mmol), followed by benzoyl chloride (853 mg, 704 μL, 1.05 eq., 6.07 mmol). The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was filtered, and the filter cake was washed with DCM and dried under high vacuum to give tert-butyl ((1S, 3R)-3-benzamidocyclohexyl)carbamate (1.575 g, 4.946 mmol, 86% yield).

[0972] LCMS-ESI (m / z) calculated value: 318.30; found value 319.2 [M+H] + , retention time = 4.237 min (Method 10).

[0973] 1 H NMR (400MHz, DMSO-d6) δ8.26(d,J=7.9Hz,1H),7.83(d,J=7.5Hz,2H),7.53–7.42(m,3H),6.84(d,J=8.0Hz,1H),3.84–3.74 (m,1H),3.31–3.23(m,1H),1.95(d,J=12.0Hz,1H),1.79–1.68(m,3H),1.38(s,9H),1.31–1.17(m,3H),1.11–1.02(m,1H).

[0974] Step 1-2. Synthesis of N-((1R,3S)-3-aminocyclohexyl)benzamide hydrochloride

[0975] To a stirred white suspension of ((1S,3R)-3-benzamidocyclohexyl)-carbamic acid tert-butyl ester (1.570 g, 1 eq, 4.931 mmol) in 1,4-dioxane (35 mL) was added 4M hydrogen chloride in 1,4-dioxane (10 eq, 49.31 mmol). The resulting mixture was heated at 50 °C for 19 hours. The reaction mixture was directly concentrated and dried under high vacuum to give N-((1R,3S)-3-aminocyclohexyl)benzamide hydrochloride (1.201 g, 4.714 mmol, 96% yield).

[0976] LCMS-ESI (m / z) calculated: 218.30; found: 219.2 [M+H] + , retention time = 0.261 min (Method 11).

[0977] 1 H NMR (400MHz, DMSO-d6) δ8.42(d,J=7.9Hz,1H),8.11(s,3H),7.85(d,J=7.5Hz,2H),7.55–7.41(m,3H),3.93–3.80(m ,1H),3.18–3.04(m,1H),2.14(d,J=11.8Hz,1H),1.92(d,J=12.0Hz,1H),1.79(d,J=11.4Hz,2H),1.48–1.20(m,4H).

[0978] Step 1-3. Synthesis of N-((1R,3S)-3-((2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)benzamide (Example 2)

[0979] To a solution of 4-chloro-2-(trifluoromethyl)quinoline (55 mg, 1 eq., 0.24 mmol) and N-((1R, 3S)-3-aminocyclohexyl)benzamide hydrochloride (60 mg, 1 eq., 0.24 mmol) in DMSO (2 mL) was added DIPEA (0.12 g, 0.16 mL, 4 eq., 0.94 mmol). The vial was capped and the resulting solution was stirred at 130 °C for 18 hours. The reaction mixture was cooled to room temperature, passed through a syringe filter, and the filtrate was purified by preparative HPLC (ISCO ACCQPrep 150) to give N-((1R, 3S)-3-((2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)benzamide (13.4 mg, 32.4 μmol, 14% yield).

[0980] LCMS-ESI (m / z) calculated: 413.44; found: 414.3 [M+H] + , retention time = 5.687 min (Method 9).

[0981] 1 H NMR (400MHz, DMSO-d6) δ8.42(d,J=8.5Hz,1H),8.34(d,J=7.9Hz,1H),7.92–7.80(m,3H),7.73(t,J=7.6Hz,1H),7.58–7.37(m,5H),6.9 0(s,1H),4.10–3.99(m,1H),3.93–3.82(m,1H),2.19(d,J=12.0Hz,1H),2.01–1.80(m,3H),1.56(q,J=12.1Hz,2H),1.46–1.29(m,2H).

[0982] Example 3

[0983] Synthesis of Example 3

[0984]

[0985] Step 1-1. Synthesis of tert-butyl N-[(1S,3R)-3-[(4-fluorobenzoyl)amino]cyclohexyl]carbamate

[0986] To a solution of tert-butyl N-[(1S, 3R)-3-aminocyclohexyl]carbamate (0.8 g, 3.7 mmol, 1 eq) and TEA (567 mg, 5.60 mmol, 779 uL, 1.5 eq) in DCM (5 mL) was added 4-fluorobenzoyl chloride (592 mg, 3.73 mmol, 448 uL, 1 eq) at 0 °C. The resulting mixture was stirred at 0 °C for 1 hour. The reaction mixture was diluted with H2O (50 mL) and EA (50 mL). The mixture was filtered, and the resulting filter cake was concentrated under reduced pressure to obtain a crude product. The filtrate was extracted with EA (50 mL x 2). The combined organic layers were washed with saturated aqueous NaCl solution (50 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give tert-butyl N-[(1S,3R)-3-[(4-fluorobenzoyl)amino]cyclohexyl]carbamate (1.26 g, crude product), which was used in the next step without further purification.

[0987] LCMS-ESI (m / z) calculated: 336.40; found: 237.2 [M+H-Boc] + , retention time = 0.9 min (Method 2).

[0988] 1 H NMR (400MHz, DMSO-d6) δ = 8.30 (d, J = 8.0Hz, 1H), 7.92-7.88 (m, 2H), 7.30-7.24 (m, 2H), 6.85 (d, J = 8.0Hz, 1H), 3. 81-3.73(m,1H),3.27-3.28(m,1H),1.95(d,J=11.2Hz,1H),1.78-1.71(m,3H),1.37(s,9H),1.31-1.02(m,4H).

[0989] Step 1-2. Synthesis of N-[(1R,3S)-3-aminocyclohexyl]-4-fluoro-benzamide

[0990] A sample of tert-butyl N-[(1S, 3R)-3-[(4-fluorobenzoyl)amino]cyclohexyl]carbamate (1.16 g, 3.45 mmol, 1 eq) was added to HCl / MeOH (4M, 15 mL, 17.40 eq) at 25 °C. The mixture was stirred for 1 hour at 25 °C. The reaction mixture was concentrated under reduced pressure to obtain a residue. The residue was dissolved in MeOH (50 mL), and then resin (base) was added and filtered to remove insoluble particles. The mother liquor was concentrated under reduced pressure to obtain a crude product, N-[(1R, 3S)-3-aminocyclohexyl]-4-fluoro-benzamide (0.81 g, 3.43 mmol, 99.41% yield), which was used in the next step without further purification.

[0991] 1 H NMR (400MHz, DMSO-d6)δ=8.52-8.46(m,1H),7.96-7.92(m,2H),7.30-7.25(m,2H),3.85-3.83(m,1H),3 .06-3.01(m,1H),2.14(d,J=10.8Hz,1H),1.93(d,J=11.2Hz,1H),1.78-1.76(m,2H),1.49-1.26(m,4H).

[0992] Step 1-3. Synthesis of 4-fluoro-N-[(1R,3S)-3-[[2-(trifluoromethyl)quinazolin-4-yl]amino]cyclohexyl]benzamide (Example 3)

[0993] A mixture of 4-chloro-2-(trifluoromethyl)quinazoline (80 mg, 344 umol, 1 eq.), N-[(1R, 3S)-3-aminocyclohexyl]-4-fluorobenzamide (163 mg, 688 umol, 2 eq.) and DIEA (222 mg, 1.72 mmol, 300 uL, 5 eq.) in DMSO (2 mL) was stirred for 1 hour at 120° C. The reaction mixture was filtered. The filtrate was purified by preparative HPLC (column: Unisil 3-100C18 Ultra 150*50mm*3um; mobile phase: [water (0.225% FA)-ACN]; B%: 50%-70%, 10 minutes) and lyophilized to give 4-fluoro-N-[(1R,3S)-3-[[2-(trifluoromethyl)-quinazolin-4-yl]amino]cyclohexyl]benzamide (60 mg, 138umol, 40% yield).

[0994] LCMS-ESI (m / z) calculated: 432.4; found: 433.2 [M+H-Boc] + , retention time = 0.941 min (Method 2).

[0995] 1 H NMR (400MHz, DMSO-d6) δ = 8.54 (d, J = 8.0Hz, 1H), 8.45-8.38 (m, 2H), 7.93-7.81 (m, 4H), 7.69-7.65 (m, 1H), 7.31-7 .25(m,2H),4.34-4.29(m,1H),4.00-3.89(m,1H),2.19(d,J=11.6Hz,1H),1.99-1.85(m,3H),1.62-1.30(m,4H).

[0996] Example 4

[0997] Synthesis of Example 4

[0998]

[0999] Step 1-3. Synthesis of 4-methoxy-N-[(1R,3S)-3-[[5-methyl-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]benzamide

[1000] A mixture of 4-chloro-5-methyl-2-(trifluoromethyl)quinoline (120 mg, 489 umol, 1 eq.), N-[(1R, 3S)-3-aminocyclohexyl]-4-methoxy-benzamide (170 mg, 685 umol, 1.4 eq.) and DIEA (189 mg, 1.47 mmol, 255 uL, 3 eq.) in NMP (1 mL) was stirred at 120° C. for 16 hours. The mixture was cooled to room temperature, filtered and concentrated. The filtrate was purified by preparative HPLC (column: Phenomenex luna C18 150*25mm*10um; mobile phase: [water (0.225% FA)-ACN]; B%: 32%-62%, 10 minutes) and lyophilized to give 4-methoxy-N-[(1R,3S)-3-[[5-methyl-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]benzamide (8.7 mg, 19umol, 4% yield).

[1001] LCMS-ESI (m / z) calculated: 457.5; found: 458.1 [M+H] + , retention time = 0.846 min (Method 8).

[1002] 1H NMR (400MHz, DMSO-d6) δ = 8.44-8.38 (m, 1H), 8.18 (br d,J=7.6Hz,1H),7.84(d,J=8.9Hz,2H),7.70(d,J=8.1Hz,1H),7.58-7.51(m, 1H),7.28(d,J=7.0Hz,1H),6.97(d,J=8.9Hz,2H),6.90-6.85(m,1H),6.31(br d,J=7.5Hz,1H),4.06-3.95(m,1H),3.85-3.75(m,4H),2.96-2.90(m,3H),2.32-2.24(m,1H),2.11-2.03(m,1H),1.89(br d,J=10.8Hz,1H),1.81(br d,J=13.1Hz,1H),1.61-1.45(m,2H),1.39-1.26(m,2H).

[1003] Example 5

[1004] Synthesis of Example 5

[1005]

[1006] Synthesis of 4-chloro-7-methyl-2-(trifluoromethyl)quinoline

[1007] A mixture of 7-methyl-2-(trifluoromethyl)quinoline-4-ol (150 mg, 660 umol, 1 eq.) and POCl (2.02 g, 13.2 mmol, 1.23 mL, 20 eq.) in ACN (1 mL) was stirred at 90 ° C for 2 hours. The mixture was cooled to 20 ° C. and slowly poured into water (20 mL), extracted with EtOAc (20 mL), and the organic layer was collected and concentrated under reduced pressure to give crude 4-chloro-7-methyl-2-(trifluoromethyl)quinoline (150 mg), which was used without further purification.

[1008] LCMS-ESI (m / z) calculated: 245.6; found: 246.0 [M+H] + , retention time = 1.018 min (Method 2).

[1009] Step 1-2. Synthesis of 4-methoxy-N-[(1R,3S)-3-[[7-methyl-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]benzamide

[1010] A mixture of 4-chloro-7-methyl-2-(trifluoromethyl)quinoline (150 mg, 611 umol, 1 eq), N-[(1R, 3S)-3-aminocyclohexyl]-4-methoxy-benzamide (227 mg, 914 umol, 1.5 eq) and DIEA (237 mg, 1.83 mmol, 319 uL, 3 eq) in NMP (0.5 mL) was stirred at 120° C. for 16 hours. The mixture was cooled to room temperature, filtered and concentrated. The filtrate was purified by preparative HPLC (column: Phenomenex luna C18 150*25mm*10um; mobile phase: [water (0.225% FA)-ACN]; B%: 32%-62%, 10 minutes) and lyophilized to give 4-methoxy-N-[(1R,3S)-3-[[7-methyl-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]benzamide (23.5 mg, 51 umol, 8%).

[1011] LCMS-ESI (m / z) calculated: 457.49; found: 458.1 [M+H] + , retention time = 0.818 min (Method 2).

[1012] 1 H NMR (400MHz, DMSO-d6) δ = 8.31 (d, J = 8.8Hz, 1H), 8.21-8.13 (m, 1H), 7.83 (d, J = 8.8H z,2H),7.67(s,1H),7.39(dd,J=1.3,8.7Hz,1H),7.31(d,J=8.1Hz,1H),6.97(d,J= 8.8Hz,2H),6.82(s,1H),4.07-3.96(m,1H),3.80(s,4H),2.47(s,3H),2.20-2.12( m,1H),2.00-1.93(m,1H),1.91-1.78(m,2H),1.61-1.47(m,2H),1.45-1.27(m,2H).

[1013] Example 6

[1014] Synthesis of Example 6

[1015]

[1016] Step 1-1: Synthesis of N-[(1R,3S)-3-[[8-bromo-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-4-methoxy-benzamide

[1017] N-[(1R, 3S)-3-aminocyclohexyl]-4-methoxy-benzamide (52.8 mg, 213 umol, 1.1 equiv) and DIEA (50.0 mg, 386 umol, 67 uL, 2 equiv) were added to a solution of 8-bromo-4-chloro-2-(trifluoromethyl)quinoline (60 mg, 193 umol, 1 equiv) in DMSO (1 mL). The mixture was stirred at 125 ° C for 12 hours. The reaction mixture was added to water (20 mL) and extracted with EA (20 mL × 2). The combined organics were washed with brine, dried over Na2SO4, and concentrated in vacuo to obtain a residue. The residue was purified by preparative TLC (SiO 2 , PE:EA=2:1) ​​to give N-[(1R,3S)-3-[[8-bromo-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-4-methoxy-benzamide (60 mg, 115 umol, 59% yield).

[1018] LCMS-ESI (m / z) calculated: 522.6; found: 522.1 / 524.1 [M+H] + , retention time = 0.977 min (Method 2).

[1019] Step 1-2: Synthesis of 4-[[(1S,3R)-3-[(4-methoxybenzoyl)amino]cyclohexyl]amino]-2-(trifluoromethyl)quinoline-8-carboxylate

[1020] To a solution of N-[(1R,3S)-3-[[8-bromo-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-4-methoxy-benzamide (60 mg, 115 umol, 1 eq.), Et3N (34.9 mg, 345 umol, 48 uL, 3 eq.) in MeOH (10 mL) was added Pd(dppf)Cl2.CH2Cl2 (9.4 mg, 11.5 umol, 0.1 eq.) at 25°C. The suspension was degassed under vacuum and purged with CO several times. The reactants were heated to 70°C and stirred under a CO (50 psi) atmosphere for 16 hours. The reaction mixture was cooled to room temperature and Et3N (34.9 mg, 345 umol, 48 uL, 3 eq.) and Pd(dppf)Cl2 CH2Cl2 (28.1 mg, 34.5 umol, 0.3 eq.) were added. The suspension was degassed under vacuum and purged with CO several times, and then warmed to 70°C and stirred under a CO (50 psi) atmosphere for 16 hours. Thiourea (resin) (1 g) was then added to the reaction mixture and stirred at 20°C for 2 hours. The reaction mixture was filtered, and the filter cake was washed with MeOH (10 mL×3). The filtrate was concentrated in vacuo to give a residue, which was purified by preparative HPLC (column: Phenomenex luna C18 150*25mm*10um; mobile phase: [water (0.225% FA)-ACN]; B%: 35%-65%, 10 minutes) to give 4-[[(1S, 3R)-3-[(4-methoxybenzoyl)amino]cyclohexyl]amino]-2-(trifluoromethyl)quinoline-8-carboxylic acid methyl ester (7.4 mg, 14.8umol, 13% yield).

[1021] LCMS-ESI (m / z) calculated: 501.5; found: 502.3 [M+H] + , retention time = 0.980 min (Method 2).

[1022] 1H NMR (400MHz, DMSO) δ = 8.56 (d, J = 7.6Hz, 1H), 8.18 (d, J = 7.8Hz, 1H), 7.89-7.80 (m, 3H), 7.59 (dd, J = 7.2, 8. 4Hz,1H),7.53(d,J=8.2Hz,1H),7.00-6.94(m,3H),4.09-3.96(m,1H),3.87(s,4H),3.80(s,3H),2.17(br d,J=11.9Hz,1H),1.97(br d,J=11.5Hz,1H),1.92-1.77(m,2H),1.55(q,J=12.0Hz,2H),1.46-1.26(m,2H).

[1023] The compounds listed in Table 1 were prepared using the procedure of Scheme 1.

[1024] Table 1

[1025]

[1026]

[1027]

[1028]

[1029] Solution 2

[1030]

[1031] Reagents: base (t-Bu-ONa, TEA, Cs2CO3), coupling reagent (Pd(OAc)2, 1-BuXPhosPd, Pd(dppf)Cl2), solvent (1,4-dioxane)

[1032] Example 7

[1033] Synthesis of Example 7

[1034]

[1035] Step 2: Synthesis of 4-methoxy-N-((1R,3S)-3-((2-(trifluoromethyl)quinolin-5-yl)amino)cyclohexyl)benzamide

[1036] A mixture of 5-bromo-2-(trifluoromethyl)quinoline (97 mg, 1 eq, 351 μmol), N-((1R,3S)-3-aminocyclohexyl)-4-methoxybenzamide hydrochloride (100 mg, 1 eq, 351 μmol), cesium carbonate (343 mg, 3 eq, 1.05 mmol), palladium(II) acetate (3.9 mg, 0.05 eq, 17.6 μmol) and BINAP (22 mg, 0.10 eq, 35 μmol) in 1,4-dioxane (3 mL) was degassed with nitrogen for 5 minutes. The vial was capped and the resulting mixture was heated at 100 °C. After stirring at 100 °C for 20 h, the reaction mixture was cooled to room temperature, passed through a syringe filter, and the filtrate was directly loaded / purified by preparative HPLC (ISCO ACCQPrep 150) to give 4-methoxy-N-((1R,3S)-3-((2-(trifluoromethyl)quinolin-5-yl)amino)cyclohexyl)benzamide (49 mg, 111 μmol, 32% yield).

[1037] LCMS-ESI (m / z) calculated: 443.47; found: 444.2 [M+H] + , retention time = 0.987 min (Method 11).

[1038] 1 H NMR(400MHz, DMSO-d6)δ9.02(d,J=8.8Hz,1H),8.16(d,J=7.8Hz,1H),7.81(dd,J=8.7, 6.8Hz,3H),7.66(t,J=8.1Hz,1H),7.29(d,J=8.3Hz,1H),6.97(d,J=8.4Hz,2H),6.81( d,J=7.9Hz,1H),6.43(d,J=7.6Hz,1H),4.02–3.92(m,1H),3.79(s,3H),3.65–3.56(m, 1H), 2.27 (d, J = 12.1Hz, 1H), 2.09–2.03 (m, 1H), 1.92–1.80 (m, 2H), 1.56–1.27 (m, 4H).

[1039] Example 8

[1040] Synthesis of Example 8

[1041]

[1042] Step 2: 4-methoxy-N-((1R,3S)-3-((3-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)benzene Synthesis of amides

[1043] A mixture of 4-bromo-3-(trifluoromethyl)quinoline (97 mg, 1 eq, 351 μmol), N-((1R,3S)-3-aminocyclohexyl)-4-methoxybenzamide hydrochloride (100 mg, 1 eq, 351 μmol), cesium carbonate (343 mg, 3 eq, 1.05 mmol), palladium(II) acetate (3.9 mg, 0.05 eq, 17.6 μmol) and BINAP (22 mg, 0.10 eq, 35.1 μmol) in 1,4-dioxane (3 mL) was degassed with nitrogen. The vial was capped and the resulting mixture was heated at 100 °C. After stirring for 20 h, the reaction mixture was cooled to room temperature, passed through a syringe filter, and the filtrate was directly loaded / purified by preparative HPLC (ISCO ACCQPrep 150) to give 4-methoxy-N-((1R,3S)-3-((3-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)benzamide (6.5 mg, 15 μmol, 4% yield).

[1044] LCMS-ESI (m / z) calculated: 443.47; found: 444.2 [M+H] + , retention time = 0.488 min (Method 11).

[1045] 1 H NMR (400MHz, DMSO-d6) δ8.70(s,1H),8.37(d,J=8.6Hz,1H),8.18(d,J=7.7Hz,1 H),7.93(d,J=8.4Hz,1H),7.80(d,J=8.2Hz,3H),7.61(t,J=7.6Hz,1H),6.96(d, J=8.4Hz,2H),6.03(d,J=9.9Hz,1H),3.79(s,5H),2.07(d,J=12.0Hz,1H),1.95 (d,J=12.5Hz,1H),1.80(d,J=9.0Hz,2H),1.65–1.47(m,2H),1.37–1.24(m,2H).

[1046] The compounds listed in Table 2 were prepared using the procedure of Scheme 2.

[1047] Table 2

[1048]

[1049] Example 9

[1050] Synthesis of Example 9

[1051]

[1052] Synthesis of 2-(Difluoromethyl)quinolin-4-ol

[1053] Aniline (0.5 g, 5.37 mmol, 490 uL, 1 equivalent) and ethyl 4,4-difluoro-3-oxobutanoate (892 mg, 5.37 mmol, 1 equivalent) were added to PPA (26.9 mmol, 10 mL, 5.00 equivalent) at 140 ° C. The reaction mixture was stirred for 12 hours at 140 ° C. The reaction mixture was cooled to room temperature, poured into water (50 mL), and extracted with ethyl acetate (4X 50 mL). The combined organic matter was dried over Na2SO4, filtered and concentrated under vacuum to obtain a residue. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate=1:2) to obtain 2-(difluoromethyl)quinoline-4-ol (0.2 g, 1.02 mmol, 19% yield).

[1054] LCMS-ESI (m / z) calculated: 195.17; found: 196.4 [M+H] + , retention time = 0.777 min (Method 2).

[1055] Synthesis of 4-chloro-2-(difluoromethyl)quinoline

[1056] POCl3 (430mg, 2.80mmol, 261uL, 2.74 equivalents) was added dropwise to a solution of 2-(difluoromethyl)quinoline-4-ol (200mg, 1.02mmol, 1 equivalent) in DCE (3mL) at 0°C. The reaction mixture was then heated at 80°C for 12 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to obtain a brown oil. The residue was purified by column chromatography (silica gel, petroleum ether / ethyl acetate=10:1) to obtain 4-chloro-2-(difluoromethyl)quinoline (200mg, 936umol, 91% yield).

[1057] LCMS-ESI (m / z) calculated: 213.61, found: 214.0 [M+H] + , retention time = 0.930 min (Method 2).

[1058] Step 2: Synthesis of N-[(1R,3S)-3-[[2-(difluoromethyl)-4-quinolyl]amino]cyclohexyl]-4-methoxy-benzamide

[1059] A mixture of 4-chloro-2-(difluoromethyl)quinoline (30 mg, 140 umol, 1 eq.), N-[(1R, 3S)-3-aminocyclohexyl]-4-methoxybenzamide (35 mg, 140 umol, 1 eq.), [2-(2-aminophenyl)phenyl]-methylsulfonyloxy-palladium, di-tert-butyl-[2-(2,4,6-triisopropylphenyl)phenyl]phosphine (22 mg, 28 umol, 0.2 eq.) and t-BuONa (27 mg, 281 umol, 2 eq.) in tert-amyl alcohol (1 mL) was heated at 100° C. for 3 hours. The reaction mixture was cooled to room temperature, poured into water (10 mL), extracted with ethyl acetate (2 x 10 mL), and the combined organics were dried and concentrated in vacuo to give a residue. The residue was purified by preparative HPLC (column: Waters Xbridge 150*25mm*5um; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 32%-62%, 8 minutes) to give N-[(1R,3S)-3-[[2-(difluoromethyl)-4-quinolyl]amino]cyclohexyl]-4-methoxy-benzamide (3 mg, 6.7umol, 5% yield).

[1060] LCMS-ESI (m / z) calculated: 425.47, found: 426.2 [M+H] + , retention time = 0.797 min (Method 2).

[1061] Solution 3

[1062]

[1063] Reagents: Step 3-1. R1X, base (DIPEA), solvent (DMSO, NMP), 130°C; Step 3-2. HCl, solvent (1,4-dioxane); Step 3-3. R2COCl, base (DIPEA), solvent (DMF)

[1064] Example 10

[1065] Synthesis of Example 10

[1066]

[1067] Step 3-1. Synthesis of tert-butyl ((1R,3S)-3-((2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamate

[1068] To a solution of 4-chloro-2-(trifluoromethyl)quinoline (1.08g, 1 equivalent, 4.65mmol) and ((1R, 3S)-3-aminocyclohexyl)carbamic acid tert-butyl ester (0.996g, 1 equivalent, 4.65mmol) in DMSO (12mL) was added DIPEA (2.40g, 3.2mL, 4 equivalents, 18.6mmol). The vial was capped and the resulting solution was heated at 130°C. After stirring at 130°C for 3 hours, the reaction mixture was cooled to room temperature. The reaction mixture was diluted with water and extracted with EtOAc (3x 20mL). The organic layers were combined, washed with brine, and concentrated under reduced pressure. The residue was purified by flash column chromatography (ISCO Gold 120 g, 0-80% EtOAc / hexanes) to give tert-butyl ((1R,3S)-3-((2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamate (0.584 g, 1.43 mmol, 31% yield).

[1069] LCMS-ESI (m / z) calculated: 409.45, found: 410.3 [M+H] + , retention time = 4.976 min (Method 10).

[1070] 1 H NMR (400MHz, DMSO-d6) δ8.40(d,J=8.5Hz,1H),7.87(d,J=8.4Hz,1H),7.72(t,J=7.6Hz,1H),7.54(t,J=7.6Hz,1H),7.35(d,J=8.1Hz,1H),6.94–6.75(m ,2H),3.81–3.70(m,1H),3.52–3.39(m,1H),2.07(d,J=12.0Hz,1H),1.91(d ,J=12.2Hz,1H),1.84–1.71(m,2H),1.50–1.28(m,12H),1.17–1.07(m,1H).

[1071] Step 3-2. Synthesis of (1S, 3R)-N1-(2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride

[1072] To a stirred suspension of tert-butyl ((1R,3S)-3-((2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamate (580 mg, 1 eq, 1.42 mmol) in 1,4-dioxane (10 mL) was added 4M hydrogen chloride in 1,4-dioxane (3.54 mL, 4.00 moles, 10 eq, 14.2 mmol). The resulting mixture was stirred at 50 °C for 16 hours. The reaction mixture was filtered and the resulting filter cake was washed with diethyl ether and dried under high vacuum to give (1S,3R)-N1-(2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride (491 mg, 1.42 mmol, 100% yield).

[1073] LCMS-ESI (m / z) calculated: 309.2, found: 310.2 [M+H] + , retention time = 1.294 min (Method 10).

[1074] 1 H NMR (400MHz, DMSO-d6) δ8.59(d,J=8.5Hz,1H),8.22(s,4H),7.99(d,J=8.4Hz,1H),7.83(t,J=7.7Hz,1H),7.63(t,J=7.6Hz,1H),7.03(s,1H) ,4.06–3.94(m,1H),3.32–3.20(m,1H),2.25(d,J=11.7Hz,1H),2.03– 1.81(m,3H),1.68–1.56(m,1H),1.54–1.41(m,2H),1.39–1.27(m,1H).

[1075] Step 3-3. Synthesis of 3-methoxy-N-((1R,3S)-3-((2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)benzamide

[1076] 3-(Methoxycarbonyl)benzoic acid chloride (12 mg, 1.2 eq., 78 μmol) was added to a solution of (1S, 3R)-N1-(2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine (20 mg, 1 eq., 65 μmol) and DIEA (25 mg, 3 eq., 0.19 mmol) in DMF (1.5 mL). The reaction mixture was stirred at 25 °C for 18 hours. The crude mixture was purified by Waters preparative HPLC (20-90% 0.1% formic acid / MeCN and 0.1% formic acid / water) to give 3-methoxy-N-((1R, 3S)-3-((2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)benzamide (8.4 mg, 19 μmol, 29% yield).

[1077] LCMS-ESI (m / z) calculated: 443.47, found: 444.20 [M+H] + , retention time = 7.592 minutes (Method 1).

[1078] 1 H NMR (400MHz, DMSO-d6) δ8.43(d,J=8.5Hz,1H),8.32(d,J=7.9Hz,1H),7.89(d,J=8.4Hz,1H),7. 74(t,J=7.7Hz,1H),7.56(t,J=7.6Hz,1H),7.52–7.30(m,4H),7.08(d,J=8.2Hz,1H),6.90(s,1 H),4.05(d,J=11.8Hz,1H),3.88(d,J=7.9Hz,1H),3.80(d,J=1.8Hz,3H),2.19(d,J=12.1Hz,1H ),1.99(d,J=12.2Hz,1H),1.87(dd,J=25.2,12.8Hz,2H),1.72–1.53(m,2H),1.51–1.20(m,2H).

[1079] Example 11

[1080] Synthesis of Example 11

[1081]

[1082] Step 3-1. Synthesis of tert-butyl ((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamate

[1083] To a stirred solution of 4,6-dichloro-2-(trifluoromethyl)quinoline (1.241 g, 1 eq., 4.666 mmol) and ((1R, 3S)-3-aminocyclohexyl)carbamic acid tert-butyl ester (1.0 g, 1 eq., 4.666 mmol) in DMSO (6 mL) was added DIPEA (2.41 g, 3.30 mL, 4 eq., 18.7 mmol). The vial was capped and heated at 130 ° C for 3 hours. The reaction mixture was cooled to room temperature, diluted with water (10 mL), and extracted with EtOAc (3 x 15 mL). The organic layers were combined, washed with brine and concentrated in vacuo. The crude residue was purified by flash silica gel column chromatography (0-100% 10% MeOH / EtOAc and hexanes) to afford tert-butyl ((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamate (1.229 g, 2.768 mmol, 59% yield).

[1084] Step 3-2. Synthesis of (1S, 3R)-N1-(6-chloro-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride

[1085] To tert-butyl ((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamate (1.229 g, 1 eq, 2.768 mmol) in 1,4-dioxane (10 mL) was added 4M hydrogen chloride in 1,4-dioxane (1.51 g, 10.4 mL, 4.00 moles, 15 eq, 41.5 mmol). The vial was capped and heated at 50 °C for 14 hours. The reaction mixture was cooled to room temperature, filtered, and the filter cake was washed with diethyl ether (2 x 10 mL) and dried under high vacuum to give (1S,3R)-N1-(6-chloro-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride (1.15 g, 3.02 mmol, 100% yield).

[1086] LCMS-ESI (m / z) calculated: 343.1, found: 344.1 [M+H] + , retention time = 0.66 min (Method 11).

[1087] 1 H NMR (400MHz, DMSO-d6) δ8.64(s,1H),7.95(d,J=9.0Hz,1H),7.91–7.84(m,1H),7.79(d,J=8.9Hz,1H),6.97(s,1H),3.97– 3.85(m,1H),3.57(s,3H),3.31–3.19(m,1H),2.30–2.22(m,1H),2.04–1.89(m,2H),1.88–1.79(m,1H),1.64–1.27(m,4H).

[1088] Step 3-3. Synthesis of N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-2-methylbenzamide

[1089] To a solution of (1S, 3R)-N1-(6-chloro-2-(trifluoromethyl)quinoline-4-yl)cyclohexane-1,3-diamine hydrochloride (60 mg, 1 eq., 0.16 mmol) in DMF (2 mL), DIPEA (0.11 mL, 4 eq., 0.63 mmol) was added, followed by 2-methylbenzoyl chloride (26 mg, 22 μL, 1.05 eq., 0.17 mmol). The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was passed through a syringe filter, and the filtrate was directly loaded / purified by preparative HPLC (ISCO ACCQPrep150) to obtain N-((1R, 3S)-3-((6-chloro-2-(trifluoromethyl)quinoline-4-yl)amino)cyclohexyl)-2-methylbenzamide (20 mg, 43 μmol, 27% yield).

[1090] LCMS-ESI (m / z) calculated: 461.91, found: 462.2 [M+H] + , retention time = 1.025 min (Method 11).

[1091] 1 H NMR (400MHz, DMSO-d6) δ8.60(s,1H),8.24(d,J=8.1Hz,1H),7.89(d,J=9.0Hz,1H),7.74(d,J=8.9Hz,1H),7.50(d,J=8.1Hz,1H),7.32–7.19(m,4H),6 .96(s,1H),4.05–3.86(m,2H),2.32(s,3H),2.17(d,J=12.1Hz,1H),1.98– 1.87(m,2H),1.81(d,J=13.3Hz,1H),1.60–1.45(m,2H),1.39–1.22(m,2H).

[1092] Example 12

[1093] Synthesis of Example 12

[1094]

[1095] Step 3-1. Synthesis of tert-butyl ((1R,3S)-3-((6-methyl-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamate

[1096] To a solution of ((1R, 3S)-3-aminocyclohexyl) tert-butyl carbamate (1.0 g, 1 equivalent, 4.7 mmol) and 4-chloro-6-methyl-2-(trifluoromethyl)quinoline (1.1 g, 1 equivalent, 4.7 mmol) in DMSO (12 mL), DIPEA (1.2 g, 1.6 mL, 2 equivalents, 9.3 mmol) was added. The vial was capped, and the resulting solution was heated at 130 ° C. After stirring at 130 ° C for 3 hours, the reaction mixture was cooled to room temperature. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3 x 10 mL). The organic layers were combined, washed with brine and concentrated under reduced pressure. The residue was dissolved in DCM and purified by flash column chromatography (ISCO Gold 120 g, 0-80% EtOAc / hexanes, 11 CV, ramp) to give tert-butyl ((1R,3S)-3-((6-methyl-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamate (1.3 g, 3.1 mmol, 66% yield).

[1097] LCMS-ESI (m / z) calculated: 423.48, found: 424.2 [M+H] + , retention time = 5.092 min (Method 10).

[1098] Step 3-2. Synthesis of (1S, 3R)-N1-(6-methyl-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride

[1099] To tert-butyl ((1R,3S)-3-((6-methyl-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamate (1.3 g, 1 eq, 3.1 mmol) in 1,4-dioxane (10 mL) was added 4M hydrogen chloride in 1,4-dioxane (7.7 mL, 4.00 moles, 10 eq, 31 mmol). The reaction mixture was heated at 50 °C for 18 hours, cooled to room temperature, filtered, and the filter cake was washed with diethyl ether and dried under high vacuum to give (1S,3R)-N1-(6-methyl-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride (1.1 g, 3.1 mmol, 100% yield).

[1100] LCMS-ESI (m / z) calculated: 323.82, found: 324.2 [M+H] + , retention time = 2.28 min (Method 10).

[1101] Step 3-3. Synthesis of N-((1R,3S)-3-((6-methyl-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)benzamide

[1102] To a solution of (1S, 3R)-N1-(6-methyl-2-(trifluoromethyl)quinoline-4-yl)cyclohexane-1,3-diamine hydrochloride (75 mg, 1 eq., 0.21 mmol) in DMF (1.5 mL) was added DIPEA (0.15 mL, 4 eq., 0.83 mmol), followed by benzoyl chloride (31 mg, 1.05 eq., 0.22 mmol). The resulting mixture was stirred at room temperature for 18 hours. The reaction mixture was passed through a syringe filter, and the filtrate was directly loaded / purified by preparative HPLC (ISCO ACCQPrep150) to give N-((1R, 3S)-3-((6-methyl-2-(trifluoromethyl)quinoline-4-yl)amino)cyclohexyl)benzamide (9.1 mg, 21 μmol, 10% yield).

[1103] LCMS-ESI (m / z) calculated: 427.47, found: 428.3 [M+H] + , retention time = 0.848 min (Method 11).

[1104] 1 H NMR (400MHz, DMSO-d6) δ8.33(d,J=7.9Hz,1H),8.21(s,1H),7.89–7.71(m,3H),7.60–7.40(m,4H),7.24(d,J=8.0Hz,1H),6.84(s,1H) ,4.09–3.98(m,1H),3.89–3.79(m,1H),2.49(s,3H),2.19(d,J=12.0Hz,1H),2.01–1.79(m,3H),1.62–1.48(m,2H),1.45–1.30(m,2H).

[1105] Example 13

[1106] Synthesis of Example 13

[1107]

[1108] Step 3-3. Synthesis of N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)benzamide

[1109] To a solution of (1S, 3R)-N1-(6-chloro-2-(trifluoromethyl)quinoline-4-yl)cyclohexane-1,3-diamine hydrochloride (45 mg, 1 eq., 0.12 mmol) in DMF (1.5 mL) was added DIPEA (83 μL, 4 eq., 0.47 mmol) followed by benzoyl chloride (17 mg, 1.05 eq., 0.12 mmol). The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was passed through a syringe filter and the filtrate was directly loaded / purified by preparative HPLC (ISCO ACCQPrep 150) to give N-((1R, 3S)-3-((6-chloro-2-(trifluoromethyl)quinoline-4-yl)amino)cyclohexyl)benzamide (5 mg, 0.01 mmol, 9% yield).

[1110] LCMS-ESI (m / z) calculated: 447.89, found: 448.2 [M+H] + , retention time = 1.000 min (Method 11).

[1111] 1 H NMR (400MHz, DMSO-d6) δ8.61(s,1H),8.34(d,J=7.9Hz,1H),7.89(d,J=9.0H z,1H),7.83(d,J=7.6Hz,2H),7.74(d,J=9.0Hz,1H),7.53–7.42(m,4H),6.95 (s,1H),4.09–4.01(m,1H),3.93–3.84(m,1H),2.17(d,J=12.0Hz,1H),1.97 (d,J=12.2Hz,1H),1.92–1.80(m,2H),1.60–1.50(m,2H),1.43–1.30(m,2H).

[1112] The compounds listed in Table 3 were prepared using the procedure of Scheme 3.

[1113] Table 3

[1114]

[1115]

[1116]

[1117] Solution 4

[1118]

[1119] Reagents: Step 2-4. R2COOH, peptide coupling reaction (HATU), base (DIPEA), solvent (DMF)

[1120] Example 14

[1121] Synthesis of Example 14

[1122]

[1123] Synthesis of N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-3-(methylsulfonamido)benzamide

[1124] To a stirred solution of (1S,3R)-N1-(6-chloro-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride (90 mg, 1 eq, 0.24 mmol) in DMF (2 mL) was added 3-(methylsulfonamido)benzoic acid (51 mg, 1 eq, 0.24 mmol), HATU (0.10 g, 1.1 eq, 0.26 mmol) and N-ethyl-N-isopropylpropan-2-amine (DIPEA) (92 mg, 0.12 mL, 3 eq, 0.71 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was filtered and purified by reverse phase preparative HPLC (35-->55% 0.1% formic acid / MeCN and 0.1% formic acid / H2O) to give N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-3-(methylsulfonamido)benzamide (66 mg, 123 μmol, 52% yield).

[1125] LCMS-ESI (m / z) calculated: 540.99, found: 541.2 [M+H] + , retention time = 0.906 min (Method 11).

[1126] Example 15

[1127] Synthesis of Example 15

[1128]

[1129] Synthesis of 2-amino-N-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyrimidine-5-carboxamide

[1130] HATU (50 mg, 1.5 eq., 0.13 mmol) was added to a solution of 2-aminopyrimidine-5-carboxylic acid (12 mg, 1 eq., 87 μmol) in DMF (2 mL). The resulting solution was stirred at room temperature for 10 minutes. (1S, 3R)-N1-(6-chloro-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride (30 mg, 1 eq., 87 μmol) was added to the mixture. The resulting mixture was stirred at room temperature for 19 hours. The crude mixture was directly purified by preparative HPLC to give 2-amino-N-[(1R, 3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]pyrimidine-5-carboxamide (33 mg, 71 μmol, 82% yield).

[1131] LCMS-ESI (m / z) calculated: 464.88, found: 465.2 [M+H] + , retention time = 7.332 minutes (Method 1).

[1132] 1 H NMR (400MHz, DMSO) δ8.67(d,J=1.6Hz,2H),8.61(d,J=2.4Hz,1H),8.14(d,J=7.8Hz,1 H),7.90(d,J=9.0Hz,1H),7.74(dd,J=9.1,2.2Hz,1H),7.50(d,J=7.9Hz,1H),7.18(s, 2H),6.94(s,1H),4.12–3.76(m,2H),2.18(d,J=12.0Hz,1H),1.98(d,J=12.1Hz,1H),1 .86(dd,J=26.2,13.0Hz,2H), 1.53(dq,J=23.5,12.6,11.9Hz,2H), 1.45–1.18(m,2H).

[1133] Example 16

[1134] Synthesis of Example 16

[1135]

[1136] Synthesis of N-[(1R,3S)-3-[[2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]propionamide

[1137] To a mixture of propionic acid (5 mg, 64 umol, 5 uL, 1 eq) in DMF (2 mL) was added DIPEA (8 mg, 64 umol, 11.10 uL, 1 eq), (1S, 3R)-N1-[2-(trifluoromethyl)-4-quinolyl]cyclohexane-1,3-diamine (25 mg, 70 umol, 1.1 eq, HCl) and HATU (24 mg, 64 umol, 1 eq). The reaction mixture was stirred at 30 °C for 12 hours. The reaction mixture was concentrated in vacuo to give a residue. The residue was purified by preparative HPLC (column: Unisil 3-100C18 Ultra 150*50mm*3um; mobile phase: [water (0.225% FA)-ACN]; B%: 30%-50%, 10 minutes) to give N-[(1R,3S)-3-[[2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]propanamide (3 mg, 7umol, 12% yield).

[1138] LCMS-ESI (m / z) calculated: 365.4, found: 366.1 [M+H] + , retention time = 0.731 min (Method 6).

[1139] Example 17

[1140] Synthesis of Example 17

[1141]

[1142] N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-2-methoxy-1-methyl-1H-imidazole-5-carboxamide

[1143] To a stirred solution of (1S,3R)-N1-(6-chloro-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride (120 mg, 1 eq, 316 μmol) in DMF (5 mL) was added 2-chloro-1-methyl-1H-imidazole-5-carboxylic acid (50.7 mg, 1 eq, 316 μmol), HATU (120 mg, 1 eq, 316 μmol) and DIPEA (163 mg, 0.22 mL, 4 eq, 1.26 mmol). The resulting mixture was stirred at room temperature. After stirring for 1 hour, the reaction mixture was filtered and the filtrate was directly loaded / purified by preparative HPLC (ISCO ACCQPrep 150) to give 2-chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-methyl-1H-imidazole-5-carboxamide (83.9 mg, 173 μmol, 54.7%).

[1144] LCMS-ESI (m / z) calcd: 485.1, found 486.2 [M+H]+, retention time = 9.057 min (Method 1).

[1145] To a solution of 2-chloro-N-[(1R, 3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-3-methyl-imidazole-4-carboxamide (20 mg, 1 eq., 41.13 umol) in 2-methylbutan-2-ol (2 mL) was added CH3ONa (5.4 M, 3 eq., 22.85 uL). The resulting solution was heated at 70 ° C for 23 hours. The reaction mixture was cooled to room temperature and directly purified by preparative HPLC to give N-[(1R, 3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]-cyclohexyl]-2-methoxy-3-methyl-imidazole-4-carboxamide (3.0 mg, 5.67 umol, 14% yield).

[1146] LCMS-ESI (m / z) calculated: 481.9, found: 482.3 [M+H] + , retention time = 0.472 min (Method 2).

[1147] 1 H NMR (400MHz, DMSO-d6) δ8.62-8.58(m,1H),8.37-8.29(m,1H),7.94(d,J=8.0Hz,1H),7.89(d,J=9.0H z,1H),7.76-7.71(m,1H),7.48(d,J=8.0Hz,1H),7.28(s,1H),6.92(s,1H),3.95(s,4H),3.88-3.80.

[1148] Example 18

[1149] Synthesis of Example 18

[1150]

[1151] Synthesis of N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-6-((2-fluoroethyl)amino)nicotinamide

[1152] To a solution of N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-6-fluoronicotinamide 4-411 (50 mg, 1 eq, 0.11 mmol) in NMP (4 mL) was charged 2-fluoroethyl-1-amine (6.8 mg, 1 eq, 0.11 mmol) and DIPEA (42 mg, 56 μL, 3 eq, 0.32 mmol). The resulting yellow solution was stirred at 75 °C for 18 hours. The reaction mixture was cooled to room temperature and directly purified by preparative HPLC to give N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-6-((2-fluoroethyl)amino)nicotinamide (9.0 mg, 18 μmol, 16% yield).

[1153] LCMS-ESI (m / z) calculated value: 509.93; found value 510.2 [M+H] + , retention time = 7.013 min (Method 1).

[1154] Example 19

[1155] Synthesis of Example 19

[1156]

[1157] 4-(4-(((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamoyl Synthesis of tert-butyl (5-methyl-1H-pyrazol-1-yl)piperidine-1-carboxylate

[1158] To a solution of (1S,3R)-N1-(6-chloro-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride (80 mg, 1 eq, 0.21 mmol) and DIPEA (0.15 mL, 4 eq, 0.84 mmol) in DMF (4 mL) was charged HATU (80 mg, 1 eq, 0.21 mmol) and 1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-5-methyl-1H-pyrazole-4-carboxylic acid (65 mg, 1 eq, 0.21 mmol). The resulting solution was stirred at room temperature for 1 hour. The crude mixture was directly purified by preparative HPLC to give tert-butyl 4-(4-(((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamoyl)-5-methyl-1H-pyrazol-1-yl)piperidine-1-carboxylate (83.4 mg, 131 μmol, 62% yield).

[1159] LCMS-ESI (m / z) calculated: 634.26; found: 635.3 [M+H] + , retention time = 10.514 min (Method 1).

[1160] 1 H NMR (400MHz, DMSO-d6) δ8.60 (s, 1H), 7.89 (d, J = 9.3Hz, 2H), 7.80–7.70 (m, 2 H),7.48(d,J=7.8Hz,1H),6.92(d,J=2.8Hz,1H),4.37(t,J=7.8Hz,1H),4.08 –3.92(m,3H),3.85(d,J=10.0Hz,1H),3.41(s,4H),2.90(s,2H),2.12(d,J= 11.7Hz, 1H), 1.96 (d, J = 12.4Hz, 1H), 1.89–1.73 (m, 6H), 1.54–1.25 (m, 13H).

[1161] N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-5-methyl-1-(piperidin Synthesis of 4-pyridine-1H-pyrazole-4-carboxamide

[1162] To a solution of tert-butyl 4-(4-(((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamoyl)-5-methyl-1H-pyrazol-1-yl)piperidine-1-carboxylate (78.9 mg, 1 eq, 0.12 mmol) in 1,4-dioxane (5 mL) was charged a solution of hydrogen chloride in 1,4-dioxane (4.0 M, 311 μL, 10 eq, 1.24 mmol). The resulting suspension was heated at 50 °C for 3 h. The reaction mixture was then cooled to room temperature, filtered, and the filter cake was washed with diethyl ether and dried to give N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-5-methyl-1-(piperidin-4-yl)-1H-pyrazole-4-carboxamide (57.8 mg, 108 μmol, 87.0%).

[1163] LCMS-ESI (m / z) calculated: 534.21; found: 535.3 [M+H] + , retention time = 5.987 min (Method 1).

[1164] 1H NMR(400MHz, DMSO-d6)δ9.09(d,J=10.9Hz,1H),8.81(d,J=11.1Hz,1H),8.66(s,1H),7.97–7.88(m, 2H),7.84(d,J=8.1Hz,1H),7.73(dd,J=23.2,8.4Hz,2H),6.97(s,1H),4.57–4.47(m,1H),4.02–3.85 (m,2H),3.37(d,J=12.3Hz,2H),3.06(q,J=12.9,12.1Hz,2H),2.51(s,3H),2.24–2.08(m,3H),1.96 (d,J=13.3Hz,3H),1.82(t,J=12.6Hz,2H),1.60–1.46(m,2H),1.44–1.35(m,1H),1.34–1.23(m,1H).

[1165] The compounds listed in Table 4 were prepared using the procedure of Scheme 4.

[1166] Table 4

[1167]

[1168]

[1169]

[1170]

[1171]

[1172]

[1173]

[1174]

[1175]

[1176]

[1177]

[1178]

[1179]

[1180]

[1181]

[1182]

[1183]

[1184]

[1185]

[1186]

[1187]

[1188]

[1189]

[1190]

[1191]

[1192]

[1193]

[1194]

[1195]

[1196]

[1197]

[1198]

[1199]

[1200]

[1201]

[1202]

[1203]

[1204]

[1205]

[1206]

[1207]

[1208]

[1209]

[1210]

[1211]

[1212]

[1213]

[1214]

[1215]

[1216]

[1217]

[1218]

[1219]

[1220]

[1221]

[1222]

[1223]

[1224]

[1225]

[1226]

[1227]

[1228]

[1229]

[1230]

[1231]

[1232]

[1233]

[1234]

[1235]

[1236]

[1237]

[1238]

[1239]

[1240]

[1241]

[1242]

[1243]

[1244]

[1245]

[1246]

[1247]

[1248]

[1249]

[1250] Solution 5

[1251]

[1252] Reagents: i. Coupling conditions described in Scheme 3 or 4; ii. R3X, X is halogen, mesyl, tosyl or any other activating group

[1253] Example 21

[1254] Synthesis of Example 21

[1255]

[1256] Synthesis of N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-3-cyano-1-(difluoromethyl)-1H-pyrazole-4-carboxamide

[1257] To N-[(1R, 3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl] amino] cyclohexyl] -3-cyano-1H-pyrazole-4-carboxamide (60mg, 1 equivalent, 130umol), (2-chloro-2,2-difluoro-acetyl) sodium oxide (39.5mg, 2 equivalents, 259umol) and Cs2CO3 (85mg, 2 equivalents, 259umol) in DMF (1mL) solution. The resulting solution was heated at 100 ° C for 1 hour. The reaction mixture was cooled to room temperature and directly purified by preparative HPLC to obtain N-[(1R, 3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl] amino] cyclohexyl] -3-cyano-1-(difluoromethyl) pyrazole-4-carboxamide (2.3mg, 4.45umol, 3.44% yield).

[1258] LCMS-ESI (m / z) calculated: 512.87, found: 513.2 [M+H] + , retention time = 0.575 min (Method 2).

[1259] 1 H NMR(400MHz, chloroform-d)δ8.46(s,1H)8.03(br d,J=8.88Hz,1H)7.71(s,1H)7.65(br d,J=8.76Hz,1H)7.04-7.26(m,1H)6.78(s,1H)6.24(br d,J=6.88Hz,1H)5.01(br d,J=6.88Hz,1H)4.16-4.25(m,1H)3.73(br d,J=7.00Hz,1H)2.63(br d,J=11.13Hz,1H)2.18-2.31(m,2H)2.01-2.06(m,1H)1.29-1.45(m,4H).

[1260] Example 22

[1261] Synthesis of Example 22

[1262]

[1263] Synthesis of N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-3-(difluoromethyl)-1-(fluoromethyl)-1H-pyrazole-4-carboxamide

[1264] To a solution of N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-3-(difluoromethyl)-1H-pyrazole-4-carboxamide (100 mg, 1 eq., 188.58 umol) in MeCN (2 mL) was added fluoro(iodo)methane (33.18 mg, 1.1 eq., 207.44 umol) and K2CO3 (52.13 mg, 2 eq., 377 umol). After heating at 50 °C for 2 h, the reaction mixture was cooled to room temperature and directly purified by preparative HPLC to give N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-5-(difluoromethyl)-1-(fluoromethyl)pyrazole-4-carboxamide (11.7 mg, 22.2 umol, 12% yield).

[1265] LCMS-ESI (m / z) calculated: 519.2, found: 520.2 [M+H] + , retention time = 0.517 min (Method 2).

[1266] 1 H NMR (400MHz, DMSO-d6) δ = 8.60 (d, J = 2.1Hz, 1H), 8.49 (d, J = 7.9Hz, 1H), 8.27 (s, 1H), 7.90 (d, J = 9.0Hz, 1H), 7.88-7.60 (m, 2H), 7.50 (br d,J=8.0Hz,1H),6.95(s,1H),6.33(s,1H),6.20(s,1H),4.11-3.83.

[1267] Example 23

[1268] Synthesis of Example 23

[1269]

[1270] Synthesis of 5-chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-methyl-1H-pyrrole-3-carboxamide

[1271] To a solution of 5-chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1H-pyrrole-3-carboxamide (50 mg, 1 eq, 0.11 mmol) in DMF (2 mL) was added sodium hydride (5.1 mg, 60% Wt, 1.2 eq, 0.13 mmol) at 0° C. After stirring for 30 min, iodomethane (23 mg, 9.9 μL, 1.5 eq, 0.16 mmol) was added and the resulting mixture was stirred at room temperature for 18 h. The crude mixture was directly purified by preparative HPLC to give 5-chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-methyl-1H-pyrrole-3-carboxamide (23.8 mg, 49.0 μmol, 46% yield).

[1272] LCMS-ESI (m / z) calculated: 485.33, found: 485.2 [M+H] + , retention time = 9.522 minutes (Method 1).

[1273] 1 H NMR(400MHz,DMSO-d6)δ8.60(s,1H),7.89(d,J=8.9Hz,1H),7.73(d,J=9.2H z,1H),7.66(d,J=8.1Hz,1H),7.48(d,J=7.9Hz,1H),7.36(s,1H),6.92(s,1H ),6.54(s,1H),3.99–3.80(m,2H),3.56(s,3H),2.12(d,J=12.1Hz,1H),1.95 (d,J=12.4Hz,1H),1.87–1.76(m,2H),1.59–1.42(m,2H),1.39–1.23(m,2H).

[1274] Example 24

[1275] Synthesis of Example 24

[1276]

[1277] Synthesis of 5-chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(2,2-difluoroethyl)-1H-pyrrole-3-carboxamide

[1278] To a solution of 5-chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1H-pyrrole-3-carboxamide (88 mg, 1 eq, 0.19 mmol) in DMF (2 mL) was added sodium hydride (9.0 mg, 60% Wt, 1.2 eq, 0.22 mmol) at 0° C. After stirring for 30 minutes, 2,2-difluoroethyl trifluoromethanesulfonate (60 mg, 37 μL, 1.5 eq, 0.28 mmol) was added and the resulting mixture was stirred at room temperature for 18 hours. The crude mixture was directly purified by preparative HPLC to give 5-chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(2,2-difluoroethyl)-1H-pyrrole-3-carboxamide (53.7 mg, 100 μmol, 54%).

[1279] LCMS-ESI (m / z) calculated: 535.34, found: 535.2 [M+H] + , retention time = 9.755 min (Method 1).

[1280] 1 H NMR (400MHz, DMSO-d6) δ8.60 (s, 1H), 7.89 (d, J = 9.1Hz, 1H), 7.75 (dd, J = 14.6 ,8.8Hz,2H),7.52–7.41(m,2H),6.92(s,1H),6.62(s,1H),6.31(t,J=54.6Hz ,1H),4.45(t,J=15.6Hz,2H),4.02–3.81(m,2H),2.12(d,J=11.9Hz,1H),1.9 6(d,J=12.4Hz,1H),1.88–1.77(m,2H),1.60–1.43(m,2H),1.40–1.23(m,2H).

[1281] Example 25

[1282] Synthesis of Example 25

[1283]

[1284] Synthesis of 3-chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(methylsulfonyl)-1H-pyrazole-4-carboxamide

[1285] To a suspension of 3-chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1H-pyrazole-4-carboxamide (100 mg, 1 eq, 212 μmol) in DCM (3 mL) was added triethylamine (85.7 mg, 118 μL, 4 eq, 847 μmol) followed by DMAP (5.17 mg, 0.2 eq, 42.3 μmol) and methanesulfonic anhydride (73.8 mg, 2 eq, 423 μmol). The resulting mixture was stirred at room temperature for 1 hour and then heated at 50 °C for 1 hour. The reaction mixture was cooled to room temperature and purified directly by preparative HPLC to give 3-chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(methylsulfonyl)-1H-pyrazole-4-carboxamide (19.4 mg, 35.2 μmol, 17% yield).

[1286] LCMS-ESI (m / z) calculated: 550.38, found: 550.1 [M+H] + , retention time = 9.645 min (Method 1).

[1287] 1 H NMR (400MHz, DMSO-d6) δ8.88(s,1H),8.59(s,1H),8.29(d,J=7.7Hz,1H),7.90(d,J=9.0Hz,1H),7.74(d,J=9.1Hz,1H),7.48(d,J=8.0H z,1H),6.95(s,1H),4.01–3.83(m,2H),3.68(s,3H),2.17(d,J=11.8Hz,1H),2.01–1.78(m,3H),1.60–1.34(m,3H),1.29–1.19(m,1H).

[1288] Example 26

[1289] Synthesis of Example 26

[1290]

[1291] N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(2-hydroxy-2-methyl Synthesis of (4-(2-propyl)-3-methyl-1H-pyrazole-4-carboxamide

[1292] To a solution of 3-methyl-1H-pyrazole-4-carboxylic acid (33 mg, 263 umol, 1 eq.) and (1S, 3R)-N1-[6-chloro-2-(trifluoromethyl)-4-quinolyl]cyclohexane-1,3-diamine hydrochloride (100 mg, 263 umol, 1 eq.) in DMF (4 mL) was added DIEA (102 mg, 789 umol, 137 uL, 3 eq.) and HATU (120 mg, 316 umol, 1.2 eq.). After stirring at room temperature for 2 hours, the solvent was removed in vacuo. Water (20 mL) and EtOAc (20 mL) were added to the crude residue. The aqueous layer was extracted with EtOAc (3 x 20 mL), washed with water (3 x 25 mL), dried over sodium sulfate, filtered through celite and concentrated in vacuo to give N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-3-methyl-1H-pyrazole-4-carboxamide (109 mg, 241 umol) which was used without further purification.

[1293] To a solution of crude N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-3-methyl-1H-pyrazole-4-carboxamide (109 mg, 241 umol, 1 eq) in DMF (2 mL) was added 2,2-dimethyloxirane (61 mg, 844 umol, 74.97 uL, 3.5 eq) and K2CO3 (67 mg, 482 umol, 2 eq). The reaction mixture was heated at 100°C for 12 hours, then the reaction mixture was cooled to room temperature and concentrated in vacuo to give a crude solid. The crude solid was purified by preparative HPLC [(FA): column: Phenomenex luna C18 150x 25mm10um; mobile phase: [water (0.225% FA)-ACN]; B%: 38%-68%, 10 minutes] and lyophilized to give N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(2-hydroxy-2-methylpropyl)-3-methyl-1H-pyrazole-4-carboxamide (2.5 mg, 4.6 umol, 2% yield).

[1294] LCMS-ESI (m / z) calculated: 523.2, found: 524.2 [M+H] + , retention time = 0.461 min (Method 11).

[1295] 1H NMR (400MHZ, DMSO-D6) δ = 8.60 (D, J = 2.0HZ, 1H), 8.10 (S, 1H), 7.89 (D, J = 9.0HZ, 1H), 7.79-7.69 (M, 2H), 7.48 (BR D,J=7.9HZ,1H),6.92(S,1H),6.96-6.89(M,1H),4.00-3.79(M,1H),2.30(S,1H),2.32-2.24(M,1H),2.19-2.09(M,1H),1.96(BR D,J=11.6HZ,1H),1.91-1.74(M,2H),1.59-1.43(M,2H),1.39-1.19(M,2H),1.10-1.00(M,6H)

[1296] Example 27

[1297] Synthesis of Example 27

[1298]

[1299] 3-Chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(piperidin- Synthesis of 4-amino-1H-pyrazole-4-carboxamide

[1300] To a stirred solution of 3-chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1H-pyrazole-4-carboxamide (50 mg, 1 eq, 0.11 mmol) was added tert-butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate (44 mg, 1.5 eq, 0.16 mmol) and cesium carbonate (86 mg, 2.5 eq, 0.26 mmol). The resulting suspension was heated and stirred at 90 °C for 18 hours. The reaction mixture was directly purified by preparative HPLC to give tert-butyl 4-(3-chloro-4-(((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamoyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (35.7 mg, 54.5 μmol, 51% yield) as a solid.

[1301] LCMS-ESI (m / z) calculated: 654.21, found: 655.1 [M+H] + , retention time = 1.140 min (Method 11).

[1302] 1H NMR(400MHz, DMSO-d6)δ8.60(s,1H),8.31(s,1H),7.89(d,J=8.2Hz,1H),7.81–7.70(m,2H),7.48(d,J=7.9Hz,1H),6.93(s,1H),4.39–4.2 8(m,1H),4.10–3.81(m,4H),2.91(s,2H),2.19–2.11(m,1H),2.04–1. 93(m,2H),1.93–1.74(m,4H),1.73–1.63(m,1H),1.55–1.22(m,13H).

[1303] To a stirred solution of tert-butyl 4-(3-chloro-4-(((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamoyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (32.2 mg, 1 eq, 49.1 μmol) in 1,4-dioxane (2 mL) was added 4M HCl in 1,4-dioxane (123 μL, 10 eq, 491 μmol). The resulting suspension was heated at 50 °C for 18 h. The reaction mixture was cooled to room temperature and dissolved in MeOH and purified directly by preparative HPLC to give 3-chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(piperidin-4-yl)-1H-pyrazole-4-carboxamide (8.9 mg, 16 μmol, 33%) as a solid.

[1304] LCMS-ESI (m / z) calcd: 554.16, found 554.9 [M+H]+, retention time = 6.170 min (Method 1).

[1305] 1H NMR(400MHz,DMSO-d6)δ8.60(d,J=2.3Hz,1H),8.31(s,1H),8.23(s,1H),7.89(d,J=9.0Hz,1H), 7.84(d,J=7.8Hz,1H),7.74(dd,J=9.0,2.2Hz,1H),7.49(d,J=8.0Hz,1H),6.93(s,1H),4.38–4. 24(m,1H),3.99–3.83(m,2H),3.27–3.15(m,3H),2.82–2.74(m,2H),2.16(d,J=11.9Hz,1H),2.0 9–2.01(m,2H),1.96(d,J=11.3Hz,1H),1.92–1.78(m,4H),1.59–1.42(m,2H),1.40–1.22(m,2H).

[1306] Example 28

[1307] Synthesis of Example 28

[1308]

[1309] N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-3-cyano-1-(2,2- Synthesis of (2-(2-(difluoroethyl)-1H-pyrazole-4-carboxamide

[1310] To a solution of N-[(1R, 3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-5-cyano-1H-pyrazole-4-carboxamide (50 mg, 1 eq., 108 umol) in DMF (3 mL) was added K2CO3 (44.8 mg, 3 eq., 324 umol) and 2,2-difluoroethyl trifluoromethanesulfonate (30.0 mg, 1.3 eq., 140 umol). The resulting mixture was heated at 60 ° C for 1 hour. The mixture was cooled to room temperature, filtered directly, and the filtrate was collected. The residue was purified by preparative HPLC to give -(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-3-cyano-1-(2,2-difluoroethyl)pyrazole 4-carboxamide (11 mg, 21 umol, 19% yield) as a solid.

[1311] LCMS-ESI (m / z) calculated: 526.2, found: 527.3 [M+H] + , retention time = 0.594 min (Method 11).

[1312] 1H NMR (400MHz, methanol-d4) δ = 8.37 (d, J = 2.3Hz, 1H), 8.32 (s, 1H), 7.91 (d, J = 9.0Hz, 1H), 7.69 (dd, J = 2.3, 9.0Hz, 1H), 6.91 (s, 1H), 6.42-6.12 (m, 1H), 4 .72(dt,J=3.5,14.6Hz,2H),4.09-4.00(m,1H),3.87-3.77(m,1H),2.43 -2.36(m,1H),2.17-1.92(m,3H),1.70-1.58(m,1H),1.55-1.36(m,3H).

[1313] Example 29

[1314] Synthesis of Example 29

[1315]

[1316] N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-5-(difluoromethyl)- Synthesis of 1-(Fluoromethyl)-1H-pyrazole-4-carboxamide

[1317] To a solution of N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-3-(difluoromethyl)-1H-pyrazole-4-carboxamide (100 mg, 189 umol, 92% purity, 1 eq) in MeCN (2 mL) was added fluoro(iodo)methane (33 mg, 207 umol, 1.1 eq) and K2CO3 (52 mg, 377 umol, 2 eq). The resulting mixture was heated at 50°C for 2 h. The mixture was cooled to room temperature, filtered, and the crude product was purified by reverse phase HPLC: column (Phenomenexluna C18 150*25mm*10um), conditions (water (0.225% FA)-ACN) to give N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-3-(difluoromethyl)-1-(fluoromethyl)pyrazole-4-carboxamide (33% yield).

[1318] LCMS-ESI (m / z) calculated: 519.1, found: 520.1 [M+H] + , retention time = 0.517 min (Method 11).

[1319] 1H NMR (400MHz, DMSO-d6) δ = 8.60 (d, J = 2.1Hz, 1H), 8.49 (d, J = 7.9Hz, 1H), 8.27 (s, 1H), 7.90 (d, J = 9.0Hz, 1H), 7.88-7.60 (m, 2H), 7.50 (br d,J=8.0Hz,1H),6.95(s,1H),6.33(s,1H),6.20(s,1H),4.11-3.83(m,2H),2.18(br d,J=12.0Hz,1H),2.03-1.88(m,2H),1.84(br d,J=13.1Hz,1H),1.59-1.49(m,2H),1.44-1.27(m,2H).

[1320] The compounds listed in Table 5 were prepared using the procedure of Scheme 5.

[1321] Table 5

[1322]

[1323]

[1324]

[1325]

[1326]

[1327]

[1328]

[1329]

[1330] Solution 6

[1331]

[1332] Reagents: i. R2-mesylate or R2-triflate, base (K2CO3); ii. NaOH or LiOH aqueous solution / THF; iii. Peptide coupling conditions (HATU), base (DIPEA), solvent (DMF); iv. Including R2 deprotection or further modification

[1333] Example 30

[1334] Synthesis of Example 30

[1335]

[1336] 3-Chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(2,2,2- Synthesis of (trifluoroethyl)-1H-pyrazole-4-carboxamide

[1337] Cesium carbonate (1.12g, 3 equivalents, 3.44mmol) was added in batches to a stirred solution of 3-chloro-1H-pyrazole-4-formic acid ethyl ester (200mg, 1 equivalent, 1.15mmol) in DMF (5mL) at room temperature within 2 minutes. After stirring for 30 minutes, 2,2,2-trifluoromethylsulfonic acid trifluoroethyl ester (798mg, 3 equivalents, 3.44mmol) was added dropwise within 2 minutes. The reaction mixture was stirred for 14 hours. Water (5mL) was added, and the mixture was extracted with EtOAc (3x 5mL), dried over sodium sulfate, filtered through diatomaceous earth and concentrated in vacuo to obtain 3-chloro-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-formic acid ethyl ester and 5-chloro-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-formic acid ethyl ester 87:13 mixture, which can be used without further purification.

[1338] To a stirred solution of crude ethyl 3-chloro-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxylate and ethyl 5-chloro-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxylate mixture (294 mg, 1 eq., 1.15 mmol) in THF (6 mL) was added a 1 M aqueous solution of sodium hydroxide (5.7 mL, 5 eq., 5.73 mmol). The reaction mixture was heated at 50 °C for 14 h. 10 mL of 3 M HCl was added. The aqueous layer was extracted with EtOAc (3 x 10 mL), dried over sodium sulfate, filtered through celite and concentrated in vacuo to give a mixture of 3-chloro-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxylic acid and 5-chloro-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxylic acid (276 mg, 1.21 mmol, 105%) which was used without further purification.

[1339] To a stirred solution of (1S,3R)-N1-(6-chloro-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride (100 mg, 1 eq., 0.264 mmol) in DMF (1.5 mL) was added a crude mixture of 3-chloro-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxylic acid and 5-chloro-1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-carboxylic acid (60 mg, 1 eq., 0.264 mmol), N-ethyl-N-isopropylpropan-2-amine (DIPEA) (0.138 mL, 3 eq., 0.793 mmol) and HATU (111 mg, 1.1 eq., 0.291 mmol). The reaction mixture was stirred at room temperature for 2 hours. The residue was purified by reverse phase HPLC ( The mixture was purified by HPLC-MS / MS (5% 4-nitropropane-2-yl)-4-nitropropane-2-yl)-2-nitropropane-2-yl)- ...

[1340] LCMS-ESI (m / z) calculated: 553.09, found: 553.8 [M+H] + , retention time = 10.114 min (Method 1).

[1341] 1 H NMR (400MHz, DMSO-d6) δ8.60(d,J=10.9Hz,1H),8.35(s,1H),8.06(d,J=7.9Hz,1H),7.90(d,J=9.0Hz,1H),7.74(dd,J=9.0,2.3Hz, 1H),7.48(d,J=7.9Hz,1H),5.21(q,J=9.0Hz,1H),4.01-3.83(m,2H),2.17(d,J=12.0Hz,1H),2.00-1.78(m,3H),1.61-1.21(m,4H).

[1342] Example 31

[1343] Synthesis of Example 31

[1344]

[1345] 3-Chloro-N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-1-(2-hydroxy Synthesis of (2-methylpropyl)pyrazole-4-carboxamide

[1346] To a solution of 3-chloro-1H-pyrazole-4-carboxylic acid ethyl ester (9.0 g, 52 mmol, 1 eq.) and 2,2-dimethyloxirane (11.2 g, 155 mmol, 13.7 mL, 3 eq.) in DMF (100 mL) was added K2CO3 (14.3 g, 103 mmol, 2 eq.), and the resulting mixture was heated at 60 ° C for 2 hours. The reactant was cooled to room temperature, diluted with water, and then extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a crude residue. The residue was purified by flash silica gel chromatography eluting with [ethyl acetate / petroleum ether] (25%) to give 3-chloro-1-(2-hydroxy-2-methyl-propyl)pyrazole-4-carboxylic acid ethyl ester (60% yield) as an oil.

[1347] LCMS-ESI (m / z) calcd.: 246.1, found 247 [M+H]+, retention time = 0.478 min (Method 14).

[1348] 1 H NMR (400MHz, DMSO-d6) δ = 8.22 (s, 1H), 4.77 (s, 1H), 4.22 (q, J = 7.1Hz, 2H), 4.01 (s, 2H), 1.27 (t, J = 7.1Hz, 3H), 1.07 (s, 6H).

[1349] To a solution of ethyl 3-chloro-1-(2-hydroxy-2-methyl-propyl)pyrazole-4-carboxylate (6.6 g, 27 mmol, 1 eq.) in MeOH (25 mL) and H2O (25 mL) was added LiOH.H2O (3.37 g, 80.3 mmol, 3 eq.), and the resulting mixture was stirred at 25°C for 1.5 hours. The reaction mixture pH was adjusted to pH 5-6 with 1M HCl. The mixture was concentrated in vacuo to give a crude residue. The residue was purified by reverse phase rapid (0.1% FA conditions in H2O / CH3CN, 0%). The crude product was obtained by lyophilization. The crude product was diluted with 20 mL H2O and adjusted to pH 1-2 with 6HCl. The reaction solution was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give 3-chloro-1-(2-hydroxy-2-methyl-propyl)pyrazole-4-carboxylic acid (74% yield).

[1350] LCMS (m / z) calcd: 218.1; found 201.2 [M18+H]+, retention time = 0.272 min (Method 14).

[1351] 1 H NMR (400MHz, DMSOd6) δ = 12.62 (s, 1H), 8.16 (s, 1H), 4.77 (s, 1H), 4.00 (s, 2H), 1.07 (s, 6H).

[1352] To a solution of 3-chloro-1-(2-hydroxy-2-methyl-propyl)pyrazole-4-carboxylic acid (3.7 g, 16.92 mmol, 1 eq) in DCM (40 mL) was added TEA (5.14 g, 50.8 mmol, 7.07 mL, 3 eq), HOBt (2.29 g, 16.9 mmol, 1 eq), EDCI (3.89 g, 20.3 mmol, 1.2 eq) and (1S, 3R)-N1-[6-chloro-2-(trifluoromethyl)-4-quinolyl]cyclohexane-1,3-diamine (5.53 g, 16.08 mmol, 0.95 eq). The reactant was stirred at 25 ° C for 12 hours. The reaction solution was diluted with water (200 mL) and then extracted with DCM (2 x 200 mL). The combined organic layer is washed with brine (1x 100mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to obtain a crude residue. The residue is ground with CH3CN (40mL). The mixture is filtered, and the filter cake is collected and concentrated in vacuo to obtain a crude residue. The crude residue is purified by reverse phase flash column chromatography ([water (NH4HCO3)-ACN]; B%: 38%-68%) to obtain 3-chloro-N-[(1R, 3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl] amino] cyclohexyl]-1-(2-hydroxy-2-methylpropyl) pyrazole-4-carboxamide as a solid.

[1353] LCMS (m / z) calculated value: 543.1; found value 544.2 [M+H] + , retention time = 0.529 min (Method 14).

[1354] 1 H NMR (400MHz, DMSO-d6) δ = 8.59 (s, 1H), 8.19 (s, 1H), 7.91-7.84 (m, 2H), 7.72 (br d, J = 8.5Hz, 1H), 7.48 (br d,J=7.9Hz,1H),6.93(s,1H),4.80(s,1H),3.96(s,2H),3.95-3.79(m,2H),2.16(br d,J=11.1Hz,1H),2.07(s,1H),2.00-1.77(m,3H),1.58-1.44(m,2H),1.40-1.22(m,2H),1.07(s,6H).

[1355] Example 32

[1356] Synthesis of Example 32

[1357]

[1358] N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-3-cyano-1-(2,2, Synthesis of 2-(Trifluoroethyl)pyrazole-4-carboxamide

[1359] To a solution of 1H-pyrazole-4-carboxylic acid ethyl ester (10 g, 71.36 mmol, 1 equivalent) in THF (50 mL) was added NaH (3.42 g, 85.6 mmol, 60% purity, 1.2 equivalents) and stirred at 0 ° C under N2 for 1 hour. SEM-Cl (14.3 g, 85.6 mmol, 15.2 mL, 1.2 equivalents) was added and the mixture was stirred at 25 ° C for 2 hours. The reaction mixture was quenched with saturated NH4Cl aqueous solution (50 mL) and extracted with EtOAc (3 x 25 mL). The combined organics were washed with brine, dried over Na2SO4, and concentrated in vacuo to give a crude substance. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate=1 / 0 to 80 / 20) to give ethyl 1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxylate (15.8 g, 58.4 mmol, 82% yield) as an oil.

[1360] To a solution of 1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxylic acid ethyl ester (15.5 g, 57.3 mmol, 1 equivalent) in THF (200 mL) was added LDA (2M, 43.0 mL, 1.5 equivalents) at -70 ° C in 10 minutes. After stirring for 30 minutes, DMF (25.1 g, 344 mmol, 26.5 mL, 6 equivalents) was added. The resulting mixture was stirred for another 20 minutes at -70 ° C. The reactant was quenched with saturated NH4Cl aqueous solution (200 mL) and extracted with EtOAc (3 x 100 mL). The combined organics were washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (SiO 2 , petroleum ether / ethyl acetate=1 / 0 to 85 / 15) to give ethyl 5-formyl-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxylate (6.1 g, 20.4 mmol, 36% yield) as an oil.

[1361] To a solution of ethyl 5-formyl-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxylate (6.0 g, 20.1 mmol, 1 eq.) in EtOH (20 mL) was added NaOAc (4.95 g, 60.3 mmol, 3 eq.) and NH sTo the reaction mixture was added 4-(4-(hydroxyiminomethyl)-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxylic acid ethyl ester (8.1 g, crude product) at room temperature and stirred for 3 hours at 70 ° C. The reaction mixture was cooled to room temperature and partitioned between EtOAc (50 mL) and water (50 mL). The aqueous phase was extracted with EtOAc (2 x 20 mL). The combined organics were dried over MgSO4 and concentrated in vacuo to give ethyl 5-(hydroxyiminomethyl)-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxylate as a solid (8.1 g, crude product) which was used without further purification.

[1362] 5-(Hydroxyiminomethyl)-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxylic acid ethyl ester (7.5g, 23.9mmol, 1 equivalent) is dissolved in Ac2O(20mL) and heated at 145 ℃ for 12 hours. TLC indicates remaining 70% of starting material. In the reaction mixture, add other Ac2O(20mL), and the mixture is heated at 145 ℃ for another 12 hours. The reaction mixture is cooled to room temperature and distributed between EtOAc(25mL) and water (25mL). The aqueous phase is extracted with EtOAc(2x10mL). The combined organic matter is dried over MgSO4, and concentrated in vacuo to obtain 5-cyano-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxylic acid ethyl ester.

[1363] To a solution of ethyl 5-cyano-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxylate (350 mg, 1.18 mmol, 1 eq) in MeOH (2 mL) and H2O (2 mL) was added LiOH.H2O (149 mg, 3.55 mmol, 3 eq). After stirring at 25°C for 1 hour, the reaction mixture was concentrated in vacuo to give 5-cyano-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxylic acid (300 mg, 1.12 mmol, 95% yield) as a solid.

[1364] To a solution of 5-cyano-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxylic acid (300 mg, 1.12 mmol, 1 eq), (1S,3R)-N1-[6-chloro-2-(trifluoromethyl)-4-quinolyl]cyclohexane-1,3-diamine (427 mg, 1.12 mmol, 1 eq, HCl) in DMF (6 mL) was added DIPEA (435 mg, 3.37 mmol, 586 uL, 3 eq) and HATU (640 mg, 1.68 mmol, 1.5 eq). The resulting mixture was stirred at 25 °C for 12 hours. The mixture was partitioned between EtOAc (25 mL) and water (25 mL). The aqueous phase was extracted with EtOAc (2 x 20 mL). The combined organics were dried over MgSO4 and concentrated in vacuo to give a crude residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 63 / 37) to give N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-5-cyano-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxamide (500 mg, 843 umol, 75% yield) as a solid.

[1365] N-[(1R,3S)-3-[[6-Chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-5-cyano-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxamide (500 mg, 843 umol, 1 eq) was dissolved in TBAF (1.0 M, 10 mL, 11.9 eq) in THF and heated at 50 °C for 2 h. The mixture was filtered, and the residue was purified by preparative TLC (SiO2, PE:EtOAc=1:1, TLC, PE:EtOAc=1:1, Rf=0) and concentrated in vacuo to give N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-5-cyano-1H-pyrazole-4-carboxamide (170 mg, 367 umol, 44% yield) as a solid.

[1366] To a solution of N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-3-cyano-1H-pyrazole-4-carboxamide (100 mg, 216 umol, 1 eq) and trifluoroethyl 2,2,2-trifluoromethanesulfonate (100 mg, 432 umol, 2 eq) in MeCN (3 mL) was added CsCO (211 mg, 648 umol, 3 eq). The reaction mixture was heated at 60 ° C for 12 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo to give a residue. The crude product was purified by reverse phase HPLC: column (Phenomenex luna C18 150*25mm*10um) conditions (water (0.225% FA)-ACN) start B (50) end B (80) gradient time (minute) (10) to obtain N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-3-cyano-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxamide (19.5 mg, 35.8 umol, 16% yield, 100% purity).

[1367] C 23 H 19 LCMS (m / z) calculated for ClF6N6O: 544.1; found: 545.1 [M+H] + , retention time = 0.602 min (Method 11).

[1368] 1 H NMR (400MHz, DMSO-d6) δ=8.60-8.56(m,2H),8.46(d,J=7.6Hz,1H),7.90(d,J=9.0Hz,1H),7.74(dd,J= 2.3,9.0Hz,1H),7.47(d,J=8.0Hz,1H),6.95(s,1H),5.43(q,J=9.1Hz,2H),4.02-3.85(m,2H),2.18(br d,J=11.6Hz,1H),2.00-1.89(m,2H),1.87-1.78(m,1H),1.57-1.22(m,4H).

[1369] Example 33

[1370] Synthesis of Example 33

[1371]

[1372] N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-3-cyano-1-(2-hydroxy Synthesis of (2-methylpropyl)pyrazole-4-carboxamide

[1373] To a solution of N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-5-cyano-1H-pyrazole-4-carboxamide (45 mg, 97 umol, 1 eq) and 2,2-dimethyloxirane (10.5 mg, 146 umol, 13 uL, 1.5 eq) in DMF (2 mL) was added K2CO3 (27 mg, 194.45 umol, 2 eq). The mixture was heated at 100° C. for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product was purified by reverse phase HPLC: column (Welch Xtimate C18 150*25mm*5um) conditions (water (0.05% HCl)-ACN) to give N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-3-cyano-1-(2-hydroxy-2-methylpropyl)pyrazole-4-carboxamide (30% yield) as a solid.

[1374] LCMS-ESI (m / z) calculated: 534.2, found: 535.2 [M+H] + , retention time = 0.582 min (Method 14).

[1375] 1 H NMR (400MHz, DMSO-d6) δ = 8.49 (s, 1H), 8.04-7.95 (m, 1H), 7.71 (d, J = 8.5Hz, 1H), 7.17-7 .09(m,2H),6.91-6.84(m,1H),3.92-3.76(m,1H),3.65-3.51(m,1H),1.77-1.64(m,8H).

[1376] Example 34

[1377] Synthesis of Example 34

[1378]

[1379] N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-3-cyano-1-(2- Synthesis of (2-fluoro-2-methylpropyl)-1H-pyrazole-4-carboxamide

[1380] To a solution of N-[(1R, 3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-3-cyano-1-(2-hydroxy-2-methylpropyl)pyrazole-4-carboxamide (140 mg, 1 eq., 262 umol) in DCM (2 mL) was added DAST (127 mg, 1 eq., 785 umol, 104 uL). The reaction mixture was stirred at 25 °C for 1 hour. The solvent was filtered and the filtrate was collected. The crude product was purified by preparative HPLC to give N-[(1R, 3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-3-cyano-1-(2-fluoro-2-methylpropyl)pyrazole-4-carboxamide (23 mg, 42 umol, 15% yield) as a solid.

[1381] LCMS-ESI (m / z) calculated: 536.95, found: 537.3 [M+H] + , retention time = 0.479 min (Method 11).

[1382] 1 H NMR (400MHz, methanol-d4) δ = 8.37 (d, J = 2.1Hz, 1H), 8.27 (d, J = 1.3Hz, 1H), 7.91 (d, J = 9.0Hz, 1H), 7.69 (dd ,J=2.3,9.0Hz,1H),6.91(s,1H),4.52-4.34(m,2H),4.10-3.99(m,1H),3.86-3.76(m,1H),2.39(br d,J=12.0Hz,1H),2.16-1.93(m,3H),1.71-1.38(m,4H),1.37-1.28(m,6H).

[1383] Example 35

[1384] Synthesis of Example 35

[1385]

[1386] N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1H-pyrazole-4-carboxylate Synthesis of amines

[1387] To a stirred suspension of tert-butyl 4-(((lR,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamoyl)-lH-pyrazole-l-carboxylate (1.014 g, 1 eq, 1.885 mmol) in 1,4-dioxane (15 mL) was added HCl in 1,4-dioxane (687.2 mg, 4.712 mL, 4.00 moles, 10 eq, 18.85 mmol). The resulting mixture was heated at 50 °C for 2 hours and then concentrated under reduced pressure to give N-((lR,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-lH-pyrazole-4-carboxamide hydrochloride (1128 mg, 2.378 mmol, 126%) as a solid. The product was used in the next step without further purification.

[1388] LCMS-ESI (m / z) calculated: 437.12, found: 438.0 [M+H] + , retention time = 0.825 min (Method 11).

[1389] HATU (1.72 g, 1 eq., 4.52 mmol) was added to a stirred solution of 1-(tert-butoxycarbonyl)-1H-pyrazole-4-carboxylic acid (960 mg, 1 eq., 4.52 mmol) and DIPEA (2.34 g, 3.2 mL, 4 eq., 18.1 mmol) in DMF (10 mL). After stirring at room temperature for 10 minutes, (1S, 3R)-N1-(6-chloro-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride (1.72 g, 1 eq., 4.52 mmol) was added in one portion. The resulting mixture (brown solution) was stirred at room temperature for 18 hours. The reaction mixture was diluted with EtOAc and washed with H2O. The organic layer was collected and the aqueous layer was stripped twice with EtOAc. The organic layers were combined, washed with saturated NaHCO3 and brine, dried over Na2SO4 and concentrated under reduced pressure. The residue was dissolved in MeOH (10 mL) and purified by reverse phase flash column chromatography to give tert-butyl 4-(((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamoyl)-1H-pyrazole-1-carboxylate (1.042 g, 1.937 mmol, 43%) as a solid.

[1390] LCMS-ESI (m / z) calculated: 537.17, found: 538.0 [M+H] + , retention time = 5.264 min (Method 10).

[1391] To a stirred solution of 1-bromo-2-fluoro-2-methylpropane (64 mg, 3 eq., 0.41 mmol) followed by DMF (2 mL) was added N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1H-pyrazole-4-carboxamide hydrochloride (60 mg, 1 eq., 0.14 mmol) and potassium carbonate (28 mg, 1.5 eq., 0.21 mmol). The resulting white suspension was heated and stirred at 80 °C for 2 days. The reaction mixture was cooled to room temperature and directly purified by preparative HPLC to give N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(2-fluoro-2-methylpropyl)-1H-pyrazole-4-carboxamide (12 mg, 23 μmol, 17%) as a solid.

[1392] LCMS-ESI (m / z) calculated: 511.18, found: 512.3 [M+H] + , retention time = 8.865 min (Method 1).

[1393] 1 H NMR(400MHz,DMSO-d6)δ8.59(s,1H),8.13(s,1H),7.97(d,J=8.0Hz,1H),7.92–7.8 5(m,2H),7.76–7.71(m,1H),7.48(d,J=7.9Hz,1H),6.93(s,1H),4.33(d,J=19.9Hz, 2H),4.03–3.94(m,1H),3.91–3.83(m,1H),2.15(d,J=11.9Hz,1H),2.00–1.93(m,1H ),1.90–1.78(m,2H),1.60–1.44(m,2H),1.42–1.34(m,1H),1.27(d,J=21.5Hz,7H).

[1394] Example 36

[1395] Synthesis of Example 36

[1396]

[1397] N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(piperidin-4-yl)- Synthesis of 1H-pyrazole-4-carboxamide

[1398] To a stirred solution of (1S,3R)-N1-(6-chloro-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride (40 mg, 1 eq, 0.11 mmol) in DMF (2 mL) was added 1-(1-(tert-butoxycarbonyl)piperidin-4-yl)-1H-pyrazole-4-carboxylic acid (31 mg, 1 eq, 0.11 mmol), HATU (40 mg, 1 eq, 0.11 mmol) and DIPEA (54 mg, 73 μL, 4 eq, 0.42 mmol). The resulting mixture was stirred at room temperature for 20 hours. The reaction mixture was directly purified by preparative HPLC to give tert-butyl 4-(4-(((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamoyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (36.6 mg, 58.9 μmol, 56%) as a solid.

[1399] LCMS-ESI (m / z) calcd: 620.25, found 621.3 [M+H]+, retention time = 9.935 (Method 1).

[1400] 1 H NMR (400MHz, DMSO-d6) δ8.59(s,1H),8.23(s,1H),7.94–7.82(m,3H),7.74(d,J=8 .5Hz,1H),7.48(d,J=7.9Hz,1H),6.93(s,1H),4.36(t,J=11.8Hz,1H),4.00(s,3H ),3.87(d,J=9.5Hz,1H),2.90(s,2H),2.15(d,J=11.9Hz,1H),2.00(d,J=12.9Hz, 3H),1.89–1.69(m,4H),1.60–1.44(m,2H),1.44–1.34(m,10H),1.29–1.22(m,1H).

[1401] To a stirred solution of tert-butyl 4-(4-(((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamoyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (30.4 mg, 1 eq, 48.9 μmol) in 1,4-dioxane (1.5 mL) was added 4M HCl in 1,4-dioxane (122 μL, 10 eq, 489 μmol). The resulting white cloudy suspension was stirred at 50 °C for 2 h. The reaction mixture was then purified by preparative HPLC to give N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(piperidin-4-yl)-1H-pyrazole-4-carboxamide (11.7 mg, 22.5 μmol, 46%) as a solid.

[1402] LCMS-ESI (m / z) calcd: 520.20, found 521.2 [M+H]+, retention time = 5.861 min (Method 1).

[1403] 1 H NMR(400MHz,DMSO-d6)δ8.59(s,1H),8.20(s,1H),7.95–7.80(m,3H),7.74(d,J=9.0H z,1H),7.48(d,J=7.9Hz,1H),6.93(s,1H),4.25(t,J=11.9Hz,1H),4.02–3.94(m,1H), 3.91–3.82(m,1H),3.10(d,J=12.5Hz,2H),2.68(t,J=12.2Hz,2H),2.15(d,J=11.9Hz, 1H), 1.99 (d, J = 12.6Hz, 3H), 1.90–1.76 (m, 4H), 1.57–1.35 (m, 3H), 1.29–1.22 (m, 1H).

[1404] Example 37

[1405] Synthesis of Example 37

[1406]

[1407] Synthesis of N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(2-fluoroethyl)-1H-pyrrole-3-carboxamide

[1408] To a stirred solution of 1H-pyrrole-3-carboxylic acid methyl ester (250 mg, 1 eq., 2.00 mmol) in DMF (4 mL) was added sodium hydride (95.9 mg, 60% Wt, 1.2 eq., 2.40 mmol) at 0 ° C. The reaction mixture was stirred for 10 minutes. 1-Bromo-2-fluoroethane (380 mg, 1.5 eq., 3.00 mmol) was added and the reaction mixture was warmed to room temperature. After stirring overnight at room temperature, H2O (5 mL) was added. The aqueous layer was extracted with EtOAc (3 x 5 mL), washed with H2O (3 x 5 mL), dried over sodium sulfate, filtered through celite and concentrated in vacuo to give a crude material. The crude material was purified by silica gel chromatography (0-->50% EtOAc and hexanes) to give methyl 1-(2-fluoroethyl)-1H-pyrrole-3-carboxylate (205.3 mg, 1.199 mmol, 60.0% yield).

[1409] LCMS-ESI (m / z) calculated: 171.07, found: 172.0 [M+H] + , retention time = 0.660 min (Method 11).

[1410] To a stirred solution of 1-(2-fluoroethyl)-1H-pyrrole-3-formic acid methyl ester (205mg, 1 equivalent, 1.19mmol) in THF (6mL), sodium hydroxide (240mg, 5.99mL, 1 mole, 5 equivalents, 5.99mmol) was added. The reaction mixture was heated at 50°C for 12 hours. Additional sodium hydroxide (240mg, 5.99mL, 1 mole, 5 equivalents, 5.99mmol) and heated overnight at 70°C. The reaction mixture was cooled to room temperature, 3M HCl (10mL) was added, extracted with EtOAc (3x 10mL), dried over sodium sulfate, filtered through diatomaceous earth, and concentrated in vacuo to obtain 1-(2-fluoroethyl)-1H-pyrrole-3-formic acid (169mg, 1.08mmol, 90% yield).

[1411] LCMS-ESI (m / z) calculated value: 157.05, found value 158.0 [M+H] + , retention time = 0.487 min (Method 11).

[1412] N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(2-fluoroethyl)-1H-pyrrole-3-carboxamide was synthesized using Scheme 4 and starting from 1-(2-fluoroethyl)-1H-pyrrole-3-carboxylic acid and (1S,3R)-N1-(6-chloro-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride.

[1413] LCMS-ESI (m / z) calculated: 482.15, found: 483.2 [M+H] + , retention time = 9.764 min (Method 1).

[1414] 1 H NMR(400MHz,DMSO)δ8.61(s,1H),7.93-7.88(m,1H),7.77-7.14(m,1H),7.64-7.59(m,1H), 7.52-7.47(m,1H),7.35(s,1H),6.93(s,1H),6.79-6.75(m,1H),6.51-6.47(m,1H),4.75-4. 69(m,1H),4.62-4.58(m,1H),4.28-4.21(m,1H),4.20-4.14(m,1H),4.04-3.93(m,1H),3.9 1-3.79(m,1H),2.17-2.09(m,1H),2.01-1.91(m,1H),1.90-1.78(m,2H),1.58-1.23(m,5H).

[1415] Examples 38 and 39

[1416] Synthesis of Examples 38 and 39

[1417]

[1418] 3-Chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(2,2-difluoromethyl)- fluoroethyl)-1H-pyrazole-4-carboxamide and 5-chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino Synthesis of 1-(2,2-difluoroethyl)-1H-pyrazole-4-carboxamide

[1419] To a stirred solution of ethyl 3-chloro-1H-pyrazole-4-carboxylate (200 mg, 1 eq, 1.15 mmol) in MeCN (15 mL) was added cesium carbonate (1.49 g, 4 eq, 4.58 mmol) and 2-bromo-1,1-difluoroethane (498 mg, 3 eq, 3.44 mmol). The vial was capped, heated at 60 °C overnight, and concentrated in vacuo. The reaction mixture was cooled to room temperature, water (20 mL) was added, and the mixture was extracted with EtOAc (2 x 20 mL), dried over sodium sulfate, filtered through celite and concentrated in vacuo to give a mixture of ethyl 3-chloro-1-(2,2-difluoroethyl)-1H-pyrazole-4-carboxylate and ethyl 5-chloro-1-(2,2-difluoroethyl)-1H-pyrazole-4-carboxylate (335.3 mg, 1.405 mmol, 123%) which was used without further purification.

[1420] To a stirred solution of crude ethyl 3-chloro-1-(2,2-difluoroethyl)-1H-pyrazole-4-carboxylate and ethyl 5-chloro-1-(2,2-difluoroethyl)-1H-pyrazole-4-carboxylate (273 mg, 1 eq., 1.14 mmol) in THF (8 mL) was added sodium hydroxide (229 mg, 5.72 mL, 1 mol, 5 eq., 5.72 mmol). The reaction mixture was heated at 50 °C for 4 h. The reaction mixture was concentrated in vacuo, 3 M HCl (10 mL) was added, and the mixture was extracted with EtOAc (3 x 10 mL), dried over sodium sulfate, filtered through celite and concentrated in vacuo to give 3-chloro-1-(2,2-difluoroethyl)-1H-pyrazole-4-carboxylic acid and 5-chloro-1-(2,2-difluoroethyl)-1H-pyrazole-4-carboxylic acid (289 mg, 1.37 mmol, 120%) as a crude mixture which was used without further purification.

[1421] To a stirred solution of (1S,3R)-N1-(6-chloro-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride (100 mg, 1 eq, 264 μmol) in DMF (1.5 mL) was added crude 3 / 5-chloro-1-(2,2-difluoroethyl)-1H-pyrazole-4-carboxylic acid (55.7 mg, 1 eq, 264 μmol), N-ethyl-N-isopropylpropan-2-amine (DIPEA) (103 mg, 138 μL, 3 eq, 793 μmol) and HATU (111 mg, 1.1 eq, 291 μmol). The reaction mixture was stirred at room temperature for 2 hours. The crude mixture was purified by reverse phase HPLC (35-55% 0.1% formic acid / MeCN and 0.1% formic acid / H2O) to give 3-chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(2,2-difluoroethyl)-1H-pyrazole-4-carboxamide (70 mg, 131 μmol, 50%) and 5-chloro-N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-(2,2-difluoroethyl)-1H-pyrazole-4-carboxamide (26 mg, 48 μmol, 18%).

[1422] Example 38: LCMS-ESI (m / z) calculated value: 535.1, found value 536.1 [M+H] + , retention time = 9.368 min (Method 1).

[1423] Example 39: LCMS-ESI (m / z) calculated value: 535.1, found value 536.1 [M+H] + , retention time = 9.622 minutes (Method 1).

[1424] Example 40

[1425] Synthesis of Example 40

[1426]

[1427] (R)-3-(4-(((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)amino Synthesis of tert-butyl (1H-pyrazol-1-yl)pyrrolidine-1-carboxylate

[1428] To (S) -3- bromopyrrolidine -1- tert-butyl formate (500mg, 1.2 equivalents, 2.00mmol) in DMF (5mL) solution of ethyl 4-pyrazolecarboxylate (233mg, 1 equivalent, 1.67mmol) and cesium carbonate (1.36g, 2.5 equivalents, 4.16mmol) were loaded. The resulting suspension was heated and stirred at 90 ° C. After stirring for 19 hours, the reaction mixture was cooled to room temperature. The reaction mixture was diluted with cold water and extracted with EtOAc (3x 100mL). The organic layers were merged, washed with brine and concentrated under reduced pressure to obtain the desired product. The crude product can be used without further purification or characterization.

[1429] To a solution of (R)-1-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-1H-pyrazole-4-carboxylic acid ethyl ester (515 mg, 1 eq., 1.66 mmol) in THF (20 mL) was added 1 M sodium hydroxide (666 mg, 16.6 mL, 1.00 mole, 10 eq., 16.6 mmol). The resulting solution was heated and stirred at 50 ° C overnight. After heating at 50 ° C for 18 hours, the reaction mixture was concentrated under reduced pressure. The aqueous residue was acidified to pH 3-4 with 3N HCl. The mixture was extracted with EtOAc (3x 30 mL), and the combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to give (R)-1-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-1H-pyrazole-4-carboxylic acid (351 mg, 1.25 mmol, 75%).

[1430] To a solution of (1S,3R)-N1-(6-chloro-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride (40 mg, 1 eq, 0.11 mmol) in DMF (2 mL) was added HATU (40 mg, 1 eq, 0.11 mmol), (R)-1-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)-1H-pyrazole-4-carboxylic acid (30 mg, 1 eq, 0.11 mmol) and DIPEA (73 μL, 4 eq, 0.42 mmol). The resulting solution was stirred at room temperature for 18 hours. The crude product was directly purified by preparative HPLC to give (R)-tert-butyl 3-(4-(((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamoyl)-1H-pyrazol-1-yl)pyrrolidine-1-carboxylate (13.5 mg, 22.2 μmol, 21%).

[1431] LCMS-ESI (m / z) calculated: 606.23, found: 607.3 [M+H] + , retention time = 9.718 min (Method 1).

[1432] 1 H NMR (400MHz, DMSO-d6) δ8.59(s,1H),8.23(s,1H),7.96–7.83(m,3H),7.74(d,J=9.0Hz,1H ),7.48(d,J=7.9Hz,1H),6.93(s,1H),5.00–4.92(m,1H),4.02–3.83(m,2H),3.74–3.67(m ,1H),3.52(d,J=11.3Hz,1H),3.46–3.35(m,2H),2.29(d,J=25.7Hz,2H),2.15(d,J=11.8H z,1H),1.96(d,J=12.3Hz,1H),1.90–1.78(m,2H),1.59–1.44(m,2H),1.42–1.24(m,11H).

[1433] Example 41

[1434] Synthesis of Example 41

[1435]

[1436] N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-((R)-pyrrolidine- Synthesis of 3-amino-1H-pyrazole-4-carboxamide

[1437] To a solution of (R)-tert-butyl 3-(4-(((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)carbamoyl)-1H-pyrazol-1-yl)pyrrolidine-1-carboxylate (9.2 mg, 1 eq, 15 μmol) in 1,4-dioxane (1.5 mL) was added hydrogen chloride in 1,4-dioxane (5.5 mg, 38 μL, 4.00 moles, 10 eq, 0.15 mmol). The resulting mixture was heated at 50 °C for 2 hours. The reaction mixture was diluted in MeOH and purified directly by preparative HPLC to give N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1-((R)-pyrrolidin-3-yl)-1H-pyrazole-4-carboxamide (2.2 mg, 4.3 μmol, 29% yield).

[1438] LCMS-ESI (m / z) calculated: 506.18, found: 507.2 [M+H] + , retention time = 5.834 min (Method 1).

[1439] Example 42

[1440] Synthesis of Example 42

[1441]

[1442] N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-5-(difluoromethyl)- Synthesis of 1-ethyl-1H-pyrazole-4-carboxamide

[1443] To a solution of ethyl 5-(difluoromethyl)-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxylate (200 mg, 624 umol, 1 eq) in THF (1.5 mL) and H2O (1.5 mL) was added LiOH.H2O (79 mg, 1.9 mmol, 3 eq) and heated at 50°C for 2 hours. The reaction mixture was cooled to room temperature and neutralized to pH 7 with 5% HCl. The reaction mixture was concentrated in vacuo to give 5-(difluoromethyl)-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxylic acid (180 mg, 617 umol, 99% yield) as a solid which was used without further purification.

[1444] To a solution of 5-(difluoromethyl)-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxylic acid (175 mg, 599 umol, 1 eq.) and (1S, 3R)-N1-[6-chloro-2-(trifluoromethyl)-4-quinolyl]cyclohexane-1,3-diamine (206 mg, 599 umol, 1 eq.) in DMF (4 mL) was added HATU (341 mg, 898 umol, 1.5 eq.) and DIEA (232 mg, 1.80 mmol, 313 uL, 3 eq.). The mixture was stirred at 25 °C for 12 hours. The mixture was partitioned between EtOAc (15 mL) and water (15 mL). The aqueous phase was back extracted with EtOAc (2 x 10 mL). The combined organics were dried over MgSO4 and concentrated in vacuo to give a crude material. The crude residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 0 / 1) to give N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-5-(difluoromethyl)-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxamide (280 mg, 453 umol, 76% yield) as an oil.

[1445] To a solution of N-[(1R, 3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-5-(difluoromethyl)-1-(2-trimethylsilylethoxymethyl)pyrazole-4-carboxamide (280 mg, 453 umol, 1 eq.) in DCM (3 mL) was added TFA (924 mg, 8.10 mmol, 600 uL, 17.9 eq.). The reaction mixture was stirred at 25 °C for 1 hour. The reaction mixture was concentrated under reduced pressure to give a residue. MeOH (3 mL) and K2CO3 (313 mg, 2.26 mmol, 5 eq.) were added and heated at 50 °C for 1 hour. The mixture was cooled to room temperature and distributed between EtOAc (10 mL) and water (10 mL). The aqueous phase was extracted with EtOAc (2 x 10 mL). The combined organics were dried over MgSO4 and concentrated in vacuo to give N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-3-(difluoromethyl)-1H-pyrazole-4-carboxamide (210 mg, 396 umol, 87% yield, 92% purity) as an oil which was used without further purification.

[1446] To a solution of N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-3-(difluoromethyl)-1H-pyrazole-4-carboxamide (60 mg, 113 umol, 92% purity, 1 eq) and iodoethane (53 mg, 340 umol, 27 uL, 3 eq) in MeCN (1.5 mL) was added K2CO3 (47 mg, 340 umol, 3 eq) and the mixture was heated at 50° C. for 14 h. The mixture was cooled to room temperature and filtered to remove insoluble material. The crude product was purified by reverse phase HPLC: column (Phenomenex luna C18 150*25mm*10um) conditions (water (0.225% FA)-ACN) start B (46) end B (76) gradient time (minute) (10.5) to give N-[(1R,3S)-3-[[6-chloro-2-(trifluoromethyl)-4-quinolyl]amino]cyclohexyl]-5-(difluoromethyl)-1-ethyl-pyrazole-4-carboxamide (9.3 mg, 17.4umol, 15% yield, 97% purity) as a solid.

[1447] LCMS-ESI (m / z) calculated: 515.1, found: 516.1 [M+H] + , retention time = 0.625 min (Method 14).

[1448] 1 H NMR (400MHz, DMSO-d6) δ = 8.59 (d, J = 2.0Hz, 1H), 8.30-8.30 (m, 1H), 8.29 (d, J =8.0Hz,1H),8.09(s,1H),7.89(d,J=9.0Hz,1H),7.87-7.58(m,2H),7.48(br d,J=8.0Hz,1H),6.93(s,1H),4.29(q,J=7.1Hz,2H),4.06-3.81(m,2H),2.15(br d,J=12.1Hz,1H),1.97(br d,J=11.3Hz,1H),1.92-1.78(m,2H),1.59-1.46(m,2H),1.37(t,J=7.2Hz,3H),1.34-1.20(m,2H).

[1449] The compounds listed in Table 6 were prepared using the procedure of Scheme 6.

[1450] Table 6

[1451]

[1452] Solution 7

[1453]

[1454] Reagents: X is independently C or N. Step 6-1. Base (DIPEA), solvent (DMF); Step 6-2. NaOH aqueous solution / THF; Step 5-3. Peptide coupling conditions (HATU), base (DIPEA), solvent (DMF)

[1455] Example 43

[1456] Synthesis of Example 43

[1457]

[1458] Synthesis of 6-[(1R,3S)-3-{[6-chloro-2-(trifluoromethyl)quinolin-4-yl]amino}cyclohexyl]-5H,6H,7H-pyrrolo[3,4-b]pyridin-7-one

[1459] To a stirred solution of (1S,3R)-N1-(6-chloro-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride (50 mg, 1 eq, 0.13 mmol) in DMF (1.5 mL) was added N-ethyl-N-isopropylpropan-2-amine (DIPEA) (85 mg, 0.12 mL, 5 eq, 0.66 mmol) and methyl 3-(bromomethyl)picolinate (46 mg, 1.5 eq, 0.20 mmol). The vial was capped and heated at 40 °C over the weekend. The crude product was purified by reverse phase HPLC (35-->55% 0.1% formic acid / H2O and 0.1% formic acid / MeCN) to give 6-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (37.1 mg, 80.5 μmol, 61% yield).

[1460] LCMS-ESI (m / z) calculated: 460.13, found: 461.2 [M+H] + , retention time = 8.116 min (Method 1).

[1461] 1H NMR (400MHz, DMSO) δ8.72 (s, 1H), 8.61 (s, 1H), 8.07 (d, J = 7.9Hz, 1H), 7.91 (d, J=8.7Hz,1H),7.75(d,J=9.6Hz,1H),7.60-7.51(m,2H),7.00(s,1H),4.52(app q,J=13.0Hz,2H),4.43-4.29(m,1H),4.09-3.98(m,1H),2.20-2.12(m,1H), 2.04-1.98(m,1H),1.94-1.76(m,3H),1.69-1.56(m,2H),1.52-1.40(m,1H).

[1462] Solution 8

[1463]

[1464] Reagents: R2R3NH, di(1H-imidazol-1-yl)methanone or triphosgene, base (TEA), solvent (DCM)

[1465] Example 44

[1466] Synthesis of Example 44

[1467]

[1468] Step 7. N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-4-isobutyrylpiperazine-1-carboxamide

[1469] To a stirred solution of di(1H-imidazole-1-yl)methanone (2.14 g, 5 eq., 13.2 mmol) and triethylamine (348 mg, 479 μL, 1.3 eq., 3.44 mmol) in DCM (20 mL) was added (1S, 3R)-N1-(6-chloro-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine hydrochloride (1.00 g, 1 eq., 2.64 mmol) twice at 0 ° C., 10 minutes apart. The reaction mixture was stirred at 0 ° C. for 1 hour, and then stirred at room temperature for 30 minutes. The reaction mixture was concentrated in vacuo to give N-((1R, 3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1H-imidazole-1-carboxamide, which was dried under high vacuum and used without further purification.

[1470] To a stirred solution of N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-1H-imidazole-1-carboxamide (100 mg, 50% Wt, 1 eq, 114 μmol) in DCM (1.5 mL) was added 2-methyl-1-(piperazin-1-yl)propan-1-one (89.2 mg, 5 eq, 571 μmol) and N-ethyl-N-isopropylpropan-2-amine (DIPEA) (73.8 mg, 99.5 μL, 5 eq, 571 μmol). The reaction mixture was stirred at room temperature overnight. The crude mixture was purified by reverse phase preparative HPLC to give N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-4-isobutyrylpiperazine-1-carboxamide (29.1 mg, 55.3 μmol).

[1471] LCMS-ESI (m / z) calculated: 526, found: 526.3 [M+H] + , retention time = 8.141 min (Method 1).

[1472] Example 45

[1473] Synthesis of Example 45

[1474]

[1475] Step 5. Synthesis of N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-3-fluoro-3-methylazetidine-1-carboxamide

[1476] To a stirred solution of N-((1R, 3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-3-hydroxy-3-methylazetidine-1-carboxamide (40 mg, 1.0 eq., 0.088 mmol) in DCM (0.5 mL) at room temperature was added a solution of deoxofluoride (Deoxo-Fluor) (29 mg, 1.5 eq., 0.13 mmol). The reaction mixture was stirred at room temperature for 5 minutes. Saturated ammonium chloride solution (2 mL) was added dropwise. The aqueous layer was extracted with EtOAc / MeOH (5: 1) (2x5 mL), dried over sodium sulfate, filtered through celite and concentrated in vacuo. The crude mixture was purified by preparative HPLC to give N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-3-fluoro-3-methylazetidine-1-carboxamide (23.5 mg, 51.2 μmol, 58%).

[1477] LCMS-ESI (m / z) calcd: 458.15, found 459.2 [M+H]+, retention time = 8.638 min (Method 1).

[1478] Example 46

[1479] Synthesis of Example 46

[1480]

[1481] Synthesis of N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-2-methyl-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxamide

[1482] To an ice-cold solution of (1S,3R)-N1-(6-chloro-2-(trifluoromethyl)quinolin-4-yl)cyclohexane-1,3-diamine (60 mg, 1 eq., 0.16 mmol) and DIPEA (0.10 g, 0.14 mL, 5 eq., 0.79 mmol) in MeCN (2 mL) was added triphosgene (47 mg, 1 eq., 0.16 mmol) in one portion. The resulting mixture was stirred at 0 °C for 10 minutes. 4,5,6,7-tetrahydro-2-methylthiazolo[5,4-c]pyridine (61 mg, 2.5 eq., 0.39 mmol) was then added to the mixture followed by DIPEA (50 mg, 70 μL, 2.5 eq.). The resulting mixture was stirred at 50 °C for 18 hours. The crude mixture was purified by preparative HPLC to give N-((1R,3S)-3-((6-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)cyclohexyl)-2-methyl-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxamide (52.6 mg, 100 μmol, 64% yield).

[1483] LCMS-ESI (m / z) calcd: 524.00, found 524.2 [M+H]+, retention time = 8.534 min (Method 1).

[1484] 1H NMR(400MHz,DMSO-d6)δ8.60(s,1H),7.89(d,J=9.1Hz,1H),7.73(d,J=9.1Hz ,1H),7.45(d,J=7.8Hz,1H),6.88(s,1H),6.51(d,J=7.6Hz,1H),4.51(s,2H), 3.82–3.60(m,4H),2.67(s,2H),2.58(s,3H),2.11(d,J=11.7Hz,1H),1.94(d, J=12.2Hz,1H),1.79(t,J=15.3Hz,2H),1.53–1.37(m,2H),1.35–1.19(m,2H).

[1485] The compounds listed in Table 8 were prepared using the procedure of Scheme 8.

[1486] Table 8

[1487]

[1488]

[1489]

[1490]

[1491] Example 47

[1492] MRGPRX2 activity

[1493] CHO cells stably transfected to express human MRGPRX2 were maintained in an incubator at 37°C with 5% CO2 and grown in F12 (HAM) medium containing 10% fetal bovine serum (FBS), 1% Glutamax, 1% penicillin / streptomycin, 800 μg / mL Geneticin (G418) and 300 μg / mL Hygromycin B.

[1494] Cells were plated in 384-well assay plates in 12 μL Opti-MEM at 20,000 cells per well, and in an incubator overnight. On the day of assay, a Tecan D300E digital dispenser was used to add the compound dissolved in DMSO at 10 mM as a 10-point curve (30 uM final maximum concentration, 1:3 serial dilution). The agonist was diluted in assay buffer (final concentration of 5.7 mM Tris-HCl, 43 mM NaCl, 50 mM LiCl, pH = 8), and 2 μL of the agonist cortistatin-14 (CPC Scientific, catalog CORT-002) was added to each well. The final concentration of the agonist was 0.3 μM cortistatin. The final concentration of DMSO was kept consistent throughout the plate. The plate was incubated in the dark for 1 hour at 37 ° C, and then incubated for 1 hour at room temperature. IP-1 standards and HTRF detection reagents were added according to the IP-One-Gq kit purchased from Cisbio (Cisbio) (Part No. 62IPAPEJ) and incubated for 1 hour in the dark at room temperature. Plates were read on a Molecular Devices SpectraMax iD5 plate reader. HTRF ratios were calculated from raw data and plotted using GraphPad Prism to calculate IC50 values ​​for each compound.

[1495] Activity data for selected MRGPRX2 antagonists (relative to 0.3 uM cortistatin-14 agonist) are shown in Table 9. The activity range is indicated as follows: "++++" indicates antagonist activity <100 nM; "++++" indicates antagonist activity between 100 and 500 nM; "+++" indicates activity between 501 and 1000 nM; "++" indicates activity between 1001 and 2500 nM; and "+" indicates activity >2500 nM.

[1496] Table 9

[1497]

[1498]

[1499] Example 48

[1500] Mast cell β-hexosaminidase release assay

[1501] Human LAD2 cells (NIH) were maintained in an incubator at 37°C with 5% CO2 and cultured in StemPro-34 serum-free medium (Gibco 10639011) supplemented with 2 mM L-glutamine, 100 U / ml penicillin, 50 mg / ml streptomycin and 100 ng / ml SCF (Invitrogen PEP0860) at a concentration of 2-5 x 10 5 cells / mL, with hemidepletion performed every 1-2 weeks.

[1502] The cells were cultured at 2.5 x 10 5Cells / mL were transferred to SCF-free medium and incubated overnight. On the day of the assay, cells were washed twice in assay buffer (final concentrations of 10mM HEPES, 137mM NaCl, 5.6mM D-glucose, 2.7mMKCl, 1mM MgCl, 1.8mM CalCl2, 0.4mM Na2HPO4.7H2O, 0.04% BSA, pH = 7.4) and plated in 96-well v-bottom plates in 80 μL assay buffer at 20,000 cells per well. Antagonist compounds dissolved in DMSO at 10mM were diluted to 10 times the final desired concentration in assay buffer as a 10-point curve (10 μM final maximum concentration, 1:3 serial dilutions), and 10 μL was added to each well. Then, the plate was incubated at 37°C for 1 hour. The agonist was diluted to 10 times the desired concentration in assay buffer, and 10 μL of the appropriate agonist was added to each well. The final concentration of cortistatin-14 (Tocris 3374) used in the antagonist assay was 500 nM. The final concentration of DMSO was kept consistent throughout the plate. The plate was then incubated in a hot air oven at 37°C for 30 minutes, followed by centrifugation at 450 x g for 5 minutes at 4°C. Then, 50 μL of supernatant from each well was transferred to a 96-well flat bottom plate, each well containing 100 μL of substrate solution (3.5 mg / mL p-nitrophenyl-N-acetyl-β-D-glucosamine (Sigma 487052) in citrate buffer containing a final concentration of 40 mM citric acid, 20 mM Na2HPO4.7H2O, pH = 4.5. Then, 150 μL of 0.1% Triton-X-100 was added to the remaining cell pellet in the remaining assay buffer in each well, resuspended by pipetting up and down, and 50 μL of cell lysate was transferred to a second 96-well flat bottom plate, each well containing 100 μL of substrate solution. Then, the plate containing the transferred supernatant and cell lysate was incubated at 37° C. in a hot air oven for 90 minutes. After incubation, 50 μL of 400 mM glycine buffer (pH 10.7) was added to each well and the plate was read on a Molecular Devices SpectraMax iD5 plate reader (absorbance at 405 nm and, in the case of a reference filter, at 620 nm). After background subtraction, the percentage of degranulation (percentage of β-hexosaminidase release) was calculated as 100x (supernatant value) / (supernatant+lysate value) and subsequently analyzed using GraphPad Prism software to calculate the IC of each compound. 50 value.

[1503] Activity data for selected MRGPRX2 antagonists in the mast cell β-hexosaminidase release assay are shown in Table 10. The activity range is indicated as follows: "++++" indicates antagonist activity <100 nM; "++++" indicates antagonist activity between 100 and 500 nM; "+++" indicates activity between 501 and 1000 nM; "++" indicates activity between 1001 and 2500 nM; and "+" indicates activity >2500 nM.

[1504] Table 10

[1505] Compound No. MRGPRX2 antagonist activity Example 1 +++++ Example 14 +++++ Example 15 +++++ Example 30 +++++ Example 31 +++++ Example 32 +++++ Example 44 +++++ Example 45 ++++ 1-3 ++++ 1-8 + 3-4 ++ 4-225 +++++ 4-241 +++++ 4-303 +++++ 4-304 +++++ 4-306 +++++ 4-318 +++ 4-400 +++++ 4-411 +++++ 4-414 +++++ 4-420 +++++ 4-430 +++++ 5-2 +++++ 5-3 +++++ 8-9 ++++

[1506] Example 49

[1507] Mouse pharmacokinetic study

[1508] The compound was formulated in 5% DMSO, 5% Solutol and 90% PBS without Ca and Mg (pH 7.4) at a concentration of 5 mg / mL. Male C57BL / 6 mice (n=3 / compound) were administered a 50 mg / kg dose of each compound by oral gavage under non-fasting conditions. Blood samples were collected on K2-EDTA via the saphenous vein at 0.25 hours, 0.5 hours, 1 hour, 2 hours, 4 hours, 8 hours and 24 hours after administration, and plasma was prepared and stored at -80°C until analysis. The plasma sample preparation for analysis was completed by protein precipitation using acetonitrile (containing Verapamil as an internal standard) followed by centrifugation. The compound concentration in the extracted plasma was determined using LC-MS / MS relative to a 12-point standard curve covering a range of 1 to 4000 nM. Non-compartmental analysis was performed using Phoenix WinNonlin to estimate pharmacokinetic parameters, including area under the curve, clearance and half-life. The administered dose was confirmed by analysis of residual dose material by UPLC-UV relative to a single point calibration sample. Figure 11 presents the results of these studies.

[1509] Table 11

[1510]

[1511] Example 50

[1512] Evans Blue Vascular Permeability Assay

[1513] 8-10 week old C57BL / 6J (strain 000664; Jackson Laboratory) or MrgprX2 knock-in (Mrgb2KI; Escient Pharmaceuticals Inc.) mice were anesthetized with isoflurane and the backs were shaved 5-6 days before the start of the study. On the day of the study, mice were dosed with vehicle or 100 mg / kg, 30 mg / kg, 20 mg / kg, 10 mg / kg, or 3 mg / kg of EP8615 3 hours before Evans blue injection. Animals were restrained and injected intravenously (IV) 1% Evans blue (Catalog No. 314-13-6; Fisher Chemical) in 0.9% saline and then placed under isoflurane. Ten minutes after the IV injection, the animals were kept under anesthesia and injected intradermally The vehicle was PBS, cortistatin-14 (C-14; 300 nM; Catalog No. 3374; Tocris Biosciences), icatibant (HOE-140; Catalog No. 3014; Tocris Biosciences) or goat anti-mouse IgE ( ab9162; Abcam). Ten minutes after intradermal injection, animals were photographed and sacrificed. The skin around the injection site was punctured with an 8 mm round skin punch and weighed and placed in a 1.5 ml Eppendorf tube. Evans blue dye was extracted from the tissue by adding 1 ml of formamide (BP227-500; Fisher Scientific) to the tube, which was then vortexed and covered in foil and placed at 55°C overnight. The formamide of the extracted dye was placed in duplicate in a 96-well plate along with a standard curve of known Evans Blue concentration standards. The plate was read on a plate reader at 620 nM and the results are expressed as g dye / mg tissue. Statistical tests were performed using Graphpad Prism 8 (GraphPad Software). Data are presented as mean and standard error of the mean. Unpaired t-tests were used to compare statistical differences between groups.

[1514] The above-mentioned various embodiments can be combined to provide additional embodiments. All U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications cited in this specification and / or listed in the application data sheet are incorporated herein by reference in their entirety. If necessary, various aspects of the embodiments can be modified to provide yet other embodiments using various patents, applications and disclosed concepts.

[1515] These and other changes can be made to the embodiments in light of the above detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and claims, but should be construed to encompass all possible embodiments and the full range of equivalents to which the claims are entitled. Therefore, the claims are not limited by the present disclosure.

Claims

1. A compound having one of the following structures, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof:

2. The compound according to claim 1, wherein the compound has the structure of Example 19, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

3. The compound according to claim 1, wherein the compound has one of the following structures, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof:

4. The compound according to claim 1, wherein the compound has the structure of Example 26, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

5. The compound according to claim 1, wherein the compound has the structure of Example 27, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

6. The compound according to claim 1, wherein the compound has the structure of Example 28, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

7. The compound of claim 1, wherein the compound has the structure of Example 29, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

8. The compound according to claim 1, wherein the compound has one of the following structures, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof:

9. The compound of claim 1, wherein the compound has the structure of Example 30, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

10. The compound of claim 1, wherein the compound has the structure of Example 31, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

11. The compound of claim 1, wherein the compound has the structure of Example 32, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

12. The compound of claim 1, wherein the compound has the structure of Example 33, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

13. The compound of claim 1, wherein the compound has the structure of Example 34, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

14. The compound of claim 1, wherein the compound has the structure of Example 35, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

15. The compound of claim 1, wherein the compound has the structure of Example 36, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

16. The compound of claim 1, wherein the compound has the structure of Example 37, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

17. The compound of claim 1, wherein the compound has the structure of Example 38, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

18. The compound of claim 1, wherein the compound has the structure of Example 39, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

19. The compound of claim 1, wherein the compound has the structure of Example 40, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

20. The compound of claim 1, wherein the compound has the structure of Example 41, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

21. The compound of claim 1, wherein the compound has the structure of Example 42.

22. The compound according to claim 1, wherein the compound has the structure of compound 6-1, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

23. The compound according to claim 1, wherein the compound has the structure of compound 8-16, or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof.

24. A pharmaceutical composition comprising a compound according to any one of claims 1 to 23 or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof and at least one pharmaceutically acceptable excipient.

25. A method of modulating Mas-related G protein receptor (MRGPR) X2 or a MRGPRX2 ortholog by contacting MRGPRX2 or a MRGPRX2 ortholog with an effective amount of the pharmaceutical composition of claim 24.

26. A method of treating a MRGPRX2 or MRGPRX2 ortholog-dependent condition by administering an effective amount of the pharmaceutical composition of claim 24 to a subject in need thereof.

27. A method of treating pseudoallergic reactions, pruritus-related conditions, pain-related conditions, cancer-related conditions, inflammatory or autoimmune disorders by administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 24.

28. The method of claim 27, wherein the pseudoallergic reaction is caused by a secretagogue, a cationic peptidergic drug, an anionic peptidergic drug, a neutral peptidergic drug, a nonsteroidal antagonist drug, a neuropeptide, an antimicrobial peptide, an MCD peptide, substance P, VIP, PACAP, dynorphin, somatostatin, compound 48 / 80, cortistatin-14, mastoparan, meletin, antimicrobial peptides, ciprofloxacin, vancomycin, leuprolide, olide, goserelin, histrelin, triptorelin, cetrorelix, ganirelix, degarelix, octreotide, lanreotide, pasireotide, sermorelin, tesamorelin, icatibant, glatiramer acetate The drugs include tadalafil acetate, teriparatide, pramlintide, bleomycin, exenatide, glucagon, liraglutide, enfuvirtide, colistimethate, succinylcholine, tubocurarine, atracurium, mivacurium, and rocuronium.

29. The method of claim 27, wherein the itch-related condition is chronic pruritus; contact dermatitis; allergic blepharitis; anemia; atopic dermatitis; bullous pemphigoid; candidiasis; varicella; End-stage renal failure; hemodialysis; chronic urticaria; contact dermatitis, atopic dermatitis; dermatitis herpetiformis; diabetes; drug allergy, dry skin; dyshidrotic dermatitis; atopic eczema; eosinophilic fasciitis; epidermolysis bullosa; erythrasma; food allergy; folliculitis; fungal skin infection; hemorrhoids; herpes; HIV infection; Hodgkin's disease; hyperthyroidism; allergy to iodinated contrast dye; iron deficiency anemia; kidney disease; leukemia, porphyria; lymphoma; malignancy; mastocytosis; multiple myeloma; neurodermatitis; onchocerciasis; Paget's disease; pediculosis; Polycythemia vera; Prurigo nodularis; lichen planus; lichen sclerosus; pruritus anus; pseudorabies; psoriasis; rectal prolapse; sarcoid granuloma; scabies; schistosomiasis; scleroderma, severe stress, stasis dermatitis; swimmer's itch; thyroid disease; tinea cruris; rosacea; amyloidosis cutanea; scleroderma; acne; wound healing; burn healing; ocular pruritus; or urticaria.

30. The method of claim 28, wherein the itch-related condition is urticaria, pruritus, atopic dermatitis, dry skin, psoriasis, contact dermatitis, or eczema.

31. The method of claim 27, wherein the pain-related condition is acute pain, advanced prostate cancer, AIDS-related pain, ankylosing spondylitis, arachnoiditis, arthritis, arthrofibrosis, ataxic cerebral palsy, autoimmune atrophic gastritis, avascular necrosis, back pain, Behcet's Disease (syndrome), burning mouth syndrome, bursitis, cancer pain, carpal tunnel, cauda equina syndrome, central pain syndrome, cerebral palsy, cervical spinal stenosis, Charcot-Marie-Tooth (CMT) disease, chronic fatigue syndrome (CFS), chronic functional abdominal pain (CFAP), chronic pain, chronic pancreatitis, chronic pelvic pain syndrome, collapsed lung (pneumothorax), complex regional pain syndrome (RSD), corneal neuropathic pain, Crohn's Disease, degenerative disc disease, toothache, Dercum's disease (Dercum's Disease), Dermatomyositis, Diabetic Peripheral Neuropathy (DPN), Dystonia, Ehlers-Danlos Syndrome (EDS), Endometriosis, Eosinophilia-Myalgia Syndrome (EMS), Erythromelalgia, Fibromyalgia, Gout, Headache, Herniated Disc, Hydrocephalus, Intercostal Neuralgia, Interstitial Cystitis, Irritable Bowel Syndrome (IBS), Juvenile Dermatositis, Knee Injury, Leg Pain, Lumbar Pain-Hematuria Syndrome, Lupus, Lyme Disease, Medullary Sponge Kidney (MSK), Meralgia Paresthesia, Mesothelioma, Migraine, Musculoskeletal Pain, Myofascial Pain, Myositis, Neck Pain, Neuropathic Pain, Occipital Neuralgia, Osteoarthritis, Paget's Disease, Parsonage Turner Syndrome Syndrome), pelvic pain, periodontitis pain, peripheral neuropathy, phantom limb pain, nerve compression, polycystic kidney disease, polymyalgia rheumatica, polymyositis, porphyria, post-herniorrhagic pain syndrome, post-mastectomy, post-operative pain, pain syndrome, post-stroke pain, post-thoracotomy pain syndrome, post-herpetic neuralgia (shingles), post-polio syndrome, primary lateral sclerosis, psoriatic arthritis, pudendal neuralgia, radiculopathy, Raynaud's Disease, rheumatoid arthritis (RA), sacroiliac joint dysfunction, sarcoidosis, Scheuemann's Kyphosis Disease, sciatica, scoliosis, shingles,Herpes Zoster, Sjogren's Syndrome, Spasmodic Torticollis, Sphincter of Oddi Dysfunction, Spinocerebellar Ataxia (SCA Ataxia), Spinal Cord Injury, Spinal Stenosis, Syringomyelia, Tarlov Cysts, Transverse Myelitis, Trigeminal Neuralgia, Neuropathic Pain, Ulcerative Colitis, Vascular Pain, or Vulvar Pain.

32. The method of claim 27, wherein the inflammatory or autoimmune disorder is chronic inflammation, mast cell activation syndrome, multiple sclerosis, Steven Johnson's syndrome, toxic epidermal necrolysis, appendicitis, bursitis, cutaneous lupus, colitis, cystitis, dermatitis, phlebitis, reflex sympathetic dystrophy / complex regional pain syndrome (rsd / crps), rhinitis, tendinitis, tonsillitis, acne vulgaris, sinusitis, rosacea, psoriasis, graft versus host disease, reactive airway disorder, asthma, airway infection, allergic rhinitis, autoinflammatory disease, celiac disease, chronic prostatitis, diverticulitis, glomerulonephritis, hidradenitis suppurativa, allergies, intestinal disorders, epithelial intestinal disorders, inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, lupus erythematosus, interstitial cystitis, otitis, pelvic inflammatory disease, endometrial pain, reperfusion injury, rheumatic fever, rheumatoid arthritis, sarcoidosis, transplant rejection, psoriasis, lung inflammation, chronic obstructive pulmonary disease, permanent sputum eosinophilia, eosinophilic leukemia, eosinophilic esophagitis, eosinophilic gastritis, eosinophilic duodenitis, eosinophilic gastroenteritis, mast cell gastrointestinal disease, eosinophilic syndrome, aspirin-exacerbated respiratory disease disease), nasal polyposis, chronic sinusitis, antibody-dependent cell-mediated cytotoxicity, neurofibromatosis, schwannomatosis, tubulointerstitial nephritis, glomerulonephritis, diabetic nephropathy, allograft rejection, amyloidosis, renal vascular ischemia, reflux nephropathy, polycystic kidney disease, liver fibrosis / cirrhosis, autoimmune liver disease, biliary atresia, acute and chronic hepatitis B and C viruses, liver tumors and liver cancer, alcoholic liver disease, polycystic liver disease, hepatobiliary carcinoma, neuromyelitis optica, cardiovascular disease, inflammation induced by bacterial or viral infection, inflammation associated with SARS-CoV-2 infection or its variants and coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome, pneumonia, long / long-term / chronic COVID, post-acute sequelae of COVID-19 (PASC), myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS "brain fog"), and vasculitis.

33. The method of claim 27, wherein the cancer-related condition is adenoid cystic carcinoma, adrenal tumors, amyloidosis, anal cancer, appendix cancer, astrocytoma, ataxia-telangiectasia, Beckwith-Wiedemann syndrome, bile duct cancer, birt-hogg-dube syndrome, bone cancer, brain stem glioma, brain tumor, breast cancer (inflammatory, metastatic, male), prostate cancer, basal cell carcinoma, melanoma, colon cancer, colorectal cancer, bladder cancer, kidney cancer, lacrimal gland cancer, laryngeal and hypopharyngeal cancer, lung cancer (non-small cell, small cell), leukemia (acute lymphoblastic, acute lymphocytic, acute myeloid, B-cell prolymphocytic, chronic lymphocytic, chronic myeloid, chronic T-cell lymphocytic, eosinophilic), liver cancer, Li-Fraumeni syndrome syndrome), lymphoma (Hodgkin and non-Hodgkin), Lynch syndrome, mastocytosis, medulloblastoma, meningioma, mesothelioma, multiple endocrine neoplasms, multiple myeloma, MUTYH-associated polyposis, myelodysplastic syndrome, nasal and sinus cancers, neuroblastoma, neuroendocrine tumors, neurofibromatosis, penile cancer, parathyroid cancer, ovarian fallopian tube and peritoneal cancer, osteosarcoma, pituitary tumors, pleuropulmonary blastoma, oral and oropharyngeal cancer, thyroid cancer, uterine cancer, pancreatic cancer, Carney complex, brain and spinal cord cancer, cervical cancer, Cowden syndrome syndrome), craniopharyngioma, desmoid tumor, desmoplastic infantile ganglioglioma, ependymoma, esophageal cancer, Ewing sarcoma, eye cancer, eyelid cancer, familial adenomatous polyposis, familial GIST, familial malignant melanoma, familial pancreatic cancer, gallbladder cancer, gastrointestinal stromal tumors, germ cell tumors, gestational trophoblastic disease, head and neck cancer, hereditary breast and ovarian cancer, hereditary diffuse gastric cancer, hereditary leiomyomatosis and renal cell carcinoma, hereditary pancreatitis, hereditary papillary renal cancer, hereditary mixed polyposis syndrome, HIV / AIDS-related cancers, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, Kaposi sarcoma, small intestine cancer, stomach cancer, testicular cancer, thymoma and thymic cancer, thyroid cancer, vaginal cancer, vulvar cancer, Werner syndrome, and Xeroderma pigmentosum.